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Abstract
Cyclic guanosine monophosphate (cGMP) is an important signalling molecule which reg-
ulates critical events across all stages of the malaria parasite lifecycle. To further our
understanding of how cGMP signalling governs important events involved in blood stage
egress and invasion as well as gametocyte development and gametogenesis, this study
investigates two different members of this signalling cascade in Plasmodium falciparum
parasites. Guanylyl Cyclase α (GCα) is a large, seemingly bifunctional enzyme, which
consists of a type IV P-type ATPase domain, which is predicted to flip aminophospholipids
between lipid bilayer leaflets; and a GC domain, which is thought to be responsible for
generating cGMP. Using a combination of approaches including mutagenesis and condi-
tional disruption of PfGCα, work presented in this thesis confirms that GCα is responsible
for cGMP synthesis and that both ATPase and GC domains are required for asexual blood
stage growth. Although the exact role of the ATPase domain remains unknown, chemical
complementation of GCα-deficient parasites, which lack both ATPase and GC domains,
with a cGMP analogue has revealed that the ultimate role of the ATPase is in modulating
cGMP synthesis.
Activation of this cGMP signalling cascade culminates in the phosphorylation of numer-
ous effector proteins, many of which form part of the glideosome. This includes the
actomyosin motor protein, Myosin A (MyoA), which is phosphorylated at serine 19 (S19).
Since the glideosome generates the force required for merozoites to invade host cells,
these cGMP-dependent phosphorylation events may be involved in modulating motor
activity. In the second part of this thesis, conditional disruption of MyoA has confirmed
that the actomyosin motor is essential for red blood cell invasion, however it is dispens-
able during gametocyte development and gametogenesis. Complementation of the MyoA
knockout line with mutant versions of the protein that either mimic or ablate phosphoryla-
tion of S19 revealed that phosphorylation of this residue is important but not essential for
parasite viability. In vitro motility assays using material derived from parasites express-
ing either wild type or mutant MyoA demonstrate that non-phosphorylated MyoA displays
slower motility, providing evidence that cGMP-dependent phosphorylation is involved in
modulating the activity of the actomyosin motor.
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1 Introduction
1.1 Malaria as a global health problem
Malaria, caused by protozoan parasites from the genus Plasmodium, is a mosquito-borne
disease which remains a major health burden in many parts of the world including Sub-
Saharan Africa, Southeast Asia and South America. In 2017 alone, malaria was respons-
ible for an estimated 219 million cases and 435,000 deaths (WHO, 2018). Between 2000
and 2015, a steady decrease in malaria incidence and mortality rates was observed
namely due to improved vector control, an essential component of malaria prevention
(Bhatt et al., 2015); and the availability of artemisinin combination therapies (ACTs), the
current first line treatment for malaria infections. However, progress against malaria has
stalled in certain regions with some countries reporting increased cases (WHO, 2018).
Furthermore, tremendous selection pressure on parasite and mosquito populations over
the years has resulted in the emergence of resistance to antimalarials (Blasco et al.,
2017) and insecticides (Hemingway et al., 2016; Kleinschmidt et al., 2018) respectively,
thus threatening global initiatives to control, eliminate and eradicate malaria.
1.2 Malaria is caused by Plasmodium parasites
Plasmodium parasites are single-celled eukaryotes that belong to the Apicomplexa phylum
(Levine, 1970); a diverse group of organisms, which also includes the parasites respons-
ible for diseases such as babesiosis, cryptosporidiosis and toxoplasmosis. Apicompl-
exans are closely related to ciliates such as Paramecium and Tetrahymena, as well as
dinoflagellates. Collectively they belong to to the superphylum Alveolata which are highly
divergent from model organisms such as yeast and mice.
Malaria is transmitted by the female mosquito of the genus Anopheles. Six species of
Plasmodium are known to infect humans: P. falciparum, P. vivax, P. malariae, P. ovale
curtisi, P. ovale wallikeri and P. knowlesi. Of these species, P. falciparum gives rise to
the most severe disease manifestation and is responsible for the most fatalities. However
P. knowlesi infections also have the potential to cause severe disease (Cox-Singh et al.,
2008), owing to this species’ ability to cause high parasitemia infections in a short period
of time. While infections by the other species are rarely fatal, they cause considerable
13
morbidity.
These species have different but often overlapping geographical distributions, which are
limited to areas where the environmental conditions allow for parasite replication in the
Anopheles mosquito (Shapiro et al., 2017). P. falciparum predominates in Africa but is
also found in South America and Asia. P. vivax is the most common species found in
South America but also has a wide geographical spread similar to P. malariae. The re-
maining species occupy distinct niches with P. ovale subspecies limited to West Africa
and the zoonotic P. knowlesi, which is transmitted from macaques, restricted to South-
east Asia. As molecular diagnostic tools improve, it is becoming more apparent that
some P. ovale and P. malariae infections have gone underdiagnosed in the past, while P.
knolwesi infections have been misdiagnosed as P. malariae infections (Cox-Singh et al.,
2008). Therefore there is a growing appreciation for non-falciparum malaria infections.
1.3 Life Cycle
The highly complex life cycle of Plasmodium species encompasses two hosts; the female
Anopheles mosquito and a vertebrate host (Figure 1.1). When an infected mosquito takes
a blood meal, it releases saliva containing haploid sporozoites into the host’s skin (Sid-
janski and Vanderberg, 1997). These motile forms utilise gliding motility (Montagna et al.,
2012; Santos et al., 2017) to travel through the dermis and penetrate microvasculature
including capillaries and lymphatic vessels (Vanderberg and Frevert, 2004; Amino et al.,
2006; Hopp et al., 2015). The parasites then migrate to the liver where they invade hep-
atocytes (Frevert et al., 2005), initiating the asymptomatic pre-erythrocytic stage. The
parasite, which resides within a parasitophorous vacuole (PV), then undergoes multiple
rounds of non-synchronous nuclear replication termed schizogony. A plasma membrane
(PM) forms around the nuclei giving rise to thousands of hepatic merozoites. P. vivax and
P. ovale, are able to form dormant hypnozoites, which persist in the liver for long peri-
ods of time, eventually causing relapses several weeks, months or years later (Cogswell,
1992).
14
Figure 1.1. The Plasmodium falciparum life cycle.
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The hepatic merozoites are released from the liver within host-derived vesicles called
merosomes (Sturm et al., 2006), which protect the parasites from the host immune sys-
tem. Once in the pulmonary capillaries, the merosomes rupture releasing the merozoites
into the blood where they are able to rapidly invade erythrocytes, where they reside within
a PV, and are termed ring-stage parasites due to their appearance in Giemsa-stained
blood smears. The parasite then profoundly remodels the host cell by exporting proteins
into the cytosol and onto the surface of the red blood cell (RBC), which allows the para-
site to establish new permeability pathways for acquiring nutrients from the surroundings
(Ginsburg et al., 1983). P. falciparum parasites are also able to avoid clearance by the
spleen (Langreth and Peterson, 1985) by expressing adhesins such as members of the
erythrocyte membrane protein 1 (PfEMP1) family on the surface of the RBC (Leech et al.,
1984) that help the infected cell adhere to several endothelial receptors including CD36,
thrombospondin (TSP) and intracellular adhesion molecule 1 (ICAM-1) (Pasloske and
Howard, 1994; Baruch et al., 1996); and by exporting proteins which modify the eryth-
rocyte cytoskeleton making the infected cell more rigid (Paulitschke and Nash, 1993;
Dondorp et al., 2000).
The parasite then develops into a trophozoite which feeds on hemoglobin from the host
cell (Goldberg et al., 1990), resulting in the liberation of free heme. Since free heme is
toxic, it is detoxified and polymerised into crystalline hemozoin and stored in the food
vacuole. Parasites eventually undergo further rounds of schizogony, producing a blood
stage schizont containing between 16-32 nuclei (Janse et al., 1986). Budding of the
plasma membrane and separation of the organelles results in the formation of mero-
zoites. Around 48 hours post invasion for P. falciparum parasites, in a process termed
egress, merozoites are released into the bloodstream where they rapidly reinvade RBCs,
initiating the next asexual growth cycle. Successive cycles of egress and reinvasion result
in the exponential proliferation of parasites. The molecular processes that govern egress
and invasion will be discussed in further detail in section 1.5. It is during this asexual
blood stage of the disease that the symptoms of malaria are observed; manifesting as
flu-like symptoms, cyclical febrile episodes and fatigue (Bartoloni and Zammarchi, 2012).
In more severe cases, complications can cause acute renal failure, cerebral malaria and
severe anaemia and may eventually lead to death if left untreated (Idro et al., 2011).
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In each cycle, a small proportion of parasites are able to exit asexual replication and
commit to differentiation to the sexual stage of infection in a process termed gametocyt-
ogenesis, which results in the formation of male and female gametocytes. The sexually
mature gametocyte is the only stage of the life cycle that can be transmitted to mosqui-
tos to establish an infection in the vector, however gametocytes represent a dead-end in
the vertebrate host. Therefore there needs to be a balance between the production of
asexual forms that sustain the infection, and the production of gametocytes which trans-
mit the parasite to the mosquito where gamete formation and sexual reproduction occurs.
Early work identified several factors that correlated with gametocyte formation in vitro in-
cluding stress (Chaubey et al., 2014), nutrient availability (Brancucci et al., 2017) and high
parasite burden (Bruce et al., 1990; Nacher et al., 2002). More recently, significant pro-
gress in understanding the genetic mechanisms underlying sexual commitment has been
made. This process is regulated by the activation of AP2-G, a member of the ApiAP2 fam-
ily of transcription factors, which triggers a transcriptional cascade that results in sexual
commitment (Kafsack et al., 2014; Sinha et al., 2014). Expression of AP2-G is controlled
by a protein called gametocyte development 1 (GDV1) (Eksi et al., 2012; Filarsky et al.,
2018), however it is unknown how parasites regulate GDV1 expression to either induce or
inhibit sexual commitment. Once an asexual parasite is sexually-committed, the parasite
can either complete a replicative cycle to produce progeny that develop into gametocytes
upon re-invasion, or can develop into a gametocyte within the same cycle (Bancells et al.,
2019). The time required for gametocytes to complete development varies depending
on the species; with P. falciparum gametocytes displaying the longest maturation period
of 7-15 days (Hawking et al., 1971; Bousema and Drakeley, 2011). During this time,
P. falciparum gametocytes undergo remarkable morphological changes categorised into
distinct stages (I-V) shown in figure 1.2. Later stages adopt a crescent shape, unique to
P. falciparum, which is driven by the assembly of the microtubular network and subpel-
licular membrane (Sinden, 1982; Dearnley et al., 2011; Parkyn Schneider et al., 2017), a
membranous structure which is related to the inner membrane complex (IMC) in mero-
zoites, ookinetes and sporozoites. This rigidity is thought to allow immature gametocytes
(stages I-IV) to sequester in the bone marrow to avoid splenic clearance (Joice et al.,
2014). Once mature, the microtubular network is disassembled (Dearnley et al., 2011),
and stage V gametocytes are released from the bone marrow and are found circulating
in the blood for up to 6 days (Bousema et al., 2010) where they can be taken up by a
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mosquito during a blood meal.
Figure 1.2. The stages of Plasmodium falciparum gametocyte development. The inner
membrane complex (IMC), shown in orange, is deposited as 13 disk-like structures in
gametocytes while the microtubule network, shown in brown, aligns on the IMC plates. As the
gametocyte develops, the IMC plates extend laterally through the addition of membrane to the
leading edges of the plates, eventually wrapping around the parasite. The microtubule network
extends perpendicularly across the IMC plates, driving elongation of the gametocyte as it
develops. In stage V gametocytes, the microtubule network is disassembled, while the IMC
remains. Immature stage I-IV gametocytes are sequestered in the bone marrow, while mature
stage V gametocytes are found circulating in the blood where they can be taken up by a feeding
mosquito.
Once in the mosquito midgut, gametocytes are triggered to differentiate into gametes in
response to environmental changes which include a drop in temperature coupled with
either an increase in pH (Kawamoto et al., 1991; Billker et al., 1997) or exposure to xan-
thurenic acid (XA), a mosquito-derived molecule (Billker et al., 1998). Upon activation,
both male and female gametocytes round up and emerge from the host RBC. The male
gamete undergoes three rounds of DNA replication and mitosis (Janse et al., 1986) res-
ulting in the formation of eight flagellated microgametes. Female gametogenesis on the
other hand appears less dramatic, but involves the activation and translation of many
transcripts which are transcriptionally repressed by the DDX6-type RNA helicase, devel-
opment of zygote inhibited (DOZI) (Mair et al., 2007). In a process called exflagellation,
the microgametes detach from the residual body and are able to fertilise female macro-
gametes to form a diploid zygote. The zygote then replicates its DNA to become tetraploid
and develops into a motile ookinete which is able to traverse the midgut, eventually form-
ing an oocyst which undergoes several rounds of replication. Uninuclear budding results
in the formation of around 3,000 haploid sporozoites contained within the cyst (Janse
et al., 1986; Rosenberg and Rungsiwongse, 1991). After 10-18 days, the oocyst rup-
tures, and motile sporozoites progress to the salivary glands where they mature and are
able to be transmitted to the next vertebrate host when the female mosquito takes its next
blood meal.
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The ability to continuously culture P. falciparum (Trager and Jensen, 1976) and P. know-
lesi (Moon et al., 2013; Lim et al., 2013) blood-stage parasites in human erythrocytes
has greatly contributed to expanding our understanding of the biology of the parasite.
Due to the difficulty of studying P. falciparum in the mosquito stages, much of our un-
derstanding of these stages comes from the use of mouse malaria models, including P.
berghei, P. yoelii and P. chabaudi. Using animal models also allows for investigating the
host-pathogen interactions such as immune responses and pathology during infection.
1.4 Malaria control
Several public health strategies are currently in place in order to prevent malaria transmis-
sion (WHO, 2018). These fall into four main categories which include vector control, mal-
aria prevention, diagnosis and treatment. However, due to the highly adaptable nature of
the parasites and the mosquito vectors, malaria control remains challenging. Ultimately,
in order to effectively combat malaria, an integrated approach using a strategic combin-
ation of interventions will be required along with continued investment into the research
and development of new tools.
1.4.1 Vector control strategies
Controlling mosquito populations is an integral part of malaria control, providing a highly
effective method of disrupting transmission cycles and preventing malaria infection. Since
mosquitos are vectors of other diseases such as zika, dengue, yellow fever and chikun-
gunya; interventions that target mosquitos may also help protect against these diseases.
The distribution of insecticide-treated bed nets (ITNs) and indoor residual spraying (IRS)
have significantly contributed to reductions in malaria infections over the last 50 years
(WHO, 2018). However, the expansion of mosquito populations resistant to pyrethroids
(Hemingway et al., 2016; Kleinschmidt et al., 2018), the insecticide class used in ITNs,
and other insecticides, presents a major obstacle to current vector control measures. An-
other issue is the behaviour of some Anopheles species, which tend to feed outdoors
and/or bite during the day when people are not using ITNs (Steinhardt et al., 2017).
Therefore new classes of insecticides are needed along with other interventions that tar-
get exophagic species that bite outdoors. It is becoming more apparent that tailored
interventions, which are adapted to suit the behaviours of specific population groups, will
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be required in order to make more effective use of current vector control measures (Nofal
et al., 2019).
Another vector control measure is the treatment of humans with drugs that kill mosquitos
when ingested during a blood meal. One example is Ivermectin, a well-tolerated and
widely used broad-spectrum antihelminthic drug, which can also kill Anopheles mosqui-
tos if a sufficient dose is ingested during a blood meal (Smit et al., 2018) and inhibit
P. falciparum sporogony in surviving mosquitos (Kobylinski et al., 2012). A recent ran-
domised clinical trial in Burkina Faso showed that mass drug administration (MDA) of
Ivermectin resulted in a measurable reduction in malaria incidence (Foy et al., 2019).
Biocontrol strategies, which have proven effective at targeting mosquito populations, in-
clude the use of bacterial larvicides and the introduction of larvivorous fish which feed on
mosquito larvae and pupae. A potential new biocontrol tool on the horizon is the use of
Wolbachia, an endosymbiotic bacterium which can infect mosquitos, resulting in reduced
Plasmodium oocyst density (Hughes et al., 2011; Shaw et al., 2016; Gomes and Barillas-
Mury, 2018). The release of sterile irradiated male mosquitos known as the sterile insect
technique (SIT), is another approach that can reduce mosquito numbers, however this
method is laborious and will be difficult to implement globally (Lees et al., 2015). Re-
cently, genetically modified Anopheles mosquitos harbouring a gene drive which results
in the production of sterile females through inheritance bias, resulted in population col-
lapse in a proof-of-principle lab-controlled experiment (Kyrou et al., 2018). Although this
tool may be successful in eradicating certain Anopheles species, this may have broader
ecological repercussions which must be considered before releasing mosquitos harbour-
ing gene drives into the wild.
1.4.2 Malaria Prevention
Vaccines
Vaccines are arguably one of the most efficient and cost-effective ways of preventing
or reducing the risk of contracting several infectious diseases including smallpox, polio,
measles, shingles and rabies to name a few. The development of an efficacious mal-
aria vaccine holds considerable promise in helping control malaria, yet despite decades
of research a highly effective vaccine which provides long-lasting protection against the
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parasite remains elusive (Draper et al., 2018). Although natural immunity to Plasmodium
can be acquired in holoendemic areas through repeated exposure to the parasite, this
does not confer complete protection but rather results in non-sterile immunity, where low
level parasitemias persist in the absence of diseases symptoms (Day and Marsh, 1991;
Doolan et al., 2009). This partial immunity is short-lived, since in the absence of contin-
ued exposure to the parasite or during pregnancy, immunity is lost and formerly protected
individuals become susceptible to the disease. These factors coupled with the complex
life cycle and the antigenic diversity of the parasite (Anders and Smythe, 1989; Ferreira
et al., 2004) have made developing an efficacious malaria vaccine challenging. Further-
more, several parasite antigens contain repetitive amino acid motifs, which may in-fact
dampen immune responses (Davies et al., 2017). Current malaria vaccine efforts fall
into three main categories which target different stages of the life cycle and include pre-
erythrocytic vaccines, blood-stage vaccines, and transmission-blocking vaccines (TBVs).
Pre-erythrocytic vaccines, which generate an immune response targeting sporozoites,
have been the most successful to date. Currently, the only licensed malaria vaccine can-
didate is RTS,S/AS01, a recombinant protein-based vaccine which directs an immune
response against a subunit of the major circumsporozoite protein (PfCSP). Results from
a Phase III clinical trial found that RTS,S/AS01 showed only moderate efficacy, reducing
the incidence of clinical malaria by 39% after four doses (RTS, 2015). However, the par-
tial immunity mediated by RTS,S/AS01 wanes over time and does not provide protection
against P. vivax. Despite these shortcomings, the RTS,S/AS01 vaccine could provide an
additional tool to use alongside other malaria control strategies, and may yield valuable
insights upon which a next-generation vaccine can be designed. A pilot study is cur-
rently underway in three African countries to inform on the large scale implementation
of RTS/S,AS01 (van den Berg et al., 2019). Currently, the only way to confer sterilising
immunity is by immunising with developmentally attenuated whole sporozoites (Clyde
et al., 1973; Hoffman et al., 2002). The PfSPZ vaccine, which consists of whole irradi-
ated cryopreserved sporozoites, is currently undergoing Phase I clinical trials. Although
highly efficacious in controlled human infections (Seder et al., 2013), results achieved in
the field are considerably lower (Sissoko et al., 2017). It is possible that dose regimen
optimisation may yield promising results (Ishizuka et al., 2016).
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Blood-stage vaccines, which would target either infected RBCs or merozoites, would the-
oretically help reduce disease severity or parasite burden. Vaccines targeting infected
RBCs include chemically attenuated whole-parasite blood-stage vaccines and subunits
against VAR2CSA (Pehrson et al., 2017), an antigen expressed on surface of infected
RBC that helps the parasite adhere to chondroitin sulfate A (CSA) and leads to sequest-
ration in the placenta. Considerable effort has been invested into generating vaccines
that block antigens found on the surface of merozoites from interacting with RBC recept-
ors. Potential blood-stage antigens includes various merozoite surface proteins (MSPs),
apical membrane antigen 1 (AMA1) and erythrocyte-binding antigen 175 (EBA175) to
name a few. However, there are major obstacles to overcome with blood-stage vac-
cines, including antigenic diversity, the redundancy of invasion pathways and the short
time that merozoites are exposed to the immune system. The identification of a non-
redundant, highly conserved invasion ligand, reticulocyte-binding protein homologue 5
(Rh5) (Baum et al., 2009) which interacts with the basigin receptor on the surface of
erythrocytes (Crosnier et al., 2012), has provided one of the most promising blood-stage
vaccine candidates to date. Indeed, results from a Phase I study have shown promising
results using an RH5-based vaccine which inhibited parasite growth in vitro and induced
neutralising antimalarial antibodies in vaccinated individuals (Payne et al., 2017). Future
Phase II testing will help determine the efficacy of this vaccine candidate.
Transmission-blocking vaccines (TBVs), which target the sexual stages of the life cycle,
would not prevent infection or clinical manifestation of the disease in those vaccinated, but
rather prevent parasite development within the mosquito, blocking onward transmission.
Potential TBV antigens include Pfs25, found on the surface of zygotes and ookinetes;
and Pfs230p and Pfs48/45, which are found on the surface of gametes (Kapulu et al.,
2015). These antigens tend to be more conserved than blood-stage or pre-erythrocytic
antigens, possibly due to limited immune pressure, therefore making attractive vaccine
targets. Although TBVs have not progressed beyond Phase I trials, they could ultimately
be very useful tools in low-transmission and elimination settings.
Chemoprophylaxis and preventative treatment
Antimalarial drugs such as atovaquone-proguanil, doxycycline and mefloquine can be
taken to effectively prevent malaria infections. Although chemoprophylaxis is regularly
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used by travellers visiting malaria endemic regions, it is rarely used to protect local popu-
lations; namely due to concerns regarding cost, sustainability, the potential emergence of
wide-spread resistance and the loss of naturally acquired immunity (Greenwood, 2010).
Instead, intermittent preventative treatment (IPT) is used on high risk populations in en-
demic regions including pregnant women, infants and children. This involves the adminis-
tration of a curative dose of sulfadoxine/pyrimethamine (SP) (WHO, 2007), regardless of
whether the individual is infected or not. However, the spread of resistance to SP, social
factors that lead to poor adherence (Pell et al., 2011) and the high cost of IPT pose future
concerns for its continued use (Parikh and Rosenthal, 2009).
1.4.3 Diagnosis
Malaria fatalities are preventable if detected and treated early. This relies on prompt and
effective diagnostic techniques in often resource limited settings. The current gold stand-
ard for diagnosis involves identifying parasites by microscopy in thick or thin stained blood
smears (Tangpukdee et al., 2009). However, this method requires considerable expert-
ise, especially in successfully identifying malaria species. Alternatively, rapid diagnostic
tests (RDTs), which can be used in rural settings and require minimal training, can also
be used to rapidly and efficiently determine whether an individual has a malaria infec-
tion. RDTs react with malaria-specific antigens present in the blood, and can distinguish
between P. falciparum and P. vivax infections. However, since some antigens used in
RDTs, such as histidine-rich protein 2 (PfHRP2), are not essential for parasite survival,
parasites possessing HRP2 deletions can result in false-negative RDTs (Beshir et al.,
2017; Verma et al., 2018), potentially leading to the misdiagnosis of infections. RDTs also
perform poorly on non-falciparum and non-vivax species (Tanizaki et al., 2014), therefore
providing further limitations. Molecular diagnostic tools such as polymerase chain reac-
tion (PCR) and loop-mediated isothermal amplification (LAMP) display high sensitivity,
however these are not routinely used for diagnosis in the field. Similarly, serological tests
including enzyme-linked immunosorbent assays (ELISAs) can be used as surveillance
tools for identifying past infections and determining the transmission intensity of a certain
region (Corran et al., 2007).
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1.4.4 Treatment
Current drugs
Several drugs are available to treat malaria (WHO, 2018). Currently the first line treat-
ment for malaria infections are ACTs, consisting of a potent fast-acting artemisinin deriv-
ative combined with a second less-potent slow acting partner drug. However, artemisinin
resistant parasites, initially reported in Cambodia in 2008 (Noedl et al., 2008), are now
widespread and have been reported in multiple countries in Southeast Asia including Vi-
etnam, Laos and Thailand (Ashley et al., 2014). Although artemisinin resistance presents
as a delay in parasite clearance rather than outright resistance, this facilitates the selec-
tion of partner drug resistance. As a result, not all parasites are cleared from the patient,
leading to high treatment failures rates following treatment with ACTs.
The spread of drug resistance has been observed for several other drugs which were
used prior to ACTs including chloroquine, SP, mefloquine, quinine and halofantrine (Rid-
ley, 2002). With no alternative new therapies currently available for immediate use, the
spread of artemisinin resistant parasites from Southeast Asia to Africa could lead to a
public health disaster, reversing the progress made between 2000 and 2015. To delay
this, existing drugs are currently being tested in triple artemisinin combination therapies
(TACTs) in order to slow the evolution and spread of artemisinin resistance and prevent
the concomitant development of partner drug resistance (Dini et al., 2018). This will
be done using drugs that have opposing resistance mechanisms, such as artemether-
lumefantrine and amodiaquine (Humphreys et al., 2007), to further suppress the emer-
gence of drug resistance. Trials are currently underway in Cambodia and Vietnam to test
the efficacy, safety and tolerability of TACTs (personal communication Tom Peto and Ar-
jen Dondorp, Mahidol Oxford Research Unit).
Most antimalarials target the asexual blood stages of the infection, and are therefore
unable to kill mature gametocytes and dormant P. ovale and P. vivax hypnozoites. Al-
though primaquine can eliminate both gametocytes and hypnozoites; this drug can have
life-threatening consequences if administered to individuals with glucose-6-phosphate
dehydrogenase (G6PD) deficiency (Recht et al., 2018), an enzymopothy which is par-
ticularly prevalent among populations in malaria endemic regions (Howes et al., 2013).
Therefore, even though primaquine is part of national treatment guidelines, it is not often
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prescribed. Tafenoquine, which can also be used to treat P. vivax infections, has re-
cently been approved by the United States food and drug administration (FDA). Although
tafenoquine is also contraindicated in G6PD deficient individuals, it could be used as a
single-dose treatment (Lacerda et al., 2019); unlike primaquine which has a much shorter
half-life and requires a 14-day treatment course.
Approaches for developing new malaria chemotherapies
Due to the growing threat of the spread of artemisinin resistance and the lack of safe
chemotherapies for clearing gametocyte and hypnozoite infections, there is an urgent
need for the discovery of new antimalarial compounds to expand the arsenal of malaria
chemotherapies available. This includes the development of drugs that can replace ACTs
as the frontline treatment, prevent transmission by killing gametocytes and provide a rad-
ical cure to clear hypnozoites.
There are several approaches that can be used to identify and develop new drug can-
didates (Rosenthal, 2003; Flannery et al., 2003). Existing antimalarials can be improved
upon by chemical modification of the compounds using medicinal chemistry-based ap-
proaches. This for example led to the development of chloroquine and mefloquine from
quinine (Rosenthal, 2003) and could be used in the future to improve the potency, sol-
ubility and stability of potential drug candidates. Alternatively, phenotypic screens can
also be conducted to test the effect of compounds developed for other diseases on para-
site growth and survival (Hovlid and Winzeler, 2016). Since most of these drugs have
already undergone clinical approval, it would therefore be inexpensive to repurpose them
as antimalarials. Furthermore, this approach allows for the high throughput screening of
compounds. Target-based drug discovery is another strategy that is increasingly being
used for the development of antimalarial drugs (Flannery et al., 2003). This approach
depends on broadening our understanding of the parasite’s biology in order to identify
and validate novel drug targets against which new drugs can be developed.
1.5 The molecular and cellular events that govern egress and
invasion
Egress and invasion have been important areas of research due to the essential roles that
they play during the blood-stages of the malaria life cycle. Since malaria pathology arises
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due to successive rounds of parasite egress and invasion, understanding the mechan-
isms that underlie these processes will be important for developing new therapeutics,
such as vaccines and novel drugs that target these stages.
1.5.1 Egress
Blood-stage egress is a rapid, tightly regulated process that results in the release of
mature merozoites from infected erythrocytes. This is achieved by a co-ordinated series
of proteolytic cleavage events, leading to the sequential rupture of the PVM, followed by
the red blood cell membrane (RBCM) (Hale et al., 2017) as shown in figure 1.3.
Figure 1.3. Schematic of the molecular events leading to merozoite egress from the
erythrocyte. A. Exonemes (brown) storing SUB1 and micronemes (pink) are released by the
merozoite. This can be blocked by adding PKG-specific inhibitors such as C1, C2 or ML10. B.
SUB1 cleaves several substrates including SERA5 (yellow) and SERA6 (green) and the PVM
becomes porated. C. The PVM ruptures and the RBCM becomes porated. D. The RBC ruptures,
releasing merozoites into the supernatant. This can be inhibited by adding E64.
Just prior to egress, the contents of specialised apical organelles called micronemes
and exonemes, are released onto the surface of the merozoite and into the PV, respect-
ively. The discharge of these organelles is mediated by cyclic guanosine monophosphate
(cGMP)-dependent protein kinase (PKG) (Collins et al., 2013b), which will be discussed
in further detail in section 1.7.4. However the natural egress signal, which culminates in
the activation of PKG remains unknown. Inhibition of PKG with selective adenosine tri-
phosphate (ATP)-competitive inhibitors, including compound 1 (C1) (Gurnett et al., 2002),
compound 2 (C2) (Donald et al., 2006) and ML10 (Baker et al., 2017b); can block egress
by preventing microneme and exoneme discharge. Exonemes are responsible for the
release of subtilisin like serine protease (SUB1) into the PV, while micronemes release
several proteins including erythrocyte binding antigen 175 (EBA175) and apical mem-
brane antigen 1 (AMA1), which play important downstream roles in invasion. Both AMA1
and SUB1 are proteolytically processed by plasmepsin X, a protease which plays an es-
sential role in the maturation and or activation of both these proteins (Pino et al., 2017;
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Nasamu et al., 2017). Once released into the PV, SUB1 processes several proteins in-
cluding MSP1 (Koussis et al., 2009), as well as SERA5 and SERA6 (Yeoh et al., 2007;
Ruecker et al., 2012), which are members of the serine repeat antigen (SERA) fam-
ily of cysteine-like proteases. Although SUB1 release results in RBCM poration and the
disruption of the PVM (Thomas et al., 2018), the mechanisms behind this remain unclear.
Once the PVM ruptures, the parasites are released into the RBC cytosol where mero-
zoite surface-bound processed MSP1 is able to bind to and destabilise the erythrocyte
spectrin cytoskeleton (Das et al., 2015). Cleavage of β-spectrin by the catalytically act-
ive SERA6 leads to further disruption of the cytoskeleton and results in disruption of the
RBCM. The cysteine protease inhibitor E64, which is believed to inhibit SERA6, inhibits
RBCM rupture once the PVM has ruptured (Hale et al., 2017). Proteases found in the
erythrocyte, such as calpain-1, which is activated by elevated levels of calcium, are also
involved in facilitating parasite egress (Chandramohanadas et al., 2009). Unlike SERA6;
SERA5 does not display any proteolytic activity, due to the substitution of the catalytic
cysteine for a serine residue (Stallmach et al., 2015). However, SERA5 plays an im-
portant role in regulating the kinetics of egress, since disruption of SERA5 results in the
premature and inefficient egress of merozoites (Collins et al., 2017). Finally, once the
RBCM ruptures, merozoites are released into the blood stream where they are able to
invade erythrocytes to initiate another replicative growth cycle.
1.5.2 Invasion
Upon release into the blood stream, merozoites quickly identify and invade erythrocytes
(Figure 1.4). The initial attachment of merozoites to RBCs is believed to be mediated by
various MSPs however, the receptors that MSPs bind to remain elusive. The cysteine
protease dipeptidyl aminopeptidase 3 (DPAP3) is also involved in mediating initial attach-
ment to the RBC (Lehmann et al., 2018). Upon initial contact, the parasite induces weak
deformations in the erythrocyte (Weiss et al., 2015) and utilise another subset of spe-
cialised apical organelles called rhoptries; resulting in the release of adhesins which are
concentrated at the apcial end on the surface of the merozoite. The maturation of rhoptry
proteins, including rhoptry associated protein 1, is mediated by plasmepsin IX and is
essential for invasion (Pino et al., 2017; Nasamu et al., 2017). Two classes of merozo-
ite adhesins are involved in tight attachment to the erythrocyte including the reticulocyte
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binding-like homologous proteins (RHs) which are rhoptry-derived; and the erythrocyte-
binding antigens or ligands (EBAs or EBLs) which are micronemal proteins. These ad-
hesins play an essential role during invasion by binding to receptors on the surface of the
erythrocyte, however there is redundancy between invasion pathways (Lopaticki et al.,
2011). One exception is RH5 (Baum et al., 2009), which binds to the basigin receptor on
the surface of the erythrocyte (Crosnier et al., 2012) and is the only non-redundant ligand
required for invasion. This interaction results in the formation of a pore between the para-
site and erythrocyte (Weiss et al., 2015; Volz et al., 2016) and the release of the contents
of the rhoptry bulb (Weiss et al., 2015). RH5 forms a complex with PfRH5-interacting
protein (PfRipr) and cysteine-rich protective antigen (CyRPA) (Chen et al., 2011; Reddy
et al., 2015). Although PfRipr and CyRPA do not bind to the erythrocyte, they play a
role in establishing tight junction formation (Volz et al., 2016). Upon tight attachment, the
parasite induces strong deformations in the RBC (Weiss et al., 2015) and is able to re-
orientate itself such that the apical end is facing the erythrocyte membrane. The rhoptry
neck (RON) protein RON2, which is injected into the surface of the erythrocyte, forms a
complex with RON4 and RON5 (Cao et al., 2009). RON2 binds to AMA1 on the surface
of the parasite (Cao et al., 2009; Lamarque et al., 2011), marking the tight junction and
committing the parasite to invasion (Srinivasan et al., 2011). Ligand-receptor interac-
tions, such as EBA175 binding to glycophorin A (GPA) on the RBC surface, also mediate
changes in the biophysical properties of the host cell, priming the erythrocyte for invasion
(Koch et al., 2017).
The parasite then pushes its way into the RBC via substrate-dependent motility powered
by the glideosome (Figure 1.5), which is localised between the parasite plasma mem-
brane (PPM) and IMC. The glideosome consists of a class XIV actomyosin motor, Myosin
A (MyoA) (Pinder et al., 1998), essential light chain (ELC) (Green et al., 2017; Bookwalter
et al., 2017), Myosin A-tail interacting protein (MTIP) (Bergman, 2003); known as ELC1 in
Toxoplasma, and the glideosome-associated proteins GAP40, GAP45 and GAP50 (Baum
et al., 2005; Frénal et al., 2010; Gaskins et al., 2004). MTIP and ELC bind to the tail re-
gion of MyoA (Green et al., 2006) and recruit it to GAP45, which tethers the PPM to the
IMC (Rees-Channer et al., 2006). This complex then interacts with the integral IMC pro-
teins GAP50 and GAP40 to form the assembled glideosome (Gaskins et al., 2004). Force
generated by the motor translocates actin filaments tethered to extracellular receptors via
the glideosome-associated connector (GAC) (Jacot et al., 2016) rearwards towards the
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Figure 1.4. Schematic of merozoite invasion. A. The parasite forms initial attachment to the
RBC which can occur in any orientation. This triggers the secretion of the rhoptries. B. The
merozoite forms tight attachment via interactions between EBL and RH proteins and ligands on
the surface of the RBC. The merozoite deforms the RBC as it reorientates itself. C. The tight
junction forms, making a molecular seal between the parasite and the RBC. D. As the merozoite
pushes itself into the RBC by force generated by the actomyosin motor, adhesins on its surface
are shed by several proteases. E. The RBC reseals its membrane and undergoes echinocytosis
once the parasite has fully invaded. The parasite secretes dense granules shortly after invasion
is complete.
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basal end of the parasite. This results in the forward propulsion of the parasite into the
erythrocyte. Disruption of the actin cytoskeleton with compounds such as cytochalasin B,
cytochalasin D or jasplakinolide prevents deformation of the RBC (Weiss et al., 2015) and
parasite invasion (Miller et al., 1979; Mizuno et al., 2002) suggesting that the actomyosin
motor is involved in this process. The role of the glideosome in invasion was definitively
shown by the conditional deletion of MyoA (Robert-Paganin et al., 2019) and GAP45
(Perrin et al., 2018). Parasites lacking either of these glideosome components were able
to egress, but remained attached to the erythrocyte and were unable to deform the cell
or invade.
Figure 1.5. Schematic representation of the glideosome in P. falciparum merozoites.
Located at the parasite periphery, the glideosome is required for generating the force required for
Plasmodium merozoite invasion of RBCs and also generates gliding motility seen in other
Apicomplexans. It comprises MyoA, MTIP, ELC, GAP40, GAP45 and GAP50 which are
anchored in the IMC. The glideosome generates force by propelling f-actin, which in turn is linked
to adhesins on the surface of the parasite via GAC, to the posterior end of the parasite.
As the parasite pushes its way into the erythrocyte, it forms the PV and PVM which is
made primarily from lipids stored in the rhoptry bulb, however it is possible that RBC-
derived lipids also contribute to the PVM (Sherling and van Ooij, 2016). As the tight junc-
tion moves over the merozoite, rhomboid proteases (ROM1 and ROM4) cleave proteins
on the surface of the merozoite such as EBA175 and AMA1 within their transmembrane
30
domains (O’Donnell et al., 2006; Olivieri et al., 2011), shedding them into the super-
natant. SUB2, also acts as a sheddase, cleaving proteins such as AMA1 as it translo-
cates from the apex to the basal end of the merozoite (Harris et al., 2005; Child et al.,
2013). Once the parasite is fully within the erythrocyte, the RBC undergoes echinocyt-
osis, which is characterised by small unevenly distributed projections giving it a spiky
appearance, which is thought to trigger resealing of the RBCM (Gilson and Crabb, 2009).
Once invasion is complete, the parasite secretes another set of specialised secretory
organelles called dense granules. Dense granules contain several components of the
Plasmodium translocon of exported proteins (PTEX) complex (Bullen et al., 2012), which
is found in the PVM and is involved in exporting proteins from the PV into the erythrocyte
(de Koning-ward et al., 2009; Elsworth et al., 2014; Beck et al., 2014).
1.6 Signalling pathways coordinate key life cycle events
Cell signalling pathways orchestrate fundamental processes required for cell survival by
allowing cells to sense their surroundings and mediate internal responses. Usually, this
requires a receptor found at the cell plasma membrane, which can bind extracellular
signalling molecules or ligands. Once the receptor is activated, it is able to trigger a
cascade of events that leads to a cellular response. 3’,5’-cyclic adenosine monophos-
phate (cAMP), 3’,5’-cyclic guanosine monophosphate (cGMP), calcium (Ca2+), inositol
1,4,5-triphosphate (IP3) and diacylglycerol (DAG), act as second messengers, amplify-
ing the signal cascade by activating proteins or by opening ion channels. Phosphoryla-
tion is an important reversible post-translational modification, which plays a central role
in signal transduction pathways, and is mediated by kinases and phosphatases, which
phosphorylate and dephosphorylate proteins, respectively. Phosphorylation introduces a
charged hydrophilic group to amino acid residues, potentially changing a protein’s struc-
ture or producing binding sites to interact with other proteins. As a result, this can mod-
ulate the activity of a protein or modify its function. Cross-talk between different sig-
nalling pathways allows cells to integrate several signals to form complex signalling net-
works. Tight spatiotemporal coordination of key stages throughout the malaria life cycle
is achieved through intracellular signal transduction pathways such as cyclic nucleotide,
phosphoinositide and calcium signalling.
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1.7 Cyclic nucleotide signalling
cGMP and cAMP signalling are known to regulate a wide range of processes includ-
ing retinal phototransduction (Zhang and Cote, 2005), chemotaxis (Loomis, 2014), and
smooth muscle relaxation (Eckly-Michel et al., 1997) to name a few. Adenlylyl cyclases
(ACs) catalyse the formation of cAMP from adenosine triphosphate (ATP), while guanylyl
cyclases (GCs) catalyse the formation cGMP from guanosine triphosphate (GTP). Cyclic
nucleotides are hydrolysed and inactivated by phosphodiesterases (PDEs), which can
be dual- or mono-specific. The level of cyclic nucleotide in the cell is tightly regulated
by the opposing activity of cyclases and PDEs. However, once the level of cyclic nucle-
otide reaches a critical threshold within the cell, cAMP and cGMP activate their respect-
ive kinases, cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase
(PKG). These serine/threonine kinases are then able to phosphorylate many downstream
targets, initiating a cascade of events that culminate in a cellular response. Plasmodium
parasites encode components of both cAMP and cGMP signalling pathways including
two ACs, two GCs, four PDEs, one PKG and both the catalytic and regulatory subunits of
PKA (Baker et al., 2017a).
1.7.1 Adenylyl Cyclases
Plasmodium parasites encode two ACs; ACα (PF3D7_1404600) and ACβ (PF3D7_0802600),
which are structurally divergent from mammalian ACs and from each other (Baker and
Kelly, 2004). ACα contains 6 N-terminal transmembrane domains, which share homo-
logy with voltage-gated potassium (K+) channels; and a single C-terminal catalytic do-
main which contains all the canonical residues required for cAMP synthesis. In order to
form a functional AC, it must homodimerize to form an active catalytic site. Although the
cAMP activity of PfACα has been confirmed by expression in Dicyostelium and Xenopus
oocytes (Muhia et al., 2003), the activity of the putative voltage-gated potassium channel
has not yet been demonstrated (Weber et al., 2004). Work on an AC found in Para-
mecium, which possesses similar domain architecture to ACα, has demonstrated that
it acts as both a voltage-gated potassium channel and an adenylyl cyclase (Schultz
et al., 1992). Therefore it is possible that the seemingly bifunctional nature of ACα-
could couple changes in environmental ion concentrations to cAMP production (Baker
and Kelly, 2004). ACα can form several splice variants with varying numbers of trans-
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membrane domains (Muhia et al., 2003), however it remains unclear whether these splice
variants are translated. It is maximally transcribed in stage V gametocytes, however tran-
scripts can also be detected in ookinetes and sporozoites (López-Barragán et al., 2011;
Zanghì et al., 2018). ACα-deficient P. berghei parasites show normal blood-stage growth
and development in the mosquito, however sporozoites show reduced infectivity of cul-
tured hepatocytes and mice due to the inability to secrete apical organelles (Ono et al.,
2008).
ACβ (PF3D7_0802600) is a soluble cyclase, with two pseudosymmetrical catalytic do-
mains, and is an orthologue of bicarbonate-sensitive mammalian soluble ACs. High levels
of mRNA can be detected in blood-stage schizonts (Salazar et al., 2012). Recent work
has confirmed that ACβ is the only AC capable of producing cAMP in blood-stage P.
falciparum parasites and demonstrated that it is essential for merozoite invasion of eryth-
rocytes, however ACβ-null parasites also showed an egress delay (Patel et al., 2019).
PfACβ colocalises with armadillo repeats only protein (ARO) (Patel et al., 2019), indic-
ating localisation to the rhoptries (Cabrera et al., 2012). In Toxoplasma, ARO mediates
apical localisation of rhoptries (Mueller et al., 2013), however whether it performs a sim-
ilar function in Plasmodium remains to be determined.
The only predicted cAMP effectors encoded by Plasmodium parasites are PKA and a
protein called Epac that contains putative cAMP-binding domains. Although previous
reports suggest that Epac is involved in the release of calcium and micronemes from
merozoites and is required for invasion (Dawn et al., 2014), Epac can be knocked out
and is not required for asexual growth in P. falciparum (Patel et al., 2019) and readily
undergoes truncation in culture adapted isolates (Claessens et al., 2017). Therefore al-
though Epac is not required for in vitro growth, it remains unclear whether it is essential
for other stages of the life cycle.
1.7.2 Guanylyl Cyclases
Plasmodium falciparum encodes two guanylyl cyclases; GCα (PF3D7_1138400) and
GCβ (PF3D7_1360500), which are closely related to one another (Carucci et al., 2000).
They are large integral membrane proteins which display a number of unusual character-
istics. The GC domains consist of two catalytic domains (C1 and C2), each preceded by a
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set of 6 transmembrane domains. Although the catalytic domains share structural homo-
logy to mammalian G-protein dependent adenylyl cyclases, the purine-binding residues
are consistent with those found in GCs rather than ACs. The GC activity of GCβ has
been confirmed by recombinant expression of the catalytic domains in E. coli (Carucci
et al., 2000), however neither AC nor GC activity have been demonstrated for GCα, but
the presence of purine-binding residues that are characteristic of GCs strongly suggests
that like GCβ, GCα is a functional GC. Remarkably, the N-terminal portion of Plasmodium
GCs contain a P-Type ATPase-like domain which contains a further 10 transmembrane
domains. The functional role of the ATPase remains unknown, and although it resembles
calcium transporting ATPases, key residues required for ion transport are absent (Baker
and Kelly, 2004). Instead, it has been suggested that this domain may be involved in
phospholipid transfer as the ATPase shares closest homology to aminophospholipid flip-
pases (type IV ATPases) and therefore could be involved in regulating phosphatidylserine
(PS) or phosphatidylethanolamine (PE) asymmetry across the membrane in which it is
located; or it may also play a role in regulating the activity of the GC domain. In other or-
ganisms, type IV ATPases form complexes with cell division control 50 (CDC50) proteins,
which are required for correct trafficking from the ER to the PM (Andersen et al., 2016).
Therefore it is likely that Plasmodium GCs form an interaction with CDC50 proteins; three
of which are encoded by the parasite. The bifunctional nature of Plasmodium GCs is con-
served in alveolates, including other apicomplexans such as Toxoplasma and the ciliates
Paramecium and Tetrahymena (Linder et al., 1999), which may signify a functional link
between these two domains. The transcriptional profiles of GCα and GCβ vary across
the different stages of the P. falciparum lifecycle (López-Barragán et al., 2011; Zanghì
et al., 2018). While GCα is maximally transcribed in late trophozoites and schizonts, with
transcripts also detected in gametocytes and ookinetes; GCβ transcripts are found at low
levels during the asexual stages and predominate in stage V gametocytes and ookinetes.
GCβ knockout lines have been generated in P. falciparum, P. berghei and P. yoelii, with
no phenotype observed up to and including gametocytogenesis (Hirai et al., 2006; Taylor
et al., 2008; Moon et al., 2009; Gao et al., 2018). However, in P. berghei and P. yoelii,
ookinete motility and mosquito midgut invasion were impaired (Hirai et al., 2006; Moon
et al., 2009; Gao et al., 2018). In P. yoelii GCβ localises to a site posterior to the apical
structure in the plasma membrane of mature ookinete where it creates local elevated
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levels of cGMP, activating PKG and stimulating ookinete gliding (Gao et al., 2018). This
study also revealed that the ATPase domain of GCβ, which is a pseudo ATPase since it
lacks several residues required for ATPase activity, is required for the correct localisation
of the GC domain to stimulate ookinete motility. Interaction between GCβ and CDC50.A
is also required for cGMP production, since the latter acts as a chaperone which stabil-
ises GCβ (Gao et al., 2018).
Although recent whole genome screens in P. falciparum (Zhang et al., 2018) and P.
berghei (Bushell et al., 2017) indicate that GCα is dispensable for asexual growth, re-
peated attempts to disrupt GCα in both these species have been unsuccessful, suggest-
ing an essential function during the asexual blood stage (Taylor et al., 2008; Moon et al.,
2009; Kenthirapalan et al., 2016). Using an antibody raised against the C2 domain of
GCα, the protein was detected by immunoelectron microscopy in the parasitophorous
vacuole (PV) or plasma membrane region of gametocytes, however it was not detected
in schizonts (Carucci et al., 2000) despite being the only predicted GC expressed dur-
ing the blood-stages. P. falciparum gametocyte membrane fractions display GC activity,
which is further stimulated by the addition of XA (Muhia et al., 2001). Further work will
be required to validate whether GCα is required for cGMP production in schizonts and to
determine the functional role of the ATPase domain.
Recent work in Toxoplasma gondii has shed further light on the unique biology of api-
complexan GCs. Toxoplasma encodes a single GC, which shares greater homology to
Plasmodium GCα, and localises to the PM at the basal and apical ends of the tachyzoites
(Jia et al., 2017; Brown and Sibley, 2018; Yang et al., 2019; Günay-Esiyok et al., 2019).
Conditional knockdown of TgGC revealed that it is responsible for cGMP production which
is required for parasite egress, calcium release, microneme exocytosis, motility, host cell
attachment and invasion. TgGC requires interaction with a CDC50 protein in addition to
unique GC organiser (UGO), which act as chaperones for the ATPase and GC domains,
respectively (Bisio et al., 2019). The ATPase domain is required for targeting TgGC to the
apical end of the parasite (Brown and Sibley, 2018) and mutagenesis of key residues re-
quired for ATPase activity inhibit microneme release and lytic growth (Brown and Sibley,
2018; Bisio et al., 2019). GC-mediated phospholipid flipping activity could not be detec-
ted (Bisio et al., 2019), however TgGC seems to be involved in sensing extracellular pH
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and K+ levels (Yang et al., 2019) as well as phosphatidic acid (PA) (Bisio et al., 2019), all
of which are able to trigger Ca2+ release.
1.7.3 Phosphodiesterases
The Plasmodium genome encodes 4 PDEs (α, β, γ and δ), all of which contain up to
six N-terminal transmembrane domains and a C-terminal catalytic domain which can be
either dual specific or show selective cGMP hydrolytic activity. Plasmodium PDEs are
expressed at specific stages of the life cycle, with PDEα (PF3D7_1209500) and PDEβ
(PF3D7_1321500) transcripts predominantly found in schizonts, PDEγ (PF3D7_1321600)
in sporozoites and PDEδ (PF3D7_1470500) in gametocytes (López-Barragán et al., 2011;
Zanghì et al., 2018). PDE inhibitors such as Zaprinast and BIPPO show activity against
Plasmodium PDEs, and have been useful tools for studying cyclic nucleotide signalling in
the parasite.
PDEβ is the only PDE required for asexual growth. Conditional deletion of PfPDEβ res-
ults in a premature rise in cAMP levels in schizonts, leading to hyper-activation of PKA
which leads to dysregulated phosphorylation of several substrates and a severe invasion
defect (Flueck et al., 2019). Although a small proportion of PDEβ-null parasites were able
to invade, they were unable to develop and died shortly post-invasion. PDE assays on
affinity-purified PDEβ showed that it can hydrolyse both cAMP and cGMP (Flueck et al.,
2019), while PDEα is only capable of hydrolysing cGMP, and is not required for asexual
growth (Wentzinger et al., 2008). Deletion of PDEγ in P. yoelii had a mild affect on asexual
growth resulting in a 2-fold reduction in parasitemia, but did not affect gametocyte devel-
opment or sporozoite formation. However PDEγ-deficient sporozoites exhibited elevated
levels of cGMP and impaired substrate-dependent gliding motility which impaired their
ability to infect salivary glands in mosquitos (Lakshmanan et al., 2015). Since cAMP
levels were not measured in PDEγ-null parasites, it remains unclear whether it is a dual
specific PDE. Both P. falciparum and P. berghei PDEδ knockouts have been generated,
demonstrating that it is not required for asexual growth (Taylor et al., 2008; Moon et al.,
2009). In P. falciparum, PDEδ-deficient gametocytes were able to develop normally, but
displayed a significant increase in cGMP levels and impaired gametogenesis upon stim-
ulation with XA (Taylor et al., 2008). These parasites were able to round up, but could not
emerge from the erythrocyte and male gametes displayed reduced exflagellation. In con-
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trast, P. berghei PDEδ-deficient parasites were able to undergo gametogenesis normally,
however ookinete development was severely affected whereby ookinetes dedifferentiated
into stumpy forms that did not display gliding motility (Moon et al., 2009).
1.7.4 PKG
Plasmodium species encode a single PKG (PF3D7_1436600), which is the only known
cGMP effector protein in the parasite. Unlike mammalian PKGs, which possess two
cGMP-binding domains and are able to form dimers, Plasmodium PKG is expressed as
a monomer, consisting of an N-terminal regulatory domain and a C-terminal catalytic
domain which contains four cGMP-binding domains (A, B, C and D) (Deng and Baker,
2002). However, only three of these domains display cGMP binding, since domain C
is degenerate (Deng et al., 2003). At low concentrations of cGMP, PKG is inactive due
to the docking of an autoinhibitory segment to the kinase domain (Bakkouri et al., 2019).
When cGMP levels rise, cooperative binding of cGMP results in a series of conformational
changes that leads to the release of the autoinhibitory segment to expose the active site,
and the formation of a capping triad which stabilises the active form of the protein (Kim
et al., 2015). Once activated, PKG can bind to and phosphorylate substrates.
PKG is maximally transcribed in schizonts, however transcripts can also be detected
in gametocytes and ookinetes (López-Barragán et al., 2011; Zanghì et al., 2018). PKG
is refractory to deletion in both P. falciparum and P. berghei, suggesting an essential role
during the blood-stage of infection. However, highly specific reversible ATP-competitive
inhibitors of PKG, including C1 (a pyrrole) (Gurnett et al., 2002) and C2 (an imidazo-
pyridine) (Donald et al., 2006) mentioned previously, have been instrumental in elucidat-
ing the precise role of PKG throughout the life cycle. In apicomplexan PKGs, the gate-
keeper residue of the ATP-binding site is a small threonine residue, which accommodates
the binding of these inhibitors. However, mammalian PKGs possess a bulkier gatekeeper
residue, preventing these inhibitors from accessing the gatekeeper pocket. Substitution
of the gatekeeper residue with a bulkier glutamine residue (T618Q) renders transgenic
parasites resistant to both inhibitors (McRobert et al., 2008; Brochet et al., 2014). The
use of these inhibitors in conjunction with wild type and PKG(T618Q) transgenic parasites
confirmed that PKG is the primary target of these inhibitors, however there is evidence
that C2 can also target calcium-dependent protein kinase (CDPK4) (McRobert et al.,
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2008; Fang et al., 2018), which also harbours a small gatekeeper residue adjacent to the
ATP-binding site.
In schizonts, PfPKG is mainly cytosolic with a small subpopulation that also associ-
ates with the endoplasmic reticulum (ER) (Hopp et al., 2012). Treatment with C2 or the
destabilisation of PKG blocks merozoite egress (Collins et al., 2013b; Ganter et al., 2017).
These parasites are unable to undergo microneme and exoneme secretion, and are un-
able to disrupt the PV (Hale et al., 2017). C2 treatment also prevents the hydrolysis of IP3
and the release of calcium from internal stores (Brochet et al., 2014). Quantitative global
phosphoproteomics of C2-treated WT and PKG(T618Q) parasites identified 69 proteins
that are phosphorylated in a PKG-dependent manner (Alam et al., 2015). These proteins
are involved in diverse cellular processes including egress, invasion, motor function, tran-
scriptional regulation and proteolysis. Furthermore, several PKG-dependent phosphos-
ites were identified in ACβ, GCα and PDEβ, possibly pointing towards a feedback loop
between components of cAMP and cGMP signalling (Baker et al., 2017a). However, the
exact role of these phosphorylation events in mediating egress and invasion remain un-
clear.
In gametocytes, XA-mediated rounding up and emergence from the host erythrocyte is
PKG-dependent and also acts upstream of calcium release, which is essential for ex-
flagellation (McRobert et al., 2008; Brochet et al., 2014). The inhibition of PKG also
blocks ookinete and sporozoite motility, as well as hepatocyte invasion (Moon et al., 2009;
Brochet et al., 2014; Govindasamy et al., 2016). Deletion of PKG in sporozoites, via a
temperature sensitive recombinase, revealed its involvement in the release of merosomes
from hepatocytes (Falae et al., 2010). The timing of PKG activation seems to be crucial,
since premature activation of PKG in PDEδ knockout ookinetes resulted in dedifferen-
tiation of the parasites. This phenotype could be reversed by the addition of C1 or by
deletion of GCβ in PDEδ-deficient parasites (Moon et al., 2009).
1.7.5 PKA
Plasmodium PKA consists of a regulatory domain (PKAr) containing two cAMP-binding
sites and a catalytic domain (PKAc), which are encoded by two separate genes
(PF3D7_1223100 and PF3D7_0934800, respectively). In its inactive form, PKAc is bound
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by PKAr, forming a heterodimer. Binding of cAMP to PKAr results in the release of PKAc,
which can then bind to and phosphorylate substrates.
PKAc and PKAr show similar expression profiles. They are maximally transcribed in
schizonts and sporozoites, however transcripts can also be detected in trophozoites,
gametocytes and ookinetes (López-Barragán et al., 2011; Zanghì et al., 2018). Con-
ditional deletion of PKAc in P. falciparum revealed that similar to ACβ, it is essential for
merozoite invasion, and does not affect calcium release or any of the steps leading up to
and including egress (Patel et al., 2019). Quantitative phosphoproteomics of both ACβ
and PKAc knockout lines identified several proteins which are phosphorylated in a cAMP-
dependent manner, including the cytoplasmic tail of AMA1, which has been previously
reported to be PKA-dependent and important for efficient invasion (Leykauf et al., 2010).
Interestingly, Patel et al. also showed that ACβ and PKAc-deficient parasites showed
reduced shedding of AMA1. Conversely, elevated levels of cAMP in PDEβ-deficient para-
sites, resulted in premature shedding of AMA1 (Flueck et al., 2019). Therefore it is likely
that cAMP-mediated signalling plays a critical role in regulating the shedding of AMA1.
PKA may also play a role in regulating gametocytogenesis, since gametocyte produ-
cing lines show higher PKA activity than non-gametocyte producing lines (Read and
Mikkelsen, 1991). While addition of cAMP has been reported to induce gametocyto-
genesis (Kaushal et al., 1980), attempts to reproduce these experiments have proved un-
successful and resulted in an inhibition of gametogenesis and asexual growth (Inselburg
and Banyal, 1984). Therefore it remains unclear whether PKA is involved in commitment
to gametocytogenesis. A recent study conducted in P. berghei demonstrated that PKAc-
deficient sporozoites are still able to glide and invade hepatocytes, eventually releasing
merosomes. However, merozoites were unable to invade erythrocytes (Choudhary et al.,
2019). Therefore it appears that PKA is not required for pre-erythrocytic stages.
1.8 Calcium signalling
Ca2+ is a ubiquitous signalling molecule that regulates a diverse range of cellular func-
tions including cell motility, growth and differentiation (Bootman et al., 2015). Cells main-
tain low cytosolic calcium concentrations by actively pumping calcium ions outside of the
cell via plasma membrane Ca2+ pumps (PMCAs) and into intracellular stores such as
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the endoplasmic reticulum (ER) via sarcoendoplasmic reticular Ca2+ ATPases (SERCA
pumps). Specific signals can trigger the release of Ca2+ from the ER through ryanod-
ine receptors (RyR), which are activated by elevated levels of Ca2+; and IP3 receptors
(IP3R), which are activated upon binding of IP3, a second messenger which is produced
by the hydrolysis of inositol(4,5)-bisphosphate (PIP2) by phospholipase c (PLC). Once in
the cytosol Ca2+ is able to bind to and activate various effector molecules, many of which
possess common Ca2+ binding motifs including EF hand and C2 domains.
Compared to other eukaryotes, Plasmodium species possess a smaller repertoire of
calcium-related genes, with a vast majority that remain poorly characterised (Moreno
et al., 2011). At least two P-type ATPase Ca2+ pumps are encoded by the parasite, in-
cluding ATP4, a non-SERCA subclass unique to apicomplexans; and ATP6, a canonical
SERCA pump (Krishna et al., 2001). However, genes encoding canonical IP3 or ryanod-
ine receptors have not been identified, despite pharmacological evidence of IP3-mediated
Ca2+ release (Passos and Garcia, 1998; Alves et al., 2011). Plasmodium parasites also
encode around 30 proteins with putative Ca2+ binding domains including seven Ca2+-
dependent protein kinases (CDPKs) and three protein phosphatases.
CDPKs are serine/threonine kinases found in plants and alveolates, which consist of
an N-terminal catalytic domain, an autoinhibitory domain, and a C-terminal calmodulin-
like domain which contains several Ca2+ binding sites (Moreno et al., 2011). CDPKs
display stage-specific expression patterns (López-Barragán et al., 2011; Zanghì et al.,
2018). CDPK7 appears to be involved in early intraerythrocytic development from rings to
trophozoites, with disruption of CDPK7 resulting in reduced growth (Kumar et al., 2014).
CDPK1 is refractory to knockout, however work on TgCDPK3, its homologue in Toxo-
plasma, revealed that TgCDPK3 is involved in calcium-induced egress and also appears
to modulate the activity of the actomyosin motor by phosphorylating Myosin A (Gaji et al.,
2015). In blood-stages, conditional disruption of PfCDPK5 lead to a block in microneme
release and egress (Dvorin et al., 2011; Absalon et al., 2018). This egress block appears
to act downstream of PKG activity, since exoneme release was unaffected. Mechanic-
ally released CDPK5-depleted parasites were however able to secrete micronemes and
invade erythrocytes, while C2-treated parasites were unable to secrete micronemes or
invade (Absalon et al., 2018). Another Ca2+-binding protein, double C2 (DOC2), also ap-
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pears to be required for microneme secretion in P. falciparum (Farrell et al., 2012). How-
ever, while DOC2-depleted parasites were still able to egress, they could not invade. It
is likely that DOC2 facilitates microneme-plasma membrane fusion and acts downstream
of CDPK5. The homologue of CDPK4 in Toxoplasma (TgCDPK1) is required for parasite
motility, egress and invasion (Lourido et al., 2010), however disruption of CDPK4 in P.
falciparum and P. berghei did not affect asexual growth (Dvorin et al., 2011; Billker et al.,
2004). Instead, CDPK4 was required for cell cycle progression in male gametocytes
upon XA mediated activation in P. berghei (Billker et al., 2004). Disruption of CDPK2 in
P. falciparum revealed that it is required exflagellation (Bansal et al., 2017). In P. berghei
CDPK3 is required for ookinete motility and penetration of mosquito midgut wall to form
oocysts (Ishino et al., 2006; Moon et al., 2009).
Calcium signalling is also involved in regulating several steps during invasion. Merozoites
require Ca2+ release for microneme secretion and invasion. This can be triggered by ex-
posing merozoites to low concentrations of K+, which mimic extracellular conditions in the
blood plasma (Singh et al., 2010). Basal calcium levels are then restored once EBA175
interacts with its receptor on the surface of RBCs. Merozoite attachment to erythrocytes
appears to require calcineurin, a Ca2+-regulated phosphatase which stabilises the inter-
action between parasite adhesins and RBC receptors (Paul et al., 2015).
1.9 Signalling pathways as drug targets
Signalling pathways in the malaria parasite have garnered great research interest due
to the critical roles that they play across all stages of the lifecycle. The use of chemical
tools and reverse genetics approaches have greatly improved our understanding of how
components of cGMP, cAMP and Ca2+ signalling, shown in figure 1.5, regulate egress
and invasion. The essential nature of many of these signalling components, coupled
with their divergent structure from their human orthologues, make them attractive drug
targets. As such, components of signalling pathways have been the focus of several drug
discovery programmes (Baker et al., 2017b; Penzo et al., 2019). Future work on these
signalling pathways may pave the way for the discovery of novel drugs with distinct modes
of action in the fight against antimalarial drug resistance.
41
Figure 1. 6. Schematic representation of the components of cAMP, cGMP and Ca2+
signalling in Plasmodium merozoites.
1.10 Project aims and objectives
Although several of the key signalling components utilised by the parasite during egress
and invasion have been identified, there remain gaps in our understanding of how both
these processes are regulated. For example, the initial signal which triggers egress re-
mains unknown. Work in Toxoplasma has revealed that this role may in part be fulfilled by
TgGC which can sense changes in pH, K+ and PA levels (Yang et al., 2019; Bisio et al.,
2019), leading to the activation of cGMP-signalling which triggers a cascade of events
leading to parasite egress. Whether GCα performs a similar function in Plasmodium
parasites remains unclear since it is refractory to deletion. Furthermore, although sev-
eral proteins are phosphorylated as a result of cGMP, cAMP and Ca2+ signalling, the
exact role of each of these phosphorylation events remains unclear. As mentioned pre-
viously, several proteins were identified in a phosphoproteome as being phosphorylated
in a PKG-dependent manner (Alam et al., 2015). One protein that particularly stands
out is MyoA, which was identified as being phosphorylated at a single site on serine 19
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in a cGMP-dependent manner. Intriguingly, phosphorylation of the equivalent residue in
Toxoplasma (serine 21) appears to be important for parasite motility and egress (Tang
et al., 2014; Gaji et al., 2015). A recent study has shown that mutation of the S19 phos-
phosite in recombinant PfMyoA results in greatly reduced motor speed (Robert-Paganin
et al., 2019), however it is unknown whether this phosphorylation of MyoA is required for
blood-stage growth. This project therefore set out to functionally characterise GCα and
to investigate the role of cGMP-dependent phosphorylation of MyoA at serine 19 in P.
falciparum parasites.
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2 Methods
2.1 Parasite culture
2.1.1 Asexual stage culture
P. falciparum asexual blood stages of various 3D7 background strains were cultured in
human erythrocytes of various blood groups (National Blood Transfusion Service, Lon-
don, United Kingdom) and complete medium (CM) consisting of RPMI-1640 medium (Life
Technologies) supplemented with 0.5% AlbuMAX type II (Gibco), 50 µM hypoxanthine
and 2 mM L-glutamine. Parasite cultures were incubated at 37◦C and gassed with 90%
N2, 5% CO2 and 5% O2 according to standard procedures (Trager and Jensen, 1976).
Parasitemias were routinely monitored by light microscopy examination of thin blood films
fixed with 100% methanol and stained with 10% Giemsa stain in 1x phosphate buffer (8
mM KH2PO4, 6 mM Na2HPO4, pH 7.0).
2.1.2 Gametocyte induction and culture
An adapted version of previously described techniques (Fivelman et al., 2007) was used
to obtain synchronous gametocytes. Briefly, highly synchronous ring-stage parasites at
8-10% parasitemia, 4% hematocrit were stressed by retaining half the spent culture me-
dium and replenishing the rest with fresh CM. The following day, the ’stressed’ cultures
were split to achieve a parasitemia of 2.5% at 4% hematocrit, once again retaining half
the spent CM and replenishing the rest with fresh CM. Cultures were left shaking until
the following day when all the schizonts had ruptured and reinvaded. A certain propor-
tion of the reinvaded rings should then have committed to gametocytogenesis. From
this point onwards, parasite culture medium was exchanged daily with pre-warmed CM
supplemented with heparin at 20 units/ml to prevent asexual growth.
2.1.3 Inducing gametogenesis
Mature stage V gametocytes were resuspended in RPMI containing 100 µM xanthurenic
acid (XA) containing 0.5 µg/ml α-Pfs25 and incubated at room temperature overnight.
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2.1.4 Synchronisation
Tightly synchronous parasites were obtained by purifying segmented schizonts on a 70%
Percoll (GE Healthcare) cushion and allowing them to invade fresh erythrocytes for 1-2
hours while shaking. This was followed by lysis of unruptured schizonts by treating with
5% D-sorbitol (Sigma) for 10 minutes (Lambros and Vanderberg, 1979) to obtain highly
pure and synchronous ring stage cultures.
2.1.5 Preparation and purification of merozoites
Schizonts from tightly synchronised cultures were purified by magnetic cell separation
(MACS) enrichment (Mata-Cantero et al., 2014) then allowed to rupture in pre-warmed
RPMI for 1 hour while shaking. The culture was run through the MACS column (Miltenyi
Biotech), retaining unruptured schizonts and hemozoin-associated cell debris on the
magnet and allowing merozoites to elute in the flowthrough which was then centrifuged
at 3,500 x g for 10 minutes. Merozoites samples were snap frozen in a dry ice/ethanol
slurry.
2.1.6 Rapamycin treatment of parasites
The dimerisable Cre recombinase (DiCre), which is expressed as two separate inactive
fragments each fused to a rapamycin-binding domain, can be activated in parasites by
treatment with rapamycin. Synchronous ring stage parasites were split and treated for
2-4 hours at 37◦C with either rapamycin at 50 or 100 nM, or the equivalent volume of
DMSO which served as a solvent only control. Parasites were pelleted at 1500 x g and
washed once in RPMI before culturing as standard. Typically 50 nM rapamycin was used
for GCα-related experiments, while 100 nM was used for MyoA-related experiments.
2.1.7 Parasite transfection
Highly synchronous late stage schizonts were used for transfection as previously de-
scribed for P. falciparum (Collins et al., 2013a) using the AmaxaTM 4D-Nucleofector sys-
tem (Lonza). For each transfection 20-50 µg DNA was precipitated by the addition of 0.1
volumes of 0.3 M sodium acetate (pH 5.2) and 2 volumes of 100% ethanol, followed by
a 30 minute incubation at -20◦C. DNA was pelleted by centrifuging at 12,000 x g for 10
minutes then washed twice with 70% ethanol. The DNA pellet was dried and resuspen-
ded in 10 µL Tris-EDTA buffer (TE). 100 µL of supplemented P3 primary cell solution was
45
added to the DNA and used to resuspend 25 µL of schizonts (~1.25x108 cells) obtained
from synchronous culture by Percoll enrichment before transferring to a Nucleocuvette.
Parasites were electroporated using the FP158 setting then transferred back into culture
and placed on the shaker overnight. Appropriate drug selection was applied 24 hours
post transfection, unless otherwise stated.
2.1.8 Cloning parasites by limiting dilution
Clonal parasite lines were obtained by limiting dilution and assessing for single plaque
formation as previously described (Thomas et al., 2016). The hematocrit and parasitemia
of parasite cultures were determined by using a hemocytometer and counting Giemsa-
stained slides. The cultures were diluted to give 0.3 parasites in 200 µl of culture at 1%
hematocrit per well in a 96-well plate. After 9 days, plaque formation was assessed using
an EVOS FL Cell Imaging System. Wells containing single plaques were subsequently
expanded and analysed for integration by PCR.
2.1.9 Drug cycling parasites
To promote the loss of episomes and improve the proportion of parasites that had integ-
rated a drug selection cassette, parasites were cycled on/off drug up to four times. Each
round involved culturing the parasites in the absence of drug for one week, followed by
treating them with the appropriate drug for 5 days.
2.1.10 Preparing parasite samples for western blot and DNA extraction
Parasites were released from erythrocytes by lysing in at least 5 volumes of 0.15%
saponin (Sigma) in PBS containing cOmplete EDTA-free protease inhibitor (Roche) and
1 mM PMSF. The samples were pelleted at 12,000 x g for 1 minute then washed twice in
1x PBS also containing cOmplete EDTA-free protease inhibitor (Roche) and 1 mM PMSF.
The sample pellets were snap frozen in a dry ice/ethanol slurry and stored at -80◦C.
2.2 Parasite Assays
2.2.1 SYBR Green growth inhibition assay
To determine the effect of various test compounds on parasite growth, their half maximal
effective concentration (EC50) values were determined by using the SYBR Green growth
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inhibition assay adapted from (Smilkstein et al., 2004). Test compounds were set as a
series of 2-fold serial dilutions in triplicate in a 96-well plate. Wells containing no drug or
10 nM chloroquine were also included in each plate and served as negative and positive
controls, respectively. Ring stage parasites were added to achieve a starting parasitemia
of 2% at 1% hematocrit and incubated at 37◦C in a sealed gassed chamber. After 72
hours, the assay was terminated by freezing the plates at -20◦C. After thawing the plates,
the parasites were lysed in buffer containing 20 mM Tris, 5 mM EDTA, 0.008% saponin,
0.08% Triton X-100 and 1x SYBR Green I (Molecular Probes) at pH 7.5. After incubating
at room temperature in the dark, SYBR Green fluorescence was measured using a Spec-
tramax M3 plate reader (Molecular Devices) with excitation and emission wavelengths of
485 and 535 nm, respectively. Relative fluorescence units were plotted against the logar-
ithm of drug concentrations in GraphPad Prism version 7. EC50 values were determined
by non-linear regression analysis.
2.2.2 Fluorescence activated cell sorting (FACS) growth assays
Parasites were fixed using high-quality methanol-free 4% formaldehye (Thermo Scientific),
0.1% glutaraldehyde (Sigma) in 1x PBS and stored at 4◦C until required. Cells were
stained with 1x SYBR Green I (Molecular Probes) overnight. The fixative was aspirated
and the cells washed in PBS. The samples were analysed using a BD LSR II flow cyto-
meter (BD Biosciences), with 50,000 events collected for each sample. FlowJo 7 analysis
software (FlowJo LLC) was used to analyse the data. Different assays were adjusted for
starting parasitemias and growth curves were generated using GraphPad Prism version
7.
2.2.3 Calcium release assays
Changes in the levels of intracellular free Ca2+ were measured in Fluo-4-AM loaded ma-
ture P. falciparum schizonts in the presence of the PDE inhibitor, Zaprinast, or the cal-
cium ionophore, A23187. Fluo-4-AM is a non-fluorescen acetoxymethyl ester, which is
cell permeable. De-esterification of Fluo-4-AM traps Fluo-4 inside the cell. Fluo-4 acts as
a calcium indicator since it fluoresces upon binding to free Ca2+.
Mature schizonts from RAP- and DMSO-treated cultures were Percoll enriched and
~1.25x108 cells from each condition were incubated for 45 minutes in 1 ml of phenol
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red free RPMI containing 10 µM Fluo-4-AM (Invitrogen). The parasites were washed
twice in pre-warmed phenol red free RPMI, then incubated for 20 minutes to allow for de-
esterifcation of the AM ester. The parasites were washed twice more, then resuspended
in phenol red free RPMI at 1.25x108 parasites/ml. 100 µl of resuspended parasites were
added to wells on the bottom half of a 96-well plate. 3 wells containing phenol red free
RPMI were also included as a control. Baseline Fluo-4 fluorescence in each well was
read at 22 second intervals for 3 minutes using a Spectramax M3 plate reader (Molecular
Devices) pre-warmed to 37◦C with excitation and emission wavelengths of 483 and 525
nm, respectively. The plate was removed from the reader and the parasites were trans-
ferred to wells containing test compounds at a final concentration of 75 µM for Zaprinast
and 20 µM for A23187. Control wells containing DMSO only were also included as a
control. The plate was placed back in the reader and read at 22 second intervals for a
further 5 minutes. All samples were run in triplicate. Relative fluorescence units from
reads at each time point and condition were averaged and baseline and DMSO control
values subtracted. Plots were generated using GraphPad Prism version 7.
2.2.4 Measurement of intracellular cAMP and cGMP levels
Intracellular cyclic nucleotide levels in mature P. falciparum schizonts were measured us-
ing ELISA-based high-sensitivity direct cAMP and cGMP colorimetric assay kits (Enzo).
Mature schizonts from RAP- and DMSO-treated cultures that were treated with 1.5 µM
compound (C2) overnight were used for the cyclic nucleotide detection assays. Around
1.25x108 cells from each condition were incubated for 3 minutes in RPMI containing 1.5
µM C2 only or in the presence of 75 µM Zaprinast (Sigma) to inhibit PDE activity. Para-
sites were pelleted at 9,000 x g, resuspended in 100 µl of 0.1 M HCl and incubated for
10 minutes at room temperature with intermittent vortexing to complete cell lysis. The
samples were pelleted at 9,000 x g and the supernatant collected and frozen at -80◦C.
Once all biological replicates were collected, each sample was diluted by adding 400 µl
of 0.1 M HCl. Samples and standards were acetylated in order to improve sensitivity,
according to the manufacturer’s instructions.
The detection ranges were 0.078 - 20 and 0.08 - 50 pmol/ml for the cAMP and cGMP
assays, respectively. All samples and standards were set up in duplicate. Absorbance
was measured at 405 nM using a Spectramax M3 plate reader (Molecular Devices). The
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standards were used to plot a standard curve from which the concentrations of cyclic
nucleotides in the parasite samples could be determined. Plots were generated using
GraphPad Prism version 7.
2.2.5 Egress timepoint assays
Mature segmented schizonts treated with 1.5 µM C2 overnight were Percoll enriched
and washed several times in pre-warmed RPMI. Parasites were resuspended in RPMI at
3.25x108 parasites/ml and 65 µl aliquots were dispensed in 5 eppendorf tubes. To harvest
samples at each time point, parasites were pelleted at 9,000 x g and culture supernatants
were purified using 0.22 µm Costar Spin-X centrifuge filters (Corning). The parasite pellet
from the first time point was retained as a parasite loading control. Samples were subject
to western blot analysis, and probed with an α-SERA5 antibody as a measure of schizont
egress.
2.2.6 Extraction of proteins by their solubility profile
Saponin-lysed parasite pellets were repeatedly freeze/thawed after resuspending the
parasite pellets in 4 volumes of hypotonic buffer containing 5 mM Tris and 2 mM MgCl2
(pH 8) supplemented with cOmplete EDTA-free protease inhibitor (Roche) and 1 mM
PMSF. The parasite lysates were centrifuged at 12,000 x g for 10 minutes at 4◦C and
the supernatants collected and stored on ice. The parasite pellet was washed twice in
hypotonic buffer, then lysed in co-immunoprecipitation (CoIP) buffer containing 150 mM
NaCl, 10 mM Tris (pH 7.5), 0.5 mM EDTA and 1% NP40 that was supplemented with
cOmplete EDTA-free protease inhibitor (Roche) and 1 mM PMSF. The parasite lysates
were centrifuged at 12,000 x g for 10 minutes at 4◦C and the supernatants collected and
stored on ice. The hypotonic and NP40 lysates were subjected to western blot analysis.
2.2.7 RNA extraction and reverse transcription quantitative PCR (RT-qPCR)
RNA from saponin-lysed mature schizonts treated with 1.5 µM C2 was extracted with
TRIzol Reagent (Invitrogen) and purified using a Direct-zol RNA Miniprep Plus kit (Zymo
Research) according to the manufacturer’s instructions. In-column deoxyribonuclease I
treatment (Zymo Research) was performed to remove contaminating genomic DNA. RNA
yields were determined using a Nanodrop spectrophotometer (Thermo Fisher Scientific).
Complementary DNA (cDNA) synthesis was performed using 500 ng of RNA from each
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condition using All-in-One cDNA Synthesis SuperMix (Biotool) according to the manu-
facturer’s protocol and diluted 1:20 using nuclease-free water. qPCR was performed
using an ABI PRISM 7500 Fast PCR System (Thermo Fisher Scientific). Each reaction
contained 2 µl of cDNA, 300 nM of each primer and 1x SYBR Green PCR Master Mix
(Biotool) in a total volume of 20 µl. Samples were set up in triplicate, using two different
primer sets specific for MyoA and PDEα that were selected using the Primer3 online tool
(Kõressaar et al., 2018). For each experiment, genomic DNA was set up as a series
of 10-fold serial dilutions (1x106–1x10 copies) in triplicate, to be used as a standard for
absolute quantification of cDNA. The qPCR programme used was 95◦C for 10 minutes
followed by 40 cycles of 95◦C for 15 seconds and 60◦C for 60 seconds. Single amplicons
were detected for each primer pair by thermal melt assay. Under the conditions used, the
primer pair efficiencies were 97.6% and 91.4% for the MyoA and PDEα primer pairs, re-
spectively when tested on a gDNA standard ranging from 1x106 to 1x10 copies. Using the
gDNA standard, absolute quantities of MyoA and PDEα in each sample were calculated
and MyoA levels normalised to PDEα levels. Parasite samples were then normalised to
their matched untreated control.
2.3 Microscopy
2.3.1 Imaging Giemsa-stained blood films
An Olympus BX51 microscope fitted with an Olympus SC30 digital colour camera through
a 100x oil immersion objective was used to image Giemsa-stained blood films. Images
were processed in Graphic (Picta, Inc.).
2.3.2 Live parasite imaging
To image live parasites, a small amount of culture material at 50% hematocrit was added
to a microscope slide and covered with a coverslip and images were acquired using
an EVOS FL cell imaging system. To visualise nuclei, parasites were treated with 1 µ-
g/ml Hoechst 33342 for 5 minutes at 37◦C before imaging. Parasites were incubated
for 5 minutes with 5 µg/ml wheat germ agglutinin (WGA) conjugated to Alexa Fluor 488
(Invitrogen) to stain erythrocyte membranes. To stain female gametes, α-Pfs25 antibody
conjugated to Cy3, kindly provided by Michael Delves (LSHTM, London, UK) was used
at 0.5 µg/ml to stain gametes overnight as previously described (Delves et al., 2013).
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2.3.3 Time-lapse video microscopy
Egress and gametocyte rounding up were monitored by differential interference contrast
(DIC) alone or coupled with fluorescence microscopy using using a Nikon Eclipse Ti fluor-
escence microscope with a 60x oil immersion objective and fitted with a Hamamatsu
C11440 digital camera. For egress videos, segmented schizonts treated with 1.5 µM
C2 overnight were Percoll enriched and resuspended in warm CM at 0.4% hematocrit
then transferred to pre-warmed Poly-L-Lysine µ-Slide VI 0.4 (IBIDI) imaging chambers
and imaged on a temperature-controlled microscope stage held at 37◦C. For gametocyte
rounding up videos, mature stage V gametocytes were Percoll enriched and resuspen-
ded in room temperature CM containing 100 µM XA (Sigma) at 0.8 to 1.2% hematocrit
then transferred to Poly-L-Lysine µ-Slide VI 0.4 (IBIDI) imaging chambers and imaged
at room temperature. Images were taken every 2 seconds for a total of 20-30 minutes,
and the resulting videos were processed and analysed in ICY bioimage analysis software
(icy.bioimageanalysis.org). Plots were generated using GraphPad Prism version 7.
2.3.4 In vitro motility assays
Motility assays were performed as previously described (Butt et al., 2010). Motility assay
buffer (AB) containing 25 mM imidazole-HCL, 25 mM KCl, 1 mM EGTA and 4 mM MgCl2
(pH 7.4) was repeatedly degassed and flushed with nitrogen and stored in a hypodermic
syringe to prevent oxygen contamination which could lead to photobleaching (Swoboda
et al., 2012). Merozoite and saponin released schizont pellets were lysed in 4 volumes
of CoIP buffer containing 150 mM NaCl, 10 mM Tris (pH 7.5), 0.5 mM EDTA and 1%
NP40 that was supplemented with cOmplete EDTA-free protease inhibitor (Roche) and 1
mM PMSF. Samples were incubated on ice for 10 minutes then centrifuged at 12,000 x g
for 10 minutes at 4◦C and the supernatant collected and stored on ice while the motility
assay flow-cell chambers were prepared.
Custom flow-cell chambers with an internal volume of ~10 µl were constructed by ad-
hering nitrocellulose-coated cover slips to microscope slides with strips of double-sided
tape. α-mCherry antibody (ab183628, Abcam) was diluted 1:50 to 7 µg/ml in AB and
was applied in the flow-cell for 5 minutes. Unbound antibody was washed out with AB
then blocked for 5 minutes with AB containing 0.5 mg/ml BSA (AB/BSA). Parasite lysates
were applied into the flow-cell and incubated for 5 minutes to capture MyoA-mCherry
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complexes. Unbound material was washed out twice with AB/BSA. AB containing 0.1
µM rhodamine-phalloidin-labelled F-actin was applied to the flow-cell and incubated for
2 minutes. Unbound actin filaments were washed out using AB/BSA. Imaging buffer (IB)
was made using AB/BSA containing 20 mM DTT, 0.2 mg/ml glucose oxidase, 0.5 mg/ml
catalase, 3 mg/ml glucose to scavenge oxygen and prevent photobleaching. The flow-
cell was washed twice with IB then viewed by fluorescence microscopy to check for actin
binding. This was done using an Axioskop 40 fluorescence microscope with a Zeiss
PlanNeofluar x100, 1.3 numeric aperature objective lens. Fluorescence was excited by
a mercury arc lamp using a rhodamine filter set (excitation filter HQ535/50, dichroic mir-
ror Q565LP, and emission filter HQ605/75; Chroma Technology), and light emitted from
the rhodamine-phalloidinâlabeled actin filament specimen was imaged using an IC-310
image-intensified charge-coupled device camera (Photon Technology International). In
order to activate the myosin motors, IB containing 2 mM ATP and 1% methylcellulose
(IB/ATP) was applied to the flow-chamber. Sequences of video frames were captured
every 40 ms using a frame grabber card (Multipix Imaging Limited). Each image se-
quence was saved as a median of five consecutive image blocks, and filaments were
manually tacked with GMimPro (Mashanov and Molloy, 2007). Non-motile or short tracks
were removed from the analysis. From the resulting velocities, frequency distribution his-
tograms were calculated (bin size of 0.02), and a Gaussian curve was fitted with Graph-
Pad Prism version 7.
2.4 Immunochemistry
2.4.1 Immunofluorescence analysis (IFA)
Thin blood smears were fixed using high-quality methanol-free 4% formaldehye (Thermo
Scientific) in 1x PBS for 20 minutes, followed by two PBS washes then permeabalized
with 0.1% Triton X-100 in 1x PBS for for 10 minutes. Detergent was washed off twice in
PBS and slides were blocked in 3% bovine serum albumin (BSA) in 1x PBS for 1 hour and
subsequently probed with primary antibodies in blocking solution for 1 hour. Slides were
washed 3 times with PBS then probed with secondary antibodies in blocking solution
for 1 hour. Slides were washed 3 times before bein mounted in ProLong Gold Antifade
Mountant containing DAPI (Thermo Fisher Scientific). Images were acquired using either
a Nikon Eclipse Ti fluorescence microscope fitted with a Hamamatsu C11440 digital cam-
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era, or an EVOS FL Cell Imaging System and overlaid in ICY bioimage analysis software
(icy.bioimageanalysis.org). All antibodies used for IFA in this study are presented in table
1.
Primary Antibodies
Target Species Dilution Provider/manufacturer
α-HA (Clone 3F10) Rat 1:250 Roche
α-mCherry
(ab183628)
Rabbit 1:500 Abcam
α-RFP (5F8) Rat 1:1,000 Chromotek
α-GAP45 Rabbit 1:1,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-GAP50 Rabbit 1:2,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-MTIP Rabbit 1:2,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-Pfs16 Mouse 1:1,000 David Baker (LSHTM, London UK)
(Baker et al., 1994)
α-Pfs25 (4B7 from
MR4 coupled to
Cy3)
Mouse 1:500
Michael Delves (LSHTM, London
UK) (Delves et al., 2013)
Secondary Antibodies
Target Conjugate Dilution Provider/manufacturer
α-Rat IgG heavy and
light chains
Alexa Fluor
488
1:500 Invitrogen Molecular Probes
α-Mouse IgG heavy
and light chains
Alexa Fluor
488
1:500 Invitrogen Molecular Probes
α-Rabbit IgG heavy
and light chains
Alexa Fluor
594
1:500 Invitrogen Molecular Probes
Table 1. List of primary and secondary antibodies used for immunofluorescence analysis
2.4.2 Western blot analysis
Saponin-released parasite pellets were lysed in 4 volumes of CoIP buffer containing 150
mM NaCl, 10 mM Tris (pH 7.5), 0.5 mM EDTA and 1% NP40 that was supplemented
with cOmplete EDTA-free protease inhibitor (Roche) and 1 mM PMSF and incubated on
ice for 10 minutes. Samples were centrifuged at 12,000 x g for 10 minutes at 4◦C and
the supernatant collected. Reducing sample buffer was added to NP40-lysed parasite
samples or culture supernatants and proteins were resolved on 4%-15% Mini-PROTEAN
TGX Stain-Free Precast Gels (Bio-Rad) or 3%-8% NuPAGE Tris-Acetate Protein Gels
(Thermo Fisher Scientific) for high molecular weight proteins. Proteins were transferred
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onto nitrocellulose membranes using a semidry Trans-Blot Turbo Transfer System (Bio-
Rad) and blocked using 10% skimmed milk in PBS containing 0.1% Tween-20 (PBST)
for 1 hour. Antibody incubations were carried out in 1% skimmed milk in PBST. After
probing with primary antibodies for at least 1 hour, membranes were washed 3 times
for 5 minutes in PBST followed by incubation with secondary antibodies conjugated to
near infrared (NIR) dyes for 1 hour. Membranes were washed 3 times for 5 minutes in
PBST followed by a single wash in PBS. Membranes were dried between Whatman 3MM
blotting papers and images using an Azure c600 Imaging System (Azure Biosystems) or
a ChemiDoc Imaging System (Bio-Rad). Densitometry quantifications were performed
using ImageJ and plotted in GraphPad Prism version 7. All antibodies used for western
blot in this study are presented in table 2.
2.5 Molecular biology techniques
2.5.1 Identifying Cas9 targeting sites
Two online guide RNA (gRNA) prediction tools, Protospacer Workbench (Macpherson
and Scherf, 2015) and Bechnling’s CRISPR gRNA design software (www.benchling.com),
were used to identify suitable CRISPR/Cas9 targeting sites in the P. falciparum genome
based on the sequences deposited in PlasmoDB for Myosin A (PF3D7_1342600) and
GCα (PF3D7_1138400). gRNA sequences were selected based on lowest probability
of off-target cleavage and closest proximity to the homology regions used to repair the
double stranded break. A list of gRNAs used in this study along with their on target and
off target scores is available in table 3 in the appendix.
2.5.2 Primer design
Primers were ordered from integrated DNA technologies (IDT). The online tool, OligoCalc
(Kibbe, 2007) was used to determine the annealing temperatures of the primers and
assess self-hybridisation and hairpin formation. Primers used in this study are listed in
table 4 in the appendix.
2.5.3 Synthetic gene design
Genes and gene fragments were manually recodonised, and the online tool Resite finder
(resitefinder.appspot.com) was used to introduce restriction enzyme sites without chan-
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Primary Antibodies
Target Species Dilution Provider/manufacturer
α-HA (Clone 3F10) Rat 1:5,000 Roche
α-PKG Rabbit 1:1,000 ENZO life sciences
α-GFP (Clones 7.1
and 13.1)
Mouse 1:5,000 Roche
α-mCherry
(ab183628)
Rabbit 1:2,500 Abcam
α-RFP (6G6) Rat 1:5,000 Chromotek
α-mNeon Green
(32F6)
Mouse 1:1,000 Chromotek
α-GAP45 Rabbit 1:2,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-GAP50 Rabbit 1:5,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-MTIP Rabbit 1:5,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-MyoA Rat 1:10,000
Judith Green (Francis Crick Insti-
tute, London UK) (Ridzuan et al.,
2012)
α-pS19 MyoA Rabbit 1:1,000
Custom antibody raised against ’N’-
RRV[pS]NVEAFDKC peptide gen-
erated by Genosphere Biotechnolo-
gies (Alam et al., 2015)
α-GAPDH Mouse 1:30,000
Claudia Daubenberger (Swiss
Tropical and Public Health Institute,
Basel Switzerland)
α-SERA5 Rabbit 1:5,000 Mike Blackman (Francis Crick Insti-
tute, London UK)
Secondary Antibodies
Target Conjugate Dilution Provider/manufacturer
α-Rabbit IgG heavy
and light chains
DyLight
680
1:5,000 Invitrogen Molecular Probes
α-Rabbit IgG heavy
and light chains
DyLight
800
1:5,000 Invitrogen Molecular Probes
α-Mouse IgG heavy
and light chains
DyLight
680
1:10,000 Invitrogen Molecular Probes
α-Mouse IgG heavy
and light chains
DyLight
800
1:5,000 Invitrogen Molecular Probes
α-Rat IgG heavy and
light chains
IRDye
680RD
1:5,000 LI-COR Odyssey
Table 2. List of primary and secondary antibodies used for western blot analysis.
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ging the coding sequence. Large genes were ordered using the GeneArt Gene Synthesis
Service (Invitrogen), while smaller fragments were ordered as gBlocks (IDT).
2.5.4 Polymerase chain reaction (PCR)
DNA used for cloning was amplified using proofreading Q5 DNA polymerase 2x mix
(NEB) or CloneAmp HiFi PCR 2x premix (TaKaRa), according to the supplier’s instruc-
tions. Either P. falciparum genomic DNA or plasmid DNA were used as PCR templates
and primers were used at 500 nM. PCRs were carried out in a C1000 Touch Thermal
Cycler (Bio-Rad). A typical PCR reaction consisted of 25 to 35 cycles of denaturation at
98◦C for 10 seconds, followed by annealing at 55-60◦C for 10 seconds, and extension at
68-72◦C. The duration of the extension step was dependent on the size of the amplicon.
PCR products generated were purified using the MinElute kit (Qiagen) after confirming
successful amplification by agarose gel electrophoresis.
2.5.5 Restriction digests
Restriction digests were set up using enzymes from New England Biolabs (NEB), Pro-
mega or Fermentas according to the manufacturer’s protocol. Plasmid digests for cloning
were purified using the MinElute kit (Qiagen) and the resulting DNA fragments were used
in subsequent cloning steps. Restriction enzymes used to linearise DNA fragments for
transfections were heat denatured according to the manufacturer’s instructions.
2.5.6 Ligation-based cloning
Digested plasmid vectors were first treated with Antarctic phosphatase (NEB), purified,
and subsequently ligated to digested inserts with complementary overhangs using T4
DNA ligase (NEB).
2.5.7 Ligation-independent cloning
The In-Fusion HD cloning kit (TaKaRa) was used for ligation-independent cloning steps,
according to the recommended protocol. Inserts for cloning were designed with 15 bp
overlaps with either end of the linearised vector.
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2.5.8 Transformation of chemocompetent bacteria
E. coli Stellar competent cells (TaKaRa) were used for In-Fusion cloning while E. coli
XL10-Gold Ultracompetent cells (Agilent) were used for ligation cloning and for the propaga-
tion of plasmid DNA. Competent cells were transformed by heatshock according to the
supplier’s guidelines then spread onto Luria-Bertani (LB) agar plates supplemented with
100 µg/ml ampicilin or 50 µg/ml kanamycin. Plates were incubated overnight at 37◦C.
2.5.9 Plasmid DNA isolation
Singe E. coli colonies were grown overnight in LB medium supplemented with 100 µ-
g/ml ampicilin or 50 µg/ml kanamycin while shaking at 37◦C. Plasmids were isolated for
small or large-scale preparations using either a MiniPrep kit (Qiagen) or a MidiPrep kit
(Macherey-Nagel). DNA yields were determined using a Nanodrop spectrophotometer
(Thermo Fisher Scientific).
2.5.10 Sequencing of DNA
Sanger sequencing was performed by EuroFins (formerly GATC) on amplicons from para-
site genomic DNA to verify correct integration and on plasmids to validate plasmid con-
struction.
2.5.11 Parasite genomic DNA isolation
DNA was isolated from saponin-released parasite pellets, which were at least 5 µl in
volume, using the QIAmp DNA Blood Mini Kit (Qiagen) according to the manufacturer’s
instructions. DNA yields were determined using a Nanodrop spectrophotometer (Thermo
Fisher Scientific).
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3 GCα is an essential "bifunctional" Guanylyl Cyc-
lase expressed in the asexual blood stage
cGMP signalling plays a vital role across all stages of the life cycle. During the asexual
blood stages, inhibition of this signalling pathway by using reversible PKG-specific in-
hibitors such as compound 2 (C2), leads to a block in Ca2+ release and the secretion
of micronemes and exonemes (Collins et al., 2013b; Brochet et al., 2014). As a result,
merozoites are unable to egress from the host erythrocyte. Despite the importance of
cGMP signalling during this stage, it remains unclear how this pathway is activated in
mature blood stage schizonts.
GCα is thought to be responsible for synthesising cGMP during the blood stages of the in-
fection, however it remains poorly characterised in Plasmodium parasites. Furthermore,
previous attempts to detect GC activity by recombinant expression of the PfGCα catalytic
domains in E. coli were unsuccessful, with activity only detectable using the catalytic do-
main of GCβ (Carucci et al., 2000). GCα is also refractory to deletion, despite several
attempts to disrupt this gene in Plasmodium parasites (Taylor et al., 2008; Moon et al.,
2009; Kenthirapalan et al., 2016). Other than its predicted role in synthesising cGMP, the
N-terminal portion of GCα encodes a P-type ATPase domain, which lacks key residues for
ion transport, but is closely related to putative aminophospholipid transporters which are
predicted to be involved in flipping phosphatidylserine (PS) or phosphatidylethanolamine
(PE) (Baker, 2004). The unique bifunctional structure of GCα is conserved across GCs
found in other alveolates including Toxoplasma, Tetrahymena and Paramecium, which
may signify a functional link between these two domains. The aim of this chapter was to
functionally characterise GCα in P. falciparum parasites during the asexual blood stages,
and generate a conditional ATPase and GC domain knockout using the dimerisable Cre
recombinase (DiCre) system (Collins et al., 2013a) to dissect the function of this protein.
3.1 Results
3.1.1 GCα is expressed during the asexual blood stages of the life cycle
In order to generate a GCα-tagged parasite line, a construct was made to introduce by
single homologous crossover a triple hemagglutinin (3xHA) epitope tag at the 3’ end of the
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endogenous GCα gene, along with a human dihydrofolate reductase (hDHFR) selection
cassette, which confers resistance to WR99210, flanked by two loxP sites (Figure 3.1.A).
The construct was transfected into 3D7 1G5 DiCre parasites (Collins et al., 2013a), which
constitutively express the dimerisable Cre recombinase (DiCre) as two separate subunits,
each fused to a rapamycin binding domain. After obtaining WR99210 resistant parasites,
four rounds of drug cycling were performed, to enrich the proportion of parasites in which
integration had occurred. Upon successful detection of integration in the population by
PCR (data not shown), parasites were treated with 100 nM rapamycin for 3 hours in or-
der to excise the floxed hDHFR cassette, leaving a single loxP site downstream of the
3xHA epitope tag. This was done so that the selection cassette could be repurposed in
future transfections. Parasites were then cloned by limiting dilution (Thomas et al., 2016)
and two clones called GCα:HA clone 1 and clone 2 were obtained. Work up until this
point was done by Christian Flueck (LSHTM, London UK), prior to the start of my PhD.
Genomic DNA was extracted from GCα:HA clone 1 and integration of the 3xHA tag and
excision of the hDHFR cassette were confirmed by PCR (Figure 3.1.B). The growth of
GCα:HA clone 1 parasites in the presence of 2.5 nM WR99210 over 3 cycles demon-
strated that this line was sensitive to the drug, confirming excision of the hDHFR cassette
and absence of episomes (Figure 3.1.C). GCα:HA clone 1 was used in subsequent ex-
periments and is referred to as GCα:HA.
According to the transcriptional profile of GCα (López-Barragán et al., 2011; Zanghì et al.,
2018), it is expressed in late trophozoites and schizonts, with maximal transcripts detec-
ted around 40-48 hours post invasion (hpi). Western blot analysis of samples harvested
from GCα:HA parasites every 4 hours from early trophozites (24 hpi) to late schizonts (48
hpi) using an α-HA antibody revealed that tagged GCα could be detected as early as 36
hpi with maximal expression detected at around 44-48 hpi (Figure 3.2.A). However, full
length GCα, which is predicted to migrate at ~499 kDa, could not be detected. Instead,
two species migrating at ~175 kDa and ~125 kDa were observed. Interestingly, there was
a shift from the 125 kDa form to the 175 kDa form over time. However, western blot ana-
lysis of unmodified 3D7 DiCre schizonts probed with the α-HA antibody revealed that the
125 kDa band is a non-specific band (Figure 3.2.B), likely due to cross reactivity of the
antibody with a protein found in the parental parasite line. Although it is unclear whether
the 175 kDa fragment is a result of degradation or physiological proteolytic processing of
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Figure 3.1. Generation of a GCα:HA tagged line. A. Schematic representation of the single
homology crossover approach used to tag the 3’end of the endogenous GCα gene with a 3xHA
tag, and subsequent RAP-mediated excision of the hDHFR cassette. Arrows represent the
relative position of oligonucleotide primers used for diagnostic PCR screens. B. Diagnostic PCR
analysis confirming successful integration of the 3xHA tag, and efficient excision of the floxed
hDHFR tag in a GCα:HA clone. C. Growth curve showing GCα:HA clone 1 parasites are
sensitive to treatment with 2.5 nM WR99210, consistent with successful excision of the hDHFR
cassette. Data presented are from counting parasites on Giemsa-stained blood smears. At least
100 parasites were counted per condition.
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GCα, a similar phenomenon is also observed in Toxoplasma where TgGC predominantly
migrates at ~125 kDA and ~75 kDa instead of at 460 kDa which would represent the full
length protein (Jia et al., 2017; Yang et al., 2019; Bisio et al., 2019; Brown and Sibley,
2018). In some studies, full-length TgGC could also be detected, however this accounted
for only a small proportion of the total population of TgGC (Yang et al., 2019; Brown and
Sibley, 2018). Therefore it is possible that full-length GCα is below the detection limit in
this experiment. Mapping of the 175 kDa fragment to the predicted domain structure of
GCα suggests that the this fragment would comprise both C1 and C2 domains along with
12 transmembrane domains (Figure 3.2.C). IFA analysis of GCα:HA C2-blocked mature
schizonts revealed that GCα localises to the parasite periphery and partially co-localises
with GAP45, an IMC-specific protein which forms part of the glideosome (Figure 3.2.D).
The IMC and plasma membrane are separated by ~20-40 nm, therefore it is difficult to
distinguish between them. However, late in schizogony, when individual merozoites are
pinched off, the residual body remains encapsulated by plasma membrane but not IMC
(Ridzuan et al., 2012). Upon close examination, it is apparent that the residual body is
surrounded by faint α-HA signal but not α-GAP45 signal. This is indicative of a plasma
membrane localisation for GCα, consistent with it being an integral plasma membrane
protein. Unlike TgGC which localises to the apical end of tachyzoites, in P. falciparum
GCα is found across the entire surface of the parasite.
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Figure 3.2. GCα is expressed in blood stage schizonts and localises to the plasma
membrane. A. Western blot showing a time course of GCα:HA expression in P. falciparum blood
stages. Parasites were harvested at the timing indicated, with representative microscopy images
shown above each sample. Scale bar, 5 µm. PKG was used as a loading control. GCα:HA
migrated as several fragments, while full length protein (~499 kDa) could not be detected. B.
Western blot analysis of unmodified 3D7 DiCre parasites showing that the α-HA antibody cross
reacts with a protein at ~125 kDa. C. Schematic representation of the domain architecture of
GCα. Horizontal lines with corresponding molecular weights show approximate fragments
observed by western blot. D. IFA analysis of mature GCα:HA schizonts showing colocalisation of
GCα-HA (green) with the IMC marker GAP45 (red). Scale bar, 5 µm.
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3.2 GCα is essential for asexual blood stage growth and is
required for egress
To determine the function of GCα and whether it is essential for asexual growth, a con-
ditional knockout (cKO) line was generated using marker-free CRISPR/Cas9-mediated
gene editing to introduce a second loxP site into GCα:HA parasites, which already pos-
sess a single loxP site downstream of the 3xHA epitope tag, by introducing an artificial
intron based on a PfSERA2 intron, harbouring a loxP site (loxPint) Jones et al. (2016)
within the ATPase domain of GCα. This was achieved by transfecting GCα:HA parasites
with a linearised repair template to introduce the loxPint sequence, along with a pool of
three different pDC2-Cas9-hDHFR plasmids Lim et al. (2017), each harbouring a differ-
ent gRNA to maximise editing efficiency of the locus (Figure 3.3.A). Parasites were then
cultured in the presence of 2.5 nM WR99210 for 9 days to select for parasites harbouring
one or more of the pDC2-Cas9-hDHFR plasmids. Parasites were observed two weeks
post transfection. gDNA was extracted from these parasites and PCR analysis confirmed
successful integration of the loxPint (Figure 3.3.B). Since the wild type locus could still be
detected in the population, the parasites were cloned by limiting dilution (Thomas et al.,
2016). Two clones were obtained called GCα:HA:cKO clone 1 and clone 2, and PCR ana-
lysis confirmed loxPint integration and the absence of the wild type locus in both clones
(Figure 3.3.C). GCα:HA:cKO clone 1 was subsequently used in all further experiments.
Addition of rapamycin to the GCα:HA:cKO line would lead to the excision of DNA se-
quences encoding part of the ATPase domain and the entire GC domain of GCα (Figure
3.4.A), disrupting the activity of both these domains. Early ring stage GCα:HA:cKO para-
sites were treated with either 50 nM RAP or the equivalent volume of DMSO for two
hours, and gDNA was extracted once the parasites had developed into mature schizonts.
PCR analysis revealed that RAP-mediated excision was highly efficient, since a band was
not amplified in the integration specific PCR following RAP treatment (Figure 3.4.B). Fur-
thermore, western blot analysis revealed that the ~175 kDa GCα band could no longer
be detected in RAP-treated GCα:HA:cKO scizonts, while the non-specific ~125 kDa band
could still be detected (Figure 3.4.C). Therefore it appears that treatment of GCα:HA:cKO
parasites with rapamycin leads to efficient excision of the GCα gene.
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Figure 3.3. Generation of a GCα:HA:cKO line. A. Schematic representation of the marker-free
CRISPR/Ca9-mediated approach used to introduce the loxPint into the ATPase domain of GCα
in GCα:HA parasites to generate the GCα:HA:cKO line. Scissors indicate CRISPR/Cas9
cleavage sites, while arrows represent the relative position of oligonucleotide primers used for
diagnostic PCR screens. B. Diagnostic PCR analysis showing successful integration of the
loxPint in the uncloned GCα:HA:cKO parasite population, however wild type locus could still be
detected. A DNA control PCR was included, which amplified a small segment at an independent
locus to test the quality of the DNA used. C. Diagnostic PCR analysis confirming successful
integration of the loxPint and absence of wild type locus in two GCα:HA:cKO clones. A DNA
control PCR was included, which amplified a small segment at an independent locus to test the
quality of the DNA used.
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Figure 3.4. Effective conditional disruption of GCα expression. A. Schematic representation
of RAP-mediated excision of a portion of the ATPase domain and the entire GC domain. Arrows
represent the relative position of oligonucleotide primers used for diagnostic PCR screens. B.
Diagnostic PCR analysis of DMSO- and RAP-treated GCα:HA:cKO parasites showing efficient
excision of the GCα gene following RAP treatment. A DNA control PCR was included, which
amplified a small segment at an independent locus to test the quality of the DNA used. C.
Western blot analysis of DMSO- and RAP-treated GCα:HA:cKO and 3D7 DiCre schizonts
probed using an α-HA antibody, showing a loss of the ~175 kDa band in the RAP-treated
parasites, while the non-specific ~125 kDa band can still be observed in both samples. The blot
was also probed using an α-PKG antibody to serve as a loading control.
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In order to assess the impact of GCα disruption on parasite viability and growth, a flow
cytometry-based replication assay was performed on DMSO- and RAP-treated GCα-
:HA:cKO parasites over 3 cycles. This revealed a complete arrest in parasite growth res-
ulting from the disruption of the GCα locus (Figure 3.5.A). Close examination of Giemsa-
stained GCα:HA:cKO parasites in the excision cycle (cycle 0) revealed that both DMSO-
and RAP-treated parasites developed normally and were able to form mature segmented
schizonts. However, there appeared to be an accumulation of schizonts and an absence
of ring stage parasites in GCα-deficient cultures (Figure 3.5.B), indicating that GCα is
required for egress. Live time-lapse microscopy performed on mature DMSO- and RAP-
treated schizonts released from a C2 block (Figure 3.6.A), confirming that GCα knockout
parasites were unable to egress (Figure 3.6.B). Consistent with this result, examination
of culture supernatants from DMSO- and RAP-treated C2 released mature schizonts re-
vealed that the PV-resident serine repeat antigen 5 (SERA5), which is released into the
culture supernatant during egress, could not be detected in supernatant samples ob-
tained from RAP-treated cultures (Figure 3.6.C). Collectively, these results establish that
GCα is required for merozoite egress and that it plays an essential role during the asexual
cycle.
Although GCα:HA:cKO parasites displayed a complete arrest in parasite growth in the
flow cytometry-based assay, after around 16 days post rapamycin treatment parasites
could be observed in culture. However, subsequent PCR analysis showed that these
parasites were not GCα knockouts since the GCα locus was intact. Owing to the fact
that the 1G5 DiCre parasite line has a tendency to lose the DiCre expression cassette
(personal communication Mike Blackman, Francis Crick Institute London, UK) it is most
likely that these parasites are DiCre revertants that have lost the ability to excise the floxed
GCα locus. Consistent with this, treatment of GCα:HA:cKO ’revertants’ with rapamycin
did not result in excision of GCα by PCR (Figure 3.7.A) and had no effect on parasite
growth in a flow cytometry-based replication assay (Figure 3.7.B).
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Figure 3.5. GCα is required for asexual growth. A. Growth curves showing parasitemias of
GCα:HA:cKO parasites treated with either DMSO or RAP, measured by flow cytometry-based
sorting of SYBR Green positive cells. Data points plotted are means from two repeat
experiments, each performed in triplicate. Error bars represent the standard deviation. B.
Representative microscopy images of Giemsa-stained parasites from DMSO- and RAP-treated
GCα:HA:cKO cultures, showing the accumulation of schizonts in RAP-treated samples. Scale
bar, 5 µm.
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Figure 3.6. GCα disruption results in a complete egress block. A. DIC and fluorescence
images from time lapse video microscopy of DMSO- and RAP-treated GCα:HA:cKO schizonts
taken at 5 minutes and 30 minutes after releasing from a C2 block. In each experiment, one
subset of parasites was treated with Hoechst to stain the nuclei so that DMSO- and RAP-treated
parasites could be viewed side by side in the same imaging chamber. In the top panel,
DMSO-treated parasites are Hoechst stained, while in the bottom panel, RAP-treated parasites
are Hoechst stained. Schizonts from the first frame that rupture over the course of the video are
circled in white. Scale bar, 10 µm. B. Quantification of the percentage of for DMSO- and
RAP-treated schizonts that egress in each 30 minute video. Data are collected from 6 videos,
with Hoechst-treated samples depicted in blue. Statistical significance was measures by
unpaired t-test, where **** signifies p < 0.0001. C. Western blot analysis monitoring the release
of SERA5 into the culture supernatant of DMSO- and RAP-treated GCα:HA:cKO schizonts, as a
measurement of egress over time. Pellet samples were included as loading controls. The lack of
SERA5 signal in supernatants from RAP-treated samples indicates impaired egress in
GCα-deficient parasites. D. Densitometry analysis of the egress assay western blot samples
shown in Figure 3.6.C., showing there is a significant difference in levels of SERA5 release into
the supernatant between DMSO- and RAP-treated GCα:HA:cKO parasites.
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Figure 3.7. GCα:HA:cKO parasites are susceptible to losing the DiCre cassette. A. Growth
curves showing parasitemias of GCα:HA:cKO DiCre revertant parasites treated with either
DMSO or RAP, measured by flow cytometry-based sorting of SYBR Green positive cells. Data
points plotted are means from two repeat experiments, each performed in triplicate. Error bars
represent the standard deviation. RAP-treatment had no effect on parasite growth. B. Diagnostic
PCR analysis of DMSO- and RAP-treated GCα:HA:cKO DiCre revertant parasites showing the
GCα gene was not excised following RAP treatment. A RAP-treated GCαHA:cKO sample was
also included as a positive control for RAP-mediated excision. A DNA control PCR reaction was
included, which amplified a small segment at an independent locus to test the quality of the DNA
used.
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3.2.1 GCα displays guanylyl cyclase activity and is responsible for cGMP
production in asexual blood stages
To evaluate the impact of GCα deletion on cyclic nucleotide production, cAMP and cGMP
assays were performed on extracts from DMSO- and RAP-treated GCα:HA:cKO mature
schizonts held in a C2 block. Parasites were blocked in C2 to prevent egress and ensure
a similar number of schizonts were used in each assay. Although no discernible changes
in cAMP levels were detected between the samples (Figure 3.8.A), deletion of GCα led to
a 94.5% reduction in cGMP levels (Figure 3.8.B). Addition of the PDE inhibitor Zaprinast,
which would block hydrolysis of cGMP, resulted in an increase in cGMP levels in DMSO-
but not RAP-treated parasites (Figure 3.8.B), confirming that schizonts are unable to
synthesise cGMP in the absence of GCα.
Since GCα-deficient parasites are unable to synthesise cGMP, it is likely that PKG is not
active in these parasites. Consistent with this, the egress phenotype of GCα knockout
parasites is indistinguishable from the egress block observed when wild type parasites
are treated with the PKG-specific inhibitor C2 (Figure 3.9.A). To determine whether Ca2+
release, a PKG-dependent process (Brochet et al., 2014), is affected in GCα knockout
parasites, Zaprinast-induced Ca2+ release was measured in DMSO- and RAP-treated
GCα:HA:cKO parasites. While Zaprinast treatment led to a 5% increase in Ca2+ levels
in DMSO-treated parasites, no measurable increase could be detected in RAP-treated
parasites (Figure 3.9.B). Despite this, DMSO- and RAP-treated parasites showed similar
response levels to the calcium ionophore A23187, which allows Ca2+ ions to cross cell
membranes; indicating that internal calcium stores were unaffected (Figure 3.9.C). These
results confirm that GCα is a functional GC and is the only GC capable of synthesising
cGMP during the asexual blood stage of the lifecycle and that GCα activity is required
PKG-dependent Ca2+ release.
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Figure 3.8. GCα disruption leads to a complete loss of cGMP production. A. Absolute
levels of cAMP in mature DMSO- and RAP-treated GCα:HA:cKO schizonts that were blocked in
1.5 µM C2. Data presented is from four independent experiments, each performed in duplicate.
Error bars represent the standard deviation. Statistical significance was measures by unpaired
t-test, n.s. indicates not significant (p > 0.05). cAMP levels remain unchanged, even when
treated with 75 µM Zaprinast for 3 minutes. B. Absolute levels of cGMP in mature DMSO- and
RAP-treated GCα:HA:cKO schizonts. Data presented is from four independent experiments,
each performed in duplicate. Error bars represent the standard deviation. Statistical significance
was measures by unpaired t-test, ** signifies p < 0.01 whereas *** signifies p < 0.001. There is a
significant reduction of cGMP synthesis in RAP-treated samples compared to DMSO-treated
samples. This difference becomes more significant when parasites are treated with 75 µM
Zaprinast for 3 minutes.
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Figure 3.9. GCα disruption phenotypically resembles chemical inhibition of PKG and
results in a block in calcium release. A. Representative images of Giemsa-stained parasites
from DMSO-treated GCα:Ha:cKO parasites in the presence of 1.5 µM C2, and RAP-treated
GCα:HA:cKO parasites. PKG inhibition leads to a similar phenotype to that observed in GCα
knockout parasites. Scale bar, 5 µm. B. Determination of calcium release using 75 µM Zaprinast
in synchronous Fluo-4-loaded mature DMSO- and RAP-treated GCα:HA:cKO parasites
measured by fluorimetry. Signals were normalised to DMSO (0% signal) and 20 µM A23187
ionophore (100%). Data plotted is from one experiment, performed in triplicate. C. Determination
of calcium stores using 20 µM A23187 ionophore in synchronous Fluo-4-loaded mature DMSO-
and RAP-treated GCα:HA:cKO parasites measured by fluorimetry. Signals were normalised to
the DMSO-treated GCα:HA:cKO levels (100% signal). Data plotted is from one experiment,
performed in triplicate.
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3.2.2 Chemical complementation of GCα knockout parasites with PET-cGMP
rescues the egress defect
Since the egress phenotype observed in GCα-deficient parasites is most likely due to
their inability to produce cGMP to activate PKG, bypassing the need for cGMP synthesis
by directly activating PKG could potentially rescue the egress defect and give rise to a
second phenotype that arises due to loss of the ATPase domain. To test this, either cGMP
or cGMP analogues were added to RAP-treated GCα:HA:cKO schizonts. The cGMP
analogues 1-NH2-cGMP and PET-cGMP were selected since they display a high affinity
for recombinant PfPKG and effectively activate the enzyme (Paul Bowyer, unpublished
work) and the latter displays good membrane permeability. Mature RAP-treated GCα-
:HA:cKO schizonts were smeared after incubating for one hour in the presence of varying
concentrations of cGMP, 1-NH2-cGMP and PET-cGMP. As can be seen in figure 3.10.,
PET-cGMP was highly effective at rescuing the egress block, resulting in the release of
merozoites at all concentrations tested. While rings with normal morphology could be
observed in the 62.5 and 31.2 µM samples, parasites incubated in higher concentrations
of PET-cGMP appeared as intracellular and extracellular pyknotic forms, indicating that
higher concentrations may be toxic. Some rings were also observed in the cGMP and
1-NH2-cGMP-treated samples, however these compounds were not as effective as PET-
cGMP at rescuing the egress defect of GCα-deficient parasites.
To determine the ideal concentration of PET-cGMP that can be used to sustain growth in
RAP-treated GCα:HA:cKO treated parasites, a SYBR Green growth assay was performed
to test parasite growth at varying concentrations of PET-cGMP over 72 hours. However,
none of the concentrations tested could rescue GCα knockout parasites (Figure 3.11.),
even at the concentrations that could induce egress. The assay was also performed using
DMSO-treated parasites to determine the EC50 of PET-cGMP against asexual parasite
replication in vitro. This revealed that PET-cGMP is toxic at high concentrations with an
EC50 of 12.49± 0.06 µM. Therefore it is likely that premature activation of PKG in early
stage parasites, when PKG is inactive due to insufficient levels of cGMP, is lethal.
To determine whether short-term incubation of mature schizonts with PET-cGMP can
be tolerated, 30 µM PET-cGMP was added to mature DMSO- and RAP-treated GCα-
73
Figure 3.10. Reversing the egress block phenotype of mature GCα knockout schizonts by
using cGMP analogues. Representative images of Giemsa-stained parasites from RAP-treated
GCα:Ha:cKO parasites in the presence of varying concentrations of cGMP, 1-NH2-cGMP and
PET-cGMP. Released merozoites and rings are circled in red. Scale bar, 5 µm.
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Figure 3.11. Continous PET-cGMP treatment is toxic and does not rescue GCα knockout
parasite growth. Growth curves of DMSO- and RAP-treated GCα:HA:cKO parasites at different
concentrations of PET-cGMP as measured in a 72 hour SYBR Green growth assay. Assays were
repeated twice and the EC50 of PET-cGMP was measured as 12.49± 0.06 µM using wild type
parasites.
:HA:cKO schizonts and was washed off ~10 hours later, once most of the schizonts
had ruptured and formed rings. This resulted in a marked decrease in toxicity, allow-
ing RAP-treated GCα:HA:cKO parasites to mature and form schizonts (data not shown).
Therefore it appears that PET-cGMP is not toxic when added to mature schizonts when
PKG is supposed to be active, however it is important to wash it off to prevent prema-
ture activation of PKG in the following cycle. A flow cytometry-based replication assay
was performed to quantify the level of rescue that could be achieved over 1 growth cycle
using DMSO- and RAP-treated GCα:HA:cKO parasites. Parasites were treated with 30
µM PET-cGMP once mature segmented schizonts had appeared in culture. After ~10
hours, PET-cGMP was washed off and samples were harvested the following day when
parasites were unsegmented schizonts. This assay revealed that PET-cGMP treatment
resulted in a 3.6-fold increase in parasitemia in RAP-treated parasites, while untreated
parasites were unable to expand (Figure 3.12.A.). Furthermore, positive growth could be
sustained over several cycles (Figure 3.12.B.). However, the resulting parasitemias at the
end of the assay were significantly lower than those of DMSO-treated controls. There-
fore it is possible to chemically complement the egress defect observed in GCα knockout
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parasites by bypassing cGMP synthesis. Surprisingly, PET-cGMP rescue did not reveal
a second ATPase knockout-related phenotype. This suggests that the ATPase domain is
either not required for asexual blood stage growth or that it is involved in mediating cGMP
synthesis, in which case chemical complementation is sufficient to bypass loss of both
ATPase and GC domains.
Figure 3.12. PET-cGMP treatment can bypass the need of cGMP synthesis by GCα. A.
Parasitemias of DMSO- and RAP-treated GCα:HA:cKO DiCre parasites cultured in the presence
of 30 µM PET-cGMP or the equivalent volume of water, as measured by flow cytometry-based
sorting of SYBR Green positive cells. PET-cGMP was added when schizonts appeared in
culture, and was washed off around 10 hours later, once rings had formed. Data points plotted
are means from two repeat experiments, each performed in triplicate. Error bars represent the
standard deviation. B. Growth curves showing parasitemias of DMSO- and RAP-treated
GCα:HA:cKO DiCre parasites over 3 cycles when treated with 30 µM PET-cGMP or the
equivalent volume of water, as measured by flow cytometry-based sorting of SYBR Green
positive cells. PET-cGMP was added when schizonts appeared in culture, and was washed off
around 10 hours later, once rings had formed. Data points plotted are the means from triplicate
values from one experiment. Error bars represent the standard deviation.
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3.2.3 The ATPase domain is essential for parasite survival
The N-terminal portion of GCα encodes a putative type IV P-type ATPase (P4-ATPase),
which is shares closest homology to putative aminophospholipid transporters (Baker,
2004), which are predicted to flip phospholipids from the outer to the inner leaflet of a
lipid bilayer. The typical domain architecture of P4-ATPases consists of a transmembrane
domain with sets of 6 and 4 transmembrane helices, which span the lipid bilayer and
interact with the transported ligand; a nucleotide binding domain, which binds to ATP; a
phosphorylation domain, which contains an aspartate residue within a conserved DKTGT
motif which gets phosphorylated to form an aspartyl phosphate intermediate; and an ac-
tuator domain, which dephosphorylates the phosphorylation domain (Kühlbrandt, 2004;
Montigny et al., 2015). GCα contains the conserved DKTGT motif in the phosphoryla-
tion domain, which is critical for ATPase activity as well as other residues conserved in
P4-ATPases predicted to function as aminophospholipid flippases (Figure 3.13.).
To investigate whether the ATPase domain of GCα is essential for parasite survival,
marker free CRISPR/Cas9-mediated gene editing was employed to introduce mutations
in the conserved aspartate residue (D756) to block formation of the aspartyl phosphate
intermediate and ablate its activity. 3D7a parasites were transfected with a pool of three
different pDC2-Cas9-hDHFR plasmids, which were used to introduce the loxPint into the
ATPase domain of GCα to generate the GCα:HA:cKO line, along with a repair template
that would introduce the D756N mutation (Figure 3.14.A). A control transfection was also
performed using a repair template that would introduce shield mutations but not change
the wild type amino acid sequence to confirm that editing of the GCα locus had occurred.
Parasites were treated with 2.5 nM WR99210 for one week to select for parasites that
had taken up one or more of the pDC2-Cas9-hDHFR plasmids. Although parasites ap-
peared in control transfections 2 weeks post transfection, parasites were never observed
when transfected with the D756N repair template, even after 6 weeks post transfection.
Transfections were repeated twice, with the same outcome. Integration was confirmed
in D756 parasites from transfections 1 (T1) and 2 (T2) by integration-specific PCR (Fig-
ure 3.14.B) confirming that the phosphorylation domain had been successfully edited in
both parasite lines. The failure to obtain parasites harbouring the D756N mutation after
multiple attempts, strongly suggests that an active ATPase domain is required for parasite
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Figure 3.13. The ATPase domain of PfGCα possesses several conserved residues
required for ATPase activity. Alignment of PfGCα and PfGCβ amino acid sequences with
human ATP8B1, mouse FETa and yeast Drs2p, which are probable aminophospholipid
transporters. The actuator, phosphorylation and nucleotide binding domains are highlighted in
red, green and blue boxes, respectively. Transmembrane domains are highlighted in grey.
Highlighted yellow numbers indicate the number of amino acids not included in the analysis,
while dashes represent gaps in the amino acid sequence. Several key residues required for
ATPase activity are conserved in GCα, however in GCβ, which possesses a pseudo-ATPase,
several of these residues are missing. Alignments were done by David Baker (LSHTM, London
UK).
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survival. These data combined with the ability to sustain positive growth of GCα knockout
parasites over several cycles by chemical complementation with PET-cGMP indicate that
the ultimate role of the ATPase domain is linked to cGMP synthesis.
Figure 3.14. Failure to mutate the D756 residue required for ATPase activity indicates the
ATPase domain is essential. A. Schematic representation of the marker-free
CRISPR/Ca9-mediated approach used to introduce the D756N mutation, or the D756 control wild
type sequence into the actuator domain of the ATPase of GCα. Scissors indicate CRISPR/Cas9
cleavage sites, while arrows represent the relative position of oligonucleotide primers used for
diagnostic PCR screens. B. Diagnostic PCR analysis confirming integration of the D756 control
wild type sequence in two independent transfections, T1 and T2 confirming successful editing of
the locus. A DNA control PCR was included, which amplified a small segment at an independent
locus to test the quality of the DNA used. The inability to obtain parasites harbouring the D756N
mutation indicates that the ATPase is essential for parasite survival.
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3.2.4 Functional analysis of the ATPase domain of GCα
Although the ATPase domain of GCα appears to be vital for parasite survival, it remains
unclear what its functional role is. As previously mentioned, it is predicted that the AT-
Pase is involved in flipping phosphatidylserine (PS) or phosphatidylethanolamine (PE). To
test this, GCα:HA:cKO parasites were transfected with a plasmid (made by Avnish Patel,
LSHTM London, UK) containing an expression cassette to drive constitutive expression
of annexin V, a protein which binds to PS, fused to an mNeon Green tag. If GCα flips PS
onto the inner leaflet of the plasma membrane, it would be expected that deletion of GCα
would lead to an accumulation of PS on the outer leaflet of the plasma membrane. There-
fore it would be predicted that in DMSO-treated GCα:HA:cKO parasites, annexin V would
bind to the PM (Figure 3.15.A), while in RAP-treated GCα:HA:cKO parasites, annexin V
would remain diffuse (Figure 3.15.B). However, since the expression levels of annexinV-
mNeonGreen were very high, it was difficult to determine by microscopy whether the dis-
tribution of cytosolic vs. membrane-bound annexinV-mNeonGreen changed in DMSO-
and RAP-treated mature schizonts and merozoites (data not shown). Therefore se-
quential protein extraction was performed by hypotonic lysis of DMSO- and RAP-treated
GCα:HA:cKO schizonts to separate cytosolic proteins from membranous and membrane-
bound proteins, which were then extracted by using a detergent-containing buffer. West-
ern blot analysis of these fractions revealed that annexinV-mNeonGreen was mainly
found in the cytosolic fraction of the RAP-treated sample, but a much fainter band was
detected in the DMSO-treated parasites (Figure 3.15.C). This would suggest that there is
less PS on the inner leaflet of the PM in the RAP-treated sample than the DMSO-treated
sample. However, since there was no increase in mNeon Green signal in the membrane
fraction of the DMSO-treated sample, the results of this experiment are difficult to in-
terpret. Therefore it remains unclear whether the ATPase domain of GCα displays PS
flipping activity.
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Figure 3.15. Phosphatidylserine flipping may be catalysed by GCα. If GCα is a capable of
flipping phosphatidylserine (depicted in yellow) it is expected that A. in DMSO-treated
GCα:HA:cKO parasites, AnnexinV-mNeonGreen would localise to the plasma membrane, while
B. in RAP-treated GCα:HA:cKO parasites, AnnexinV-mNeonGreen would display a cytosolic
localisation. C. Western blot analysis of the cytosolic and membrane fractions of DSMO- and
RAP-treated GCα:HA:cKO parasites expressing AnnexinV-mNeonGreen. PKG and GAP50 were
used as controls for the cytosolic and membrane compartments, respectively. A small amount of
PKG is also observed in the membrane fractions, consistent with previous reports (Hopp et al.,
2012). mNeon Green signal is mainly observed in the cytosolic fraction at the predicted
molecular weight of the AnnexinV-mNeonGreen fusion protein (~63 kDa) for both DMSO- and
RAP-treated samples, with a greater amount detected in the latter.
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3.3 Discussion
Recent whole genome screens in both P. falciparum (Zhang et al., 2018) and P. berghei
(Bushell et al., 2017) predict that GCα is dispensable for asexual growth, however pre-
vious attempts to disrupt GCα in Plasmodium parasites have been unsuccessful (Taylor
et al., 2008; Moon et al., 2009; Kenthirapalan et al., 2016), indicating that it plays an es-
sential role in the asexual blood stage of infection. The data described in this chapter
confirm that GCα is indeed expressed in blood stage schizonts, where it localises to the
parasite periphery. Furthermore, using the conditional DiCre system, this study has defin-
itively demonstrated that GCα is essential for asexual parasite growth. Despite deletion of
both ATPase and GC domains, the phenotype observed in GCα knockout parasites was
consistent with inhibition of PKG activity with mature GCα knockout schizonts unable to
egress, similar to a C2 block. Indeed, GCα-deficient parasites are unable to synthesise
cGMP and release Ca2+ from internal stores, consistent with PKG not being activated.
Chemical complementation with PET-cGMP led to a substantial rescue of GCα knockout
parasite growth, demonstrating that GCα could be bypassed by directly activating PKG.
Surprisingly, this growth could be sustained over several cycles, despite deletion of the
ATPase domain, which appears to be essential for parasite growth. Therefore chemical
complementation of the GC domain is sufficient to bypass the loss of the ATPase domain,
indicating that the ultimate role of the ATPase is in cGMP synthesis, potentially through
regulating the activity of the GC domain.
Despite attempting to determine whether the ATPase is involved in flipping phosphatidylser-
ine across the plasma membrane, it remains unclear whether GCα is indeed a phosphol-
ipid flippase. Studies in Toxoplasma have shown that TgGC does not display PS flipping
activity (Bisio et al., 2019). Instead several studies have shown that the ATPase domain is
required for sensing pH, K+ and phosphatidic acid (PA) levels, which leads to the release
of Ca2+ (Yang et al., 2019; Bisio et al., 2019). Further work will be required to determine
whether GCα also plays a role in sensing pH, K+ and PA levels.
Interestingly, full length GCα could not be detected by western blot analysis. Instead,
it appears to migrate as a smaller band at around 175 kDa. A similar phenomenon is also
observed in Toxoplasma (Jia et al., 2017; Bisio et al., 2019; Brown and Sibley, 2018) and
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in recombinant Paramecium GC expressed in insect cells (Linder et al., 1999). However,
Brown and Sibley have shown that the ATPase and GC domains must be expressed on
the same polypeptide in order for efficient microneme secretion to take place in Toxo-
plasma. Furthermore, the ATPase domain seems to be required for correct localisation
of the GC domain to the apical end of tachyzoites (Brown and Sibley, 2018; Bisio et al.,
2019). The results from these studies in Toxoplasma would suggest that the fragments
observed are likely an artefact due to protein degradation. It remains unclear whether
separation of the ATPase domain from the GC domain would also ablate GC activity in P.
falciparum. However, genetic complementation of the GCα:HA:cKO parasite line with a
version of GCα which expresses each domain on a separate polypeptide could be done
in the future to address this question. In Toxoplasma two chaperones are required for
correct GC localisation and activity. This includes a cell division control 50 (CDC50) and
a unique GC organiser (UGO) protein which chaperone the ATPase and GC domains,
respectively (Bisio et al., 2019). Although P. falciparum encodes three putative CDC50s,
it is unclear whether a UGO protein is encoded in the genome. BLAST analysis revealed
that a conserved protein of unknown function (PF3D7_1003000) shows closest homology
to UGO, however these proteins share only ~30% identity. Pulldowns using the GCα:HA
tagged line will be required to identify GCα interaction partners.
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4 Inducible knockdown of Myosin A using the glmS
ribozyme
Initiation of the erythrocytic stage of the malaria parasite life cycle, responsible for disease
pathology, requires active invasion of red blood cells by merozoites. This process in-
volves substrate-dependent motility powered by Myosin A (MyoA), a motor protein which
forms part of the glideosome. Typically, myosins are comprised of three domains (Sellers,
2000); the head domain, which binds to actin filaments and hydrolyses ATP; the neck do-
main, which acts as a linker for transducing force generated by the head domain and con-
tains IQ motifs which are binding sites for myosin light chains; and a tail domain, which
binds to cargo and can also have a regulatory role. Myosins generate force through a
power stroke mechanism, which couples ATP hydrolysis to conformational changes that
lead to the motor binding further along the actin filament (Tyska and Warshaw, 2002).
Most myosins move along the actin filament toward the barbed (+) end, however myosin
VI moves toward the pointed (-) end.
MyoA belongs to class XIV myosins, a unique group of single-headed myosins specific to
apicomplexans and some ciliates. Of the 6 myosins encoded by Plasmodium parasites,
only MyoA is well conserved across apicomplexans (Wall et al., 2019). At the start of this
PhD project, there were no published reports of a MyoA knockout in Plasmodium para-
sites. Two whole genome screens in P. falciparum (Zhang et al., 2018) and P. berghei
(Bushell et al., 2017) indicate that MyoA is essential for blood stage growth. In Toxo-
plasma, TgMyoA is important for egress and gliding motility and invasion (Meissner et al.,
2002; Andenmatten et al., 2013), however it is not essential since its function can be com-
pensated for by Myosin C (Egarter et al., 2014; Frénal et al., 2014). However, disruption
of GAP45 in P. falciparum parasites revealed that the actomyosin motor is required for
merozoite invasion, but not egress (Perrin et al., 2018). Therefore it is likely that MyoA is
also required for merozoite invasion of host erythrocytes.
Currently, it is unclear how the activity of MyoA is regulated, since it lacks a TEDS
consensus sequence (Heintzelman and Schwartzman, 1997), a phosphorylatable mo-
tif which regulates the mechanochemical activity of the motor (Bement and Mooseker,
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1995). As mentioned earlier in the introduction, MyoA is phosphorylated in a PKG-
dependent manner at a single site, Ser19 (Alam et al., 2015). Phosphorylation of TgMyoA
at Ser21, the equivalent residue in Toxoplasma gondii, appears to be important for effi-
cient gliding motility and egress from the host cell (Tang et al., 2014; Gaji et al., 2015). It
is possible that similar to Toxoplasma, phosphorylation of MyoA at Ser19 may also serve
as a mechanism to regulate the actomyosin motor activity in Plasmodium parasites. Prior
to investigating the effect of phosphorylation of PfMyoA on motor activity and parasite vi-
ability, the aim of this chapter was to generate a Plasmodium falciparum MyoA conditional
knockdown line using the glmS ribozyme system in order to determine whether MyoA is
essential during the blood stages of infection.
The glmS ribozyme, found in Gram-positive bacteria, is located in the 5’ untranslated re-
gion (UTR) of the glmS gene, which encodes the enzyme that synthesises glucosamine-
6-phosphate (GlcN6P) from glutamine and glucose-6-phosphate. The ribozyme is a ge-
netic regulatory element which binds to small molecules and regulates the expression
of genes at the mRNA level (Serganov and Nudler, 2013). When physiological levels of
GlcN6P are high, this small molecule binds to and activates the latent self-cleavage activ-
ity of the ribozyme, resulting in degradation of the mRNA and down-regulation of glmS
expression and GlcN production (Watson and Fedor, 2011). In 2013, Prommana et al.
showed that the glmS ribozyme could be used in P. falciparum to conditionally modulate
gene expression. This can be achieved by placing the glmS sequence in the 3’UTR of a
target gene and adding GlcN to the culture medium. Reporter genes in transgenic para-
sites harbouring the ribozyme sequence in the 3’UTR were successfully disrupted upon
addition of GlcN leading to a knockdown in mRNA and protein levels. Several studies
have since successfully used the glmS ribozyme to generate conditional gene knock-
downs (Parkyn Schneider et al., 2017; Counihan et al., 2017; Cobb et al., 2017; Ghosh
et al., 2018) with some genes showing almost complete reduction in protein levels. This
system therefore provides a conditional reverse genetic tool which allows for the study
of essential genes which otherwise cannot be directly disrupted. Since this system is
reversible and the level of knockdown can be regulated by the amount of GlcN added
to parasite cultures, it offers a more modular approach in comparison to the DiCre sys-
tem which completely disrupts gene expression and is irreversible. However, the glmS
ribozyme has had varying degrees of success, with some genes displaying only mild
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reductions in protein levels (Florentin et al., 2017).
4.1 Results
4.1.1 Generating conditional Myosin A knockdown parasite lines
In order to generate a MyoA conditional knockdown parasite line, CRISPR/Cas9-mediated
gene editing was used to introduce the glmS sequence into the 3’UTR of the endogenous
MyoA gene (Figure 4.1.A). 3D7a parasites were transfected with the pUF1-Cas9 plasmid
(Ghorbal et al., 2014), which contains the Cas9 expression cassette and the yeast di-
hydroorate dehydrogenase (yDHODH) selection marker conferring resistance to DSM1,
a potent inhibitor of the parasite DHODH; along with a linearised construct containing the
sgRNA and the repair template comprising of two homology regions flanking the cleav-
age site, and a recodonised region that would insert an mCherry gene sequence at the 3’
end of the endogenous MyoA gene and introduce the glmS sequence just after the stop
codon. The repair template would also replace the endogenous 3’UTR with the PbDT
3’UTR and introduce a hDHFR cassette which confers resistance to WR99210 in order
to select for integration. The repair template was linearised in order to prevent episome
formation and to ensure that drug pressure would select for parasites where integration
of the repair template containing the hDHFR cassette into the MyoA locus had occurred.
After transfection, parasites were treated for one week with 1.5 µM DSM1 to select for the
pUF1-Cas9 plasmid, and 2.5 nM WR99210 to select for integration of the repair template.
Parasites were subsequently cycled on/off WR99210 three times in order to enrich the
population for parasites where integration of the repair template had occurred. Upon con-
firming successful integration by PCR, the resulting parasite line was cloned by limiting
dilution (Thomas et al., 2016). Two clones were obtained and called MyoA:mCherry:glmS
clone 1 and clone 2. Genomic DNA (gDNA) was extracted from the clones and integra-
tion was confirmed by PCR while a control PCR which would only amplify a product in the
absence of integration confirmed that the clones did not contain any wild type DNA (Fig-
ure 4.1.B). Sanger sequencing was performed across the glmS sequence to confirm that
the clones did not harbour any mutations that might affect GlcN-mediated knockdown.
A second parasite line called MyoA:mCherry, which lacks the glmS sequence, was gen-
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Figure 4.1. Generation of a MyoA:mCherry:glmS conditional knockdown line. A.
Schematic representation of the CRISPR/Cas9-based approach used to introduce an mCherry
tag at the 3’ end of the endogenous MyoA gene and install the glmS ribozyme in the 3’UTR. In
the absence of GlcN, MyoA mRNA is transcribed and translated. Upon addition of GlcN,
activation of the latent self-cleavage activity of the glmS ribozyme results in degradation of the
mRNA, and knockdown of protein expression. Scissors indicate CRISPR/Cas9 cleavage sites,
while arrows represent the relative position of oligonucleotide primers used for diagnostic PCR
screens. B. Diagnostic PCR analysis confirming successful tagging of the MyoA locus in two
independent clones, and absence of WT locus. A DNA control PCR was included, which
amplified a small segment at an independent locus to test the quality of the DNA used for PCR.
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erated in a similar manner to serve as a negative control for glmS-mediated knockdown
experiments (Figure 4.2.A). gDNA was extracted from the generated line and integration
was confirmed by PCR (Figure 4.2.B). Since the wild type locus could not be detected by
PCR, the uncloned population was used in subsequent experiments.
Figure 4.2. Generation of a control MyoA:mCherry line. A. Schematic representation of the
CRISPR/Cas9-based approach used to introduce an mCherry tag at the C-terminal end of the
endogenous MyoA gene. Scissors indicate CRISPR/Cas9 cleavage sites, while arrows represent
the relative position of oligonucleotide primers used for diagnostic PCR screens. B. Diagnostic
PCR analysis confirming successful tagging of the MyoA locus, and absence of WT locus. A
DNA control PCR was included, which amplified a small segment at an independent locus to test
the quality of the DNA used for PCR.
4.2 Glucosamine displays toxicity when used at high concen-
trations
When using a compound on parasite cultures, it is important to determine whether it
displays any toxic effects. In the original paper, Prommana et al. used GlcN at concen-
trations ranging from 2.5 mM to 10 mM. Despite this, the EC50 of GlcN for P. falciparum
was not reported and the effect of GlcN on wild type parasite survival and viability was
not assessed. To determine whether the concentrations used in the paper showed any
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toxicity, the growth of MyoA:mCherry parasites grown in the absence of GlcN or in the
presence of 5 mM or 10 mM GlcN was assessed using a flow cytometry-based replica-
tion assay over two replication cycles. Culture media and GlcN were replenished every
day since GlcN is not stable at 37◦C. The results from this assay revealed that treatment
of parasites with 5 mM GlcN showed no considerable reduction in parasitemia compared
to the untreated control, while parasites treated with 10 mM GlcN showed a 65% reduc-
tion in parasitemia at the end of the assay (Figure 4.3.). Since the MyoA:mCherry line
lacks the glmS sequence, the reduction in replication observed in the presence of 10 mM
GlcN can be attributed to the toxic effects of this compound on the parasites. Therefore
5 mM GlcN was subsequently used in all further experiments.
Figure 4.3. Testing MyoA:mCherry parasite growth in the presence of 5 mM and 10 mM
GlcN. Flow cytometry-based growth curves showing the replication of MyoA:mCherry parasites
in either the absence of GlcN or in presence of 5 mM or 10 mM GlcN over two replication cycles.
10 mM GclN led to a marked reduction in parasite growth, while the growth of parasites in 5 mM
GlcN was similar to that of the 0 mM control. Results are the mean of two independent
experiments, each performed in triplicate. Error bars represent the standard deviation.
4.2.1 A partial knockdown of Myosin A results in a slight growth defect
To determine whether addition of GclN resulted in the knockdown of MyoA at the mRNA
level, RT-qPCR analysis was performed on the MyoA:mCherry control line and the MyoA:m-
Cherry:glmS clones. All three cultures were tightly synchronised to a two hour window the
cycle before. Early stage rings were then diluted to the desired parasitemia and treated
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with or without GlcN. Parasites were also treated with 1.5 µM compound 2 (C2), a PKG-
specific inhibitor that blocks egress, in order to ensure similar staging across all parasite
cultures. RNA was then harvested from these parasites at around 48 hours post inva-
sion. RT-qPCR was then performed on these samples using primers 9 and 19 to amplify
the MyoA gene and primers 20 and 21 to amplify the PDEα gene. Primer sequences
are listed in table 4 in the appendix. The relative copy number of MyoA cDNA was de-
termined by normalising against the PDEα gene (PF3D7_1209500), which has a similar
expression profile to MyoA and shows little variation in mRNA levels at 40-48 hpi when
MyoA is maximally expressed (Otto et al., 2010). Interestingly, addition of 5 mM GlcN
to the control MyoA:mCherry line resulted in a 25% increase in relative MyoA transcripts
when compared to the untreated sample (Figure 4.4.). This could have resulted either
from the upregulation of MyoA expression, or a downregulation of PDEα expression in
the presence of GlcN. However, both MyoA:mCherry:glmS clones showed a reduction in
relative MyoA transcript levels to varying degrees following treatment with GclN (Figure
4.4.). Clone 1 displayed a statistically significant reduction of 53% when compared to
the untreated sample, while the 29% reduction displayed by clone 2 was not statistically
significant.
Figure 4.4. Analysis of MyoA cDNA levels in response to GlcN treatment. qRT-PCR analysis
of MyoA cDNA levels. The bars represent the ratio of relative MyoA transcript levels in parasites
treated with with or without 5 mM GlcN. The results from each parasite line were normalised to
the matched untreated control. The data presented represent the mean of two independent
experiments, each performed in duplicate. Values are normalised for PDEα (PF3D7_1209500)
transcripts. Error bars represent the standard deviation. Statistical significance was measures by
Welch corrected t-test, * signifies p < 0.05 whereas n.s. indicates not significant (p > 0.05).
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To determine whether a knockdown of MyoA could be achieved at the protein level by
adding GlcN, western blot analysis was performed using MyoA:mCherry and MyoA:m-
Cherry:glmS parasite material harvested from C2 arrested schizonts treated with or without
GlcN for 46 hours. An α-mCherry antibody was used to probe for MyoA, while α-GAPDH
antibody was used as a loading control. Relative quantities of MyoA were estimated
by densitometry analysis of data from three independent experiments. MyoA levels in
each sample were normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
levels and expressed as a percentage of the corresponding untreated sample. When the
data from the three biological replicates was collated, there was no significant reduction of
MyoA at the protein level in any of the samples (Figure 4.5.), including MyoA:mCherry:glmS
clone 1 which displayed a significant knockdown at the mRNA level.
Figure 4.5. Ribozyme-mediated knockdown of MyoA expression. A. A representative
western blot of the MyoA:mCherry control line and MyoA:mCherry:glmS clones treated with or
without 5 mM GlcN probed with an α-mCherry antibody to determine levels of MyoA and an
α-GAPDH antibody to serve as a loading control. B. Densitometry analysis of three biological
replicates showing the relative band intensity of mCherry in each sample. This was calculated by
normalising the α-mCherry band intensity to the α-GAPDH band intensity. Relative intensities
were normalised to the matched untreated control. Statistical significance was measures by
Welch corrected t-test, where n.s. indicates not significant (p > 0.05).
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The growth of MyoA:mCherry and MyoA:mCherry:glmS parasites in the presence or ab-
sence of 5 mM GlcN was measured in a flow-cytometry based replication assay across
two cycles. MyoA:mCherry:glmS clone 1 and clone 2 showed a 28% and 45% reduction
in parasitemia respectively, while the growth of the control MyoA:mCherry parasites was
unaffected (Figure 4.6.). Therefore despite GlcN resulting in a partial downregulation of
MyoA at the mRNA and protein level in the MyoA:mCherry:glmS clones, growing para-
sites in the presence of GlcN over several cycles resulted in a significant decrease in
parasite replication rate that was not observed in the control line. The reduction in para-
site growth did not correspond to the reduced levels seen in the RT-qPCR experiments
since clone 1 showed the biggest decrease in mRNA levels, but had less of a growth
defect when compared to clone 2.
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Figure 4.6. Ribozyme-mediated knockdown of MyoA expression. A-C. Flow
cytometry-based growth curves showing the replication of MyoA:mCherry and
MyoA:mCherry:glmS clones 1 and 2 in response to 5 mM GlcN over two replication cycles. The
control MyoA:mCherry line showed no growth defect in the presence of 5 mM GlcN, while
MyoA:mCherry:glmS clone 1 and clone 2 showed a marked reduction in parasitemia at the end
of the assay, by 25% and 45%, respectively. Results are the mean of two independent
experiments, performed in triplicate. Error bars represent the standard deviation.
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4.3 Discussion
In P. falciparum parasites, Myosin A, which forms part of the glideosome, is thought to be
the motor that helps power invasion of erythrocytes during the asexual blood stages of
the lifecycle. Several attempts at generating a direct MyoA knockout in P. falciparum have
been unsuccessful, including a recent global insertional mutagenesis screen in P. fal-
ciparum (Zhang et al., 2018) along with a genome-wide mutagenesis screen in P. berghei
(Gomes et al., 2015; Bushell et al., 2017), providing evidence to suggest that MyoA is es-
sential. Therefore, to study the role of MyoA, a P. falciparum line containing the the
glmS ribozyme sequence in the 3’UTR of the MyoA gene was generated to conditionally
knockdown MyoA by adding GclN to the culture medium. Although the inducible glmS
knockdown system has been a valuable reverse genetic tool allowing for the conditional
knockdown of some P. falciparum genes, the data presented in this chapter demonstrate
that this system is only partially effective at knocking down MyoA at the mRNA and pro-
tein level. As mentioned previously, this system has shown varying degrees of success
(Florentin et al., 2017), however it remains unclear why certain genes are amenable to
GlcN-mediated knockdown while others are not.
Furthermore, the glmS system showed marked differences in the degree of effectiveness
between the MyoA:mCherry:glmS clones, and discrepancies between different types of
experiments. Although a protein level knockdown was not detected in cycle 0, a growth
defect became apparent after treating the clones for several cycles in the presence of
GlcN. Ultimately the role of MyoA could not be elucidated using this system. Therefore,
other reverse genetic approaches, such as the Cre recombinase-mediated conditional
deletion system (Collins et al., 2013a), will be required to understand the role of MyoA in
host cell invasion.
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5 Myosin A is vital for blood stage merozoite inva-
sion but is dispensible for gametocyte develop-
ment and gametogenesis
Since the level of GlcN-mediated knockdown of MyoA in the MyoA:mCherry:glmS para-
site line described in the previous chapter were not sufficient to investigate the role of
MyoA, an alternative approach was adopted to generate a conditional PfMyoA knock-
out line. This was achieved using the conditional dimerisable Cre recombinase (DiCre)
system (Collins et al., 2013a) which was also used to generate the GCα knockout line
described in Chapter 3.
5.1 Results
5.1.1 Generation of a P. falciparum Myosin A conditional knockout line
To generate a MyoA conditional knockout (cKO) using the DiCre system, a two step
approach was taken. First, a loxP site was introduced in the 5’ untranslated region
(UTR) of the endogenous MyoA gene, just upstream of the start codon using marker-free
CRISPR/Cas9-mediated gene editing. 3D7a parasites harbouring the DiCre cassette in
the Pfs47 locus (a gift from Marta Tiburcio, Francis Crick Institute London, UK) were
transfected with a linearised repair template consisting of two homology arms flanking
a loxP site, along with a pool of two different pDC2-Cas9-hDHFR plasmids (Lim et al.,
2017), each harbouring a different gRNA to maximise editing efficiency of the locus (Fig-
ure 5.1.A). Transfected parasites were cultured in the presence of 2.5 nM WR99210 for 9
days to select for parasites harbouring at least one of the pDC2-Cas9-hDHFR plasmids.
Parasites were detected after around 4 weeks and gDNA was extracted. Integration of
the repair template would lead to the removal of the two endogenous introns, effectively
making the MyoA coding sequence shorter in loxP:MyoA parasites. This was exploited
for PCR analysis to confirm successful integration of the loxP site. Indeed, the PCR amp-
lification product obtained from the transfectants was smaller than that from the parental
line (Figure 5.1.B), confirming integration of the loxP site. Since the pDC2-Cas9-hDHFR
plasmids do not encode a negative selection cassette, the resulting loxP:MyoA line was
cultured in the absence of WR99210 for 1 month to promote loss of the pDC2-Cas9-
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hDHFR plasmids so that the hDHFR cassette could be recycled in future transfections.
The parasites were cloned by limiting dilution (Thomas et al., 2016) and the resulting
loxP:MyoA clone was WR99210 sensitive, and the hDHFR cassette could not be ampli-
fied by PCR (data not shown).
Figure 5.1. Introduction of a loxP site in the MyoA 5’UTR. A. Schematic representation of the
marker-free CRISPR/Ca9-mediated approach used to introduce a loxP site into the 5’UTR of the
MyoA gene, 6 basepairs upstream of the start codon. Scissors indicate CRISPR/Cas9 cleavage
sites, while arrows represent the relative position of oligonucleotide primers used for diagnostic
PCR screens. B. Diagnostic PCR analysis showing amplification of a smaller PCR product in
loxP:MyoA parasites compared to parental wild type parasites, confirming successful integration
of the repair template and deletion of the endogenous introns in loxP:MyoA parasites.
A second CRISPR/Cas9-mediated gene editing step was carried out to introduce an
mCherry tag at the 3’end of the MyoA gene followed by a second loxP site (Figure 5.2.A).
The repair template would also replace the endogenous 3’UTR with the PbDT 3’UTR and
introduce a hDHFR cassette to select for integration. This was achieved by transfecting
clonal loxP:MyoA parasites with the linear repair template used to generate the control
MyoA:mCherry line described in Chapter 4, along with the pUF1-Cas9 plasmid (Ghorbal
et al., 2014). Following transfection, parasites were treated with 1.5 µM DSM1 to select
for the pUF1-Cas9 plasmid, and 2.5 nM WR99210 for 9 days to select for integration of
the repair template. Parasites were subsequently cycled on/off WR99210 three times, in
order to enrich the population for parasites where integration of the repair template had
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occurred. PCR analysis confirmed integration of the mCherry tag and absence of wild
type locus in the resulting MyoA:mCherry:cKO line (Figure 5.2.B).
Figure 5.2. Generation of a MyoA:mCherry:cKO line. A. Schematic representation of the
CRISPR/Cas9-mediated approach used to introduce an mCherry fluorescent tag gene at the 3’
end of the endogenous MyoA gene, along with an hDHFR cassette and a second loxP site.
Scissors indicate CRISPR/Cas9 cleavage sites, while arrows represent the relative position of
oligonucleotide primers used for diagnostic PCR screens. B. Diagnostic PCR analysis
confirming integration of the mCherry tag in MyoA:mCherry:cKO parasites and absence of wild
type locus. A DNA control PCR was included, which amplified a small segment at an
independent locus to test the quality of the DNA used.
5.1.2 Myosin A is essential for parasite invasion but not egress
The strategy was designed so that rapamycin-mediated activation of the DiCre subunits
would lead to the excision of the entire MyoA gene, and loss of mCherry signal in the
MyoA:mCherry:cKO line (Figure 5.3.A). Early ring stage MyoA:mCherry:cKO parasites
were treated with either 100 nM rapamycin or the equivalent volume of DMSO for four
hours. gDNA was harvested from the parasites once they became segmented schizonts
and PCR analysis confirmed that RAP treatment led to the excision of the MyoA gene,
however a faint integration band could still be detected in the RAP-treated sample, in-
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dicating that excision was not 100% effective (Figure 5.3.B). Western blot analysis re-
vealed an 81% reduction in MyoA-mCherry at the protein level (Figure 5.3.C) confirming
that RAP-mediated excision was effective but incomplete. Immunofluorescence imaging
also confirmed the loss of RFP signal in RAP-treated parasites, while in DMSO-treated
parasites, MyoA colocalises with GAP45 at the periphery of intracellular merozoites as
expected (Figure 5.3.D). Despite several attempts to improve the excision efficiency of
MyoA:mCherry:cKO parasites by testing different concentrations of rapamycin, treatment
times and by treating at different stages of the lifecycle, there was always a substantial
proportion of unexcised parasites (data not shown).
A flow cytometry-based growth assay was performed on DMSO- and RAP-treated MyoA:m-
Cherry:cKO parasites to assess the impact of MyoA disruption on parasite growth. MyoA-
deficient parasites displayed a significant growth defect and were unable to proliferate in
culture, confirming that MyoA is essential for parasite growth (Figure 5.4.A). Examination
of Giemsa-stained blood smears from MyoA:mCherry:cKO cultures from cycle 1 post ex-
cision showed that in RAP-treated cultures, there was an accumulation of free merozoites
and an absence of ring stage parasites, demonstrating a defect in RBC invasion (Figure
5.4.B). Although MyoA knockout parasites appear to egress normally, it is possible that
they may display minor changes in egress kinetics compared to wild type parasites.
To determine whether there were any changes in the egress kinetics in MyoA-deficient
parasites, live time-lapse DIC and fluorescence microscopy was performed on mature
DSMO- and RAP-treated MyoA:mCherry:cKO schizonts released from a C2 block that
were mixed and imaged in the same imaging chamber. As can be seen in figure 5.5.A,
both DMSO- and RAP-treated parasites were able to rupture, with no statistical difference
in the rate of egress between RAP- and DMSO-treated parasites (Figure 5.5.B). Consist-
ent with this, examination of culture supernatants from rupturing DMSO- and RAP-treated
schizonts confirmed that there were no changes in the release of the PV-resident serine
repeat antigen 5 (SERA5), which is released into the culture supernatant during egress
(Figure 5.5.C). Together, these results confirm that MyoA is not required for egress, con-
sistent with the results observed when GAP45 is disrupted in P. falciparum parasites
(Perrin et al., 2018).
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Figure 5.3. RAP treatment of MyoA:mCherry:cKO parasites results in a loss of
MyoA-mCherry expression. A. Schematic representation of RAP-mediated excision of the
entire MyoA gene. Arrows represent the relative position of oligonucleotide primers used for
diagnostic PCR screens. B. Diagnostic PCR analysis of DMSO- and RAP-treated
MyoA:mCherry:cKO parasites showing efficient yet incomplete excision of the MyoA gene
following RAP treatment. A DNA control PCR was included, which amplified a small segment at
an independent locus to test the quality of the DNA used. C. Western blot analysis of DMSO-
and RAP-treated MyoA:mCherry:cKO parasites probed with an α-mCherry antibody (ab183628)
confirming tagging of MyoA in the DMSO control samples and RAP-induced reduction in MyoA
expression levels. Blots were also probed with an α-GAPDH antibody to serve as a loading
control. D. IFA showing colocalisation of RFP and GAP45 signals at the periphery of individual
merozoites in DMSO-treated MyoA:mCherry:cKO parasites, and ablation of RFP signal by
RAP-treatment. Scale bar, 5 µm.
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Figure 5.4. Ablation of MyoA expression leads to a severe growth defect and the inability
of merozoites to invade host erythrocytes. A. Growth curves showing parasitemias of
MyoA:mCherry:cKO parasites treated with either DMSO or RAP, measured by flow
cytometry-based sorting of SYBR Green positive cells. Data points plotted are means from two
repeat experiments, each performed in triplicate. Error bars represent the standard deviation.
RAP-treatment resulted in a severe growth defect in MyoA:mCherry:cKO parasites. B.
Representative microscopy images of Giemsa-stained parasites from DMSO- and RAP-treated
MyoA:mCherry:cKO cultures, showing the presence of rings in DMSO-treated samples and the
absence of rings in RAP-treated samples, where merozoites appeared attached to erythrocytes,
indicating an invasion defect. Scale bar, 5 µm.
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Figure 5.5. Egress kinetics are not altered in MyoA knockout parasites. A. DIC and
fluorescence images from time lapse video microscopy of DMSO- and RAP-treated
MyoA:mCherry:cKO schizonts taken at 5 minutes and 30 minutes after releasing from a C2
block. DMSO-treated parasites are mCherry positive, while RAP-treated parasites are mCherry
negative due to excision of the MyoA:mCherry sequence. Schizonts from the first frame that
rupture over the course of the video are circled in white. Scale bar, 10 µm. B. Quantification of
the time taken for DMSO- and RAP-treated schizonts to egress. Data are collected from 3
videos. The average time for DMSO-treated parasites to egress was 14 minutes while for
RAP-treated parasites it was 13.26 minutes. Statistical significance was measures by unpaired
t-test, where n.s. indicates not significant (p > 0.05). C. Western blot analysis monitoring the
release of SERA5 into the culture supernatant of DMSO- and RAP-treated MyoA:mCherry:cKO
schizonts, as a measurement of egress over time. Pellet samples were included as loading
controls. D. Densitometry analysis of the egress assay western blot samples shown in figure
5.5.C., showing that no significant changes in SERA5 release into the supernatant between
DMSO- and RAP-treated MyoA:mCherry:cKO parasites.
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5.1.3 Deletion of Myosin A does not disrupt expression of other glideo-
some components or formation of the IMC
IFA (Figure 5.6.A) and western blot analysis (Figure 5.6.B) performed on DMSO- and
RAP-treated MyoA:mCherry:cKO parasites revealed that both localisation and expression
levels of Myosin A-tail interacting protein (MTIP) and glideosome-associated protein 45
and 50 (GAP45 and GAP50) were not affected upon depletion of MyoA, suggesting that
glideosome stability and assembly is not reliant on the presence of the motor protein.
On the other hand, as reported by Perrin et al., deletion of GAP45 leads to a significant
reduction in MTIP and MyoA levels, indicating that the stability of these proteins is reliant
on expression of GAP45, which may serve as a mechanism for degrading excess MyoA
that is not actively engaged with the glideosome to prevent it from binding to actin and
blocking interaction of MyoA that has formed an active complex with the glideosome.
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Figure 5.6. Glideosome assembly and stability is not affected in MyoA-deficient parasites.
A. IFA showing colocalisation of RFP signal with other glideosome components including
GAP45, GAP50 and MTIP in DMSO-treated MyoA:mCherry:cKO parasites. RAP-mediated
deletion of MyoA did not disrupt the peripheral localisation of GAP45, GAP50 or MTIP. Scale
bars, 5 µm. B. Representative western blot analysis showing the expression levels of
MyoA-mCherry, GAP45, GAP50, MTIP in DMSO and RAP-treated MyoA:mCherry:cKO
parasites. Blots were also probed with an α-GAPDH antibody to serve as a loading control. C.
Densitometry analysis of the western blot samples shown in Figure 6B. Relative band intensities
were calculated by normalising samples to the matched GAPDH signal. Samples were then
normalised to their matched DMSO-treated controls. Data presented are means from two
independent experiments. Error bars represent standard deviation. Results indicate that there
were no significant changes in expression levels of MTIP, GAP45 or GAP50 upon RAP-mediated
excision of MyoA. RAP treatment led to a significant reduction in RFP levels, consistent with
deletion of MyoA-mCherry. Statistical significance was measures by unpaired t-test, where n.s.
indicates not significant (p > 0.05) whereas *** signifies p < 0.001.
103
5.1.4 Genetic complementation of MyoA:mCherry:cKO parasites rescues
the growth defect when the endogenous MyoA gene is deleted
To confirm that the growth defect observed upon RAP treatment of MyoA:mCherry:cKO
parasites was specifically due to deletion of MyoA and not due to rapamycin treatment or
any unidentified genomic alterations in these parasites, an "inducible expression" genetic
complementation approach was employed. This approach, developed by Avnish Patel
(LSHTM London, UK), has previously been used to rescue PKA knockout parasites by
RAP-activated expression of a second ectopic copy inserted into the p230p locus (Patel
et al., 2019). MyoA:mCherry:cKO parasites were transfected with the pDC2-p230p-Cas9-
gRNA plasmid which would introduce a double strand break in the p230p locus (Knuepfer
et al., 2017; Mogollon et al., 2016) and a linearised repair template which would integrate
a promoterless second copy of the MyoA gene tagged at the 3’ end with the enhanced
green fluorescent protein (eGFP) gene (Figure 5.7.A). The repair template would also in-
troduce an expression cassette consisting of a MyoA promoter followed by a floxed cod-
ing sequence which would express cytosolic eGFP and confer resistance to blasticidin S
(BSD). The eGFP and blasticidin S deaminase (BSDr) genes were separated by a T2A
peptide, a self-cleaving peptide which would allow the two genes to be expressed as sep-
arate polypeptides. Two days after transfection, parasites were treated with 5 µg/ml BSD
(Sigma) for one week to select for integration. BSD resistant parasites, were observed
around 4 weeks post transfection and the resulting line was called MyoA:mCherry:cKO
+ p230p:MyoA(WT):eGFP. Live fluorescence microscopy confirmed that these parasites
were both mCherry and GFP positive, with the mCherry signal localising to the periphery
of individual merozoites, while the GFP signal was diffuse and encompassed the parasite
cytosol (Figure 5.7.B).
The strategy was designed so that RAP treatment of MyoA:mCherry:cKO + p230p:MyoA-
(WT):eGFP parasites would lead to deletion of the endogenous MyoA:mCherry and the
floxed eGFP-T2A-BSDr coding sequences, placing the ectopic MyoA:GFP sequence un-
der the control of the MyoA promoter (Figure 5.8.A). Early ring stage parasites were
treated with 100 nM RAP or the equivalent volume of DMSO for 3 hours and segmented
schizonts from the excision cycle were examined by live fluorescence microscopy. This
revealed that RAP-treated parasites displayed a loss in mCherry signal and a change in
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Figure 5.7. Generation of a genetically complemented MyoA:mCherry:cKO line. A.
Schematic representation of the CRISPR/Cas9-mediated approach used to generate an
inducible genetically complemented MyoA:mCherry:cKO line. Integration would lead to the
expression of cytosolic eGFP and BSDr, under the control of the MyoA promoter. Scissors
indicate CRISPR/Cas9 cleavage sites. B. Live fluorescence microscopy confirming cytosolic
expression of eGFP in MyoA:mCherry:cKO + p230p:MyoA(WT):eGFP parasites, confirming
successful integration of the repair template. The GFP and mCherry signals do not overlap,
confirming that expression of MyoA(WT)-eGFP could not be detected prior to RAP treatment.
Scale bar, 5 µm.
GFP pattern from cytosolic to peripheral, confirming deletion of the endogenous MyoA:mCherry
and expression of MyoA-GFP from the p230p locus (Figure 5.8.B). Western blot analysis
also confirmed that RAP treatment resulted in a reduction but not total loss of MyoA-
mCherry expression and induction of MyoA-GFP expression (Figure 5.8.C). However,
cytosolic eGFP which would migrate as a ~30 kDa band could not be detected in either
DMSO- or RAP-treated samples. A flow cytometry-based growth assay demonstrated
that RAP-treated MyoA:mCherry:cKO + p230p:MyoA(WT):eGFP parasites replicated at
the same rate as control DMSO-treated parasites (Figure 5.8.D), confirming efficient ge-
netic complementation of endogenous MyoA gene deletion. These results therefore con-
firm that the growth defect observed in RAP-treated MyoA:mCherry:cKO parasites is due
to loss of MyoA expression and not due to any off target effects of RAP treatment or any
genetic abnormalities of the parasite line.
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Figure 5.8. RAP-induced transgenic expression of wild type MyoA-GFP is able to rescue
the growth defect resulting from deletion of the endogenous MyoA gene. A. Schematic
representation of RAP-induced deletion of the MyoA:mCherry at the endogenous locus and and
deletion of eGFP:T2A:BSDr at the p230p locus leading to expression of the MyoA:GFP
transgene under the control of the MyoA promoter. B. Live fluorescence microscopy of
MyoA:mCherry:cKO + p230p:MyoA(WT):eGFP showing loss of mCherry signal in RAP-treated
parasites, along with a change of eGFP localisation from cytosolic to peripheral, indicating a
switch in expression from eGFP to MyoA-eGFP. Scale bar, 5 µm. C. Western blot analysis
showing the RAP-inducible switch of expression of MyoA-mCherry from the endogenous locus to
expression of MyoA-GFP from the p230p locus. A GFP-positive band at the predicted molecular
weight of MyoA-GFP (~120 kDa) could not be detected in the DMSO-treated sample, confirming
that there is no leaky expression of MyoA-GFP from the p230p locus prior to RAP treatment. D.
Growth curves showing parasitemias of MyoA:mCherry:cKO + p230p:MyoA(WT):eGFP parasites
treated with either DMSO or RAP, measured by flow cytometry-based sorting of SYBR Green
positive cells. Data points plotted are means from two repeat experiments, each performed in
triplicate. Error bars represent the standard deviation. Results show that RAP-induced
MyoA-GFP expression rescues the growth defect observed in MyoA-mCherry deficient parasites.
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5.1.5 Myosin A displays a striking stripy pattern in gametocytes
P. falciparum gametocytes undergo remarkable morphological changes as they progress
from spherical stage I to crescent-shaped stage V gametocytes, as highlighted in the
Introduction (Figure 1.2). Little is known concerning how this transformation occurs,
however, ultrastructural changes coincide with the formation of the sub-pellicular mem-
brane complex (SMC), which is analogous to the IMC of blood stage merozoites. The
SMC is deposited as 13 disk-like structures that associate with microtubules and extend
laterally across the gametocyte as it develops. Disruption of photosensitized 5-[125I]
iodonaphthalene-1-azide labeled protein-1 (PhIL1) or PhIL1 interacting protein 1 (PIP1),
two SMC proteins expressed in gametocytes, leads to a block in gametocyte elongation
and development beyond stage III (Parkyn Schneider et al., 2017), demonstrating that
these SMC proteins play an important role in gametocyte development. Other glideosome
proteins including GAP50, GAP45, MTIP and MyoA are also expressed in gametocytes
(Dearnley et al., 2011), however, it is unclear whether these proteins play a role in gam-
etocyte development or gametogenesis. Addition of cytochalasin D, which inhibits actin
polymerisation, does not affect gametocyte development, suggesting that elongation of
the gametocyte is not driven by the actomyosin motor (Dearnley et al., 2011). However,
it is possible that MyoA may perform a structural role during gametocyte development
or may be involved in mediating rounding up and emergence from the host erythrocyte
during gametogenesis.
Having generated the MyoA:mCherry:cKO line, the localisation of MyoA throughout gam-
etocyte development as well as in rounded up gametes was monitored by IFA (Figure
5.9.). In early stage IIa gametocytes, MyoA-mCherry staining appeared diffuse, con-
sistent with MyoA localisation previously reported by Dearnley et al. using an α-MyoA
antibody. However, in stage III and IV gametocytes, a striated pattern reminiscent of
PhIL1 was observed, consistent with MyoA localising to the SMC. In stage V gameto-
cytes, the striated pattern was less apparent, which is likely due to the disassembly of the
microtubular network, which gives the SMC a more relaxed structure (Parkyn Schneider
et al., 2017). In rounded-up gametes, MyoA-mCherry localised to the periphery of the
parasite, showing a dramatic rearrangement of the SMC.
107
Figure 5.9. MyoA shows a striking striated pattern in gametocytes which transitions to the
periphery once they form rounded-up gametes. IFA showing localisation of MyoA-mCherry
along with Pfs16, a gametocyte-specific PVM protein, across several stages of gametocyte
development and in rounded-up gametes from the MyoA:mCherry:cKO parasite line. In stage IIa,
MyoA appears diffuse, however a pronounced striated pattern can be observed in stage III and
IV gametocytes. In rounded-up gametes, MyoA-mCherry localises to the periphery of the
parasite and no longer displays a striated pattern. Scale bar, 10 µm.
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5.1.6 Myosin A is not required for gametocyte development or rounding
up and emerging from RBCs during gametogenesis.
To determine whether MyoA plays a role in gametocyte development or gametogenesis,
MyoA knockout gametocytes were generated by treating sexually committed MyoA:mChe-
rry:cKO rings with 100 nM RAP for 2 hours. Live fluorescence microscopy revealed that
mCherry signal could still be detected in RAP-treated stage IIa gametocytes, appearing
as a row of puncta that is reminiscent of the nascent IMC plates. However mCherry signal
was no longer observed beyond this stage (Figure 5.10.A). MyoA-deficient parasites were
able to form mature stage V gametocytes, with no discernible differences in gametocyte
numbers when compared to the DMSO-treated control. Therefore MyoA does not appear
to be required for gametocyte development.
To examine whether ablation of MyoA expression would affect gametogenesis, mature
DMSO and RAP-treated stage V gametocytes were incubated at room temperature in the
presence 100 µM XA to induce rounding up and emergence from the host erythrocyte,
and parasites were stained using α-Pfs25 antibody conjugated to Cy3, which specifically
binds to the surface of female gametes. Parasites were incubated overnight to ensure
maximal Pfs25 staining. To visualise erythrocytes, samples were stained for 5 minutes
with wheat germ agglutinin (WGA) conjugated to Alexa Fluor 488. Live fluorescence mi-
croscopy revealed that both DMSO and RAP-treated gametocytes were able to round up
and emerge from host erythrocytes (Figure 5.10.B). Since Pfs25 is only expressed by
female gametes, male gametes would not be stained by α-Pfs25. However parasites that
were not stained by WGA or α-Pfs25 could be observed, and are highlighted by white
circles. Although Pfs25 negative gametes are likely males, a male specific marker would
be required to confirm this. However, it appears that neither male nor female gametogen-
esis is affected by the deletion of MyoA.
Collectively, these results demonstrate that MyoA is not necessary gametocyte devel-
opment, consistent with cytochalasin D treatment having no effect on gametocyte mor-
phology, and is not required for XA-mediated rounding up and emergence from RBCs.
However, this study did not assess whether exflagellation was affected in MyoA knockout
parasites, therefore it remains possible that MyoA is required for this process. It is also
likely that MyoA will be involved in mediating gliding motility observed in ookinetes.
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Figure 5.10. MyoA deletion does not cause defects in gametocyte development or the
ability to round up and emerge. A. Live fluorescence microscopy showing mCherry signal in
DMSO- and RAP-treated MyoA:mCherry:cKO parasites in different stages of gametocyte
development. Although mCherry signal could be detected in RAP-treated stage IIa gametocytes,
this signal disappeared as the gametocytes developed. Both DMSO and RAP-treated samples
were able to form mature stage V gametocytes. Scale bar, 10 µm. B. Merged live fluorescence
microscopy images of brightfield (grey), Hoechst (blue), WGA (green) and Pfs25 (red) staining of
XA-induced rounded up DMSO and RAP-treated MyoA:mCherry:cKO gametes. Pfs25-stained
female emerged gametes can be observed in both samples, as well as Pfs25-negative
WGA-negative gametes, circled in white, which are likely male gametes, since Pfs25 is a
female-specific protein. Scale bar, 10 µm.
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5.2 Discussion
The work conducted in this chapter set out to establish whether MyoA is required for
asexual blood stage growth by generating a conditional PfMyoA knockout line using the
DiCre system. At the start of this project, there were no published reports of a MyoA
knockout line in Plasmodium parasites, however pharmacological evidence revealed that
inhibition of actin polymerisation with cytochalasin D led to a block in merozoite invasion,
suggesting that the motor is required for active invasion of host erythrocytes (Miller et al.,
1979). Conditional disruption of PfGAP45, an essential component of the glideosome
which recruits the MyoA:MTIP complex to the IMC, confirmed that the actomyosin motor
is indeed required for invasion (Perrin et al., 2018). Unlike in Toxoplasma, where disrup-
tion of MyoA expression leads to an egress defect (Meissner et al., 2002; Andenmatten
et al., 2013), GAP45-deficient parasites were still able to egress, indicating that this pro-
cess is not reliant on activity of the actomyosin motor.
Using the MyoA:mCherry:cKO line, this study confirms that similar to GAP45, MyoA is
not required for egress but is essential for merozoite invasion of RBCs. However, un-
like GAP45 which is required for the stable expression of other glideosome components
and glideosome assembly, deletion of MyoA did not affect the formation of the IMC or
expression levels of other glideosome components such as GAP45, GAP50 and MTIP.
Genetic complementation of the MyoA knockout line confirmed that the growth phenotype
observed in MyoA-deficient parasites is indeed due to loss of MyoA expression and not
due to genetic abnormalities in the MyoA:mCherry:cKO line.
The work presented in this chapter also attempted to elucidate the role of MyoA in gam-
etocyte development and rounding up and emergence from the host erythrocyte during
gametogenesis. Although disruption of other SMC proteins, such as PhIL1 and PIP1
leads to a stall in gametocyte development, MyoA-deficient gametocytes showed no ab-
normalities and were able to form mature stage V gametocytes. Therefore, MyoA is
not needed for the structural integrity of the SMC in gametocytes. Furthermore, MyoA-
deficient parasites were able to round up and emerge upon XA induction, indicating that
MyoA is not involved in either of these processes. This study did not test whether exfla-
gellation was affected in MyoA knockout parasites, therefore it is possible that MyoA may
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be required for exflagellation, however it remains unclear what the functional role of MyoA
is during this stage of the lifecycle.
Recently, a PfMyoA conditional knockout line has been published (Robert-Paganin et al.,
2019). Consistent with the results reported here, the study by Robert-Paganin et al. also
demonstrated that MyoA is essential for asexual blood stage growth and is required for
invasion. Both the published MyoA knockout line and the one reported here failed to
show 100% excision efficiency, despite the 5’ loxP sites being placed in different loca-
tions. Therefore it is possible that the MyoA gene is not always accessible to the Cre
recombinase, which could be due to nucleosome occupancy or other chromatin features
of this locus.
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6 PKG-dependent phosphorylation of Myosin A mod-
ulates motor activity and is important for efficient
parasite growth
Having demonstrated that Myosin A (MyoA) is essential for P. falciparum asexual blood
stage growth in Chapter 5, the aim of this chapter was to investigate the role of MyoA ser-
ine 19 (S19) phosphorylation on motor activity and determine whether this phosphoryla-
tion event is critical for parasite survival. As mentioned previously, S19 is phosphorylated
in a PKG-dependent manner, since treatment of parasites with PKG-specific inhibitors
such as C2 leads to a drastic reduction in phosphorylation of this residue (Alam et al.,
2015; Flueck et al., 2019). However, it is not known whether MyoA is a direct substrate of
PKG or whether it is phosphorylated by a protein kinase that acts downstream of PKG. In
Toxoplasma, phosphorylation of the equivalent residue (serine 21) in TgMyoA is import-
ant for parasite survival, with mutations that ablate phosphorylation of this residue leading
to inefficient motility and a 30% and 23% reduction in egress and invasion, respectively
(Tang et al., 2014; Gaji et al., 2015). Due to the close conservation of MyoA between
Plasmodium and Toxoplasma, it is predicted that phosphorylation of PfMyoA S19 may
also be important for modulating motor activity in the malaria parasite.
In Toxoplasma, phosphorylation of TgMyoA S21 is mediated by calcium-dependent pro-
tein kinase 3 (TgCDPK3) (Gaji et al., 2015) however, it remains unclear which kinase is
responsible for phosphorylation of MyoA S19 in Plasmodium parasites. Although it was
originally thought that PKAc is responsible for MyoA phosphorylation (Lasonder et al.,
2015), conditional deletion of PKAc does not disrupt MyoA phosphorylation (Patel et al.,
2019), indicating that another kinase can carry out this function. Furthermore, although
MyoA S19 phosphorylation is dependent on PKG activation (Alam et al., 2015), prema-
ture elevation of cAMP levels by disruption of PDEβ led to phosphorylation of MyoA S19,
even in the presence of C2 (Flueck et al., 2019), which specifically inhibits PKG. There-
fore it is likely that MyoA S19 is phosphorylated by a CDPK, since these kinases act
downstream of PKG activation (Absalon et al., 2018), and treatment of mature schizonts
with BAPTA-AM, a membrane-permeable calcium chelator, dramatically reduces MyoA
S19 phosphorylation (Flueck et al., 2019).
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6.1 Results
6.1.1 Myosin A S19 is rapidly phosphorylated upon activation of PKG,
achieving maximal levels of phosphorylation in merozoites
Several studies have shown that phosphorylation of MyoA S19 in mature schizonts oc-
curs in a PKG-dependent manner, since phosphorylation of this residue is drastically
reduced in schizonts treated with PKG-specific inhibitors such as C2 (Alam et al., 2015;
Flueck et al., 2019). To test whether this could be recapitulated, mature MyoA:mCherry
schizonts were treated with either 1.5 µM C2 to specifically inhibit PKG, or with 40 µM
E64, a protease inhibitor which blocks merozoite egress downstream of PKG activation
and PVM rupture (Hale et al., 2017) (Figure 6.1.A). Western blot analysis using a pan-
MyoA antibody to probe for total MyoA, and an antibody specific for MyoA phosphorylated
at S19 confirmed that this phosphorylation event was dependent on PKG activity since
phosphorylation could not be detected in the C2-blocked sample (Figure 6.1.B). To de-
termine how quickly MyoA S19 is phosphorylated upon PKG activation, a western blot
time course was performed on C2-blocked mature MyoA:mCherry schizonts that were
released into an E64 block (Figure 6.1.C). This revealed that MyoA S19 was rapidly
phosphorylated following PKG activation, with maximal levels detected 14-18 minutes
following release of the C2 block (Figure 6.1.D).
To investigate whether there are any changes in phosphorylation levels of MyoA S19 at
different stages of the asexual blood stage, the phospho-status of MyoA:mCherry E64-
blocked schizonts, purified merozoites and newly formed rings at around 0-4 hours post
invasion (Figure 6.2.A) was analysed by western blot. This revealed remarkable changes
in the phospho-status of MyoA as the parasites transition from schizonts to merozoites
and then rings (Figure 6.2.B), with a 6-fold increase in MyoA S19 phosphorylation in
merozoites, followed by a 10-fold reduction in rings (Figure 6.2.C). This dramatic increase
in phosphorylation during the free merozoite stage, where the actomyosin motor is re-
quired for invasion, could point towards a regulatory role of this phosphorylation event.
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Figure 6.1. MyoA S19 is rapidly phosphorylated upon PKG activation. A. Schematic
representation showing stages at which C2 and E64 treatment block schizont rupture. B.
Western blot analysis of MyoA:mCherry C2 and E64-blocked schizont samples probed with a
phosphoS19-specific MyoA antibody and a pan-specific MyoA antibody to determine relative
levels of phosphorylation in each sample. C. Densitometry analysis of the western blot samples
shown in Figure 1B. Relative band intensities were calculated by normalising pS19 MyoA to total
MyoA signal in each sample. D. Western blot showing a time course of MyoA S19
phosphorylation in MyoA:mCherry schizonts released from a C2 block into an E64 block. The
blot was probed with a phosphoS19-specific MyoA antibody and a pan-specfic MyoA antibody to
determine relative levels of phosphorylation in each sample. E. Densitometry analysis of the
western blot samples shown in Figure 1D showing MyoA S19 is rapidly phosphorylated upon
PKG activation. Relative band intensities were calculated by normalising pS19 MyoA to total
MyoA signal in each sample.
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Figure 6.2. MyoA S19 undergoes pronounced stage-dependent changes in
phosphorylation during egress and invasion. A. Schematic representation of the parasite
samples analysed. B. Western blot analysis of MyoA:mCherry E64-blocked schizonts,
merozoites and ring stage samples probed with a phosphoS19-specific MyoA antibody and a
pan-specfic MyoA antibody to determine relative levels of phosphorylation in each sample. C.
Densitometry analysis of the western blot samples shown in figure 6.2.B showing dynamic
changes in MyoA S19 phosphorylation as the parasites transition from schizonts to merozoites
then rings. Relative band intensities were calculated by normalising pS19 MyoA to total MyoA
signal in each sample.
116
6.1.2 Introducing mutations into the endogenous Myosin A locus to mimic
or ablate Myosin A S19 phosphorylation
To determine whether phosphorylation of MyoA S19 is critical for P. falciparum asexual
blood stage growth, marker free CRISPR/Cas9-mediated gene editing was employed to
attempt to introduce mutations which would either mimic or ablate phosphorylation of this
residue. While substitution of the serine residue with an aspartic acid residue (S19D), a
negatively charged residue which would mimic the negative charge introduced by phos-
phorylation; substitution with an alanine residue (S19A) would prevent phosphorylation at
this site. To introduce these mutations into the parasite genome, the repair template used
to introduce the loxP site upstream of the MyoA start codon in Chapter 5 was modified
to install the S19A or S19D mutations into the endogenous MyoA locus. 3D7a parasites
were transfected with a pool of two pDC2-Cas9-hDHFR plasmids (Lim et al., 2017), each
harbouring a different gRNA to maximise editing efficiency, along with each of these repair
templates, which were delivered as linearised plasmids (Figure 6.3.A). The original repair
template used to generate the loxP:MyoA line, which would not change the coding se-
quence, was also transfected to serve as a positive control for integration. Parasites were
then treated with 2.5 nM WR99210 for 9 days to select for parasites harbouring at least
one of the pDC2-Cas9-hDHFR plasmids. Around 4 weeks post transfection, parasites
were observed for all transfections. gDNA was extracted from the parasites and subject
to PCR analysis to determine whether the repair template had integrated. Integration
would lead to the amplification of a smaller PCR product (~1.6 kb) compared to wild type
parasites (~2 kb), since integration of the repair template would result in the deletion of
two endogenous introns found in the MyoA gene. This revealed that both the S19 control
and S19D mutations had successfully integrated into the endogenous MyoA locus, how-
ever integration could not be detected in the parasites transfected with the repair template
that would introduce the S19A mutation (Figure 6.3.B). Instead, amplification of a larger
PCR product indicated that parasites in the S19A transfection were wild type parasites.
Transfections were repeated twice, however integration of the S19A mutation could not
be achieved indicating that this mutation may be lethal or lead to a fitness cost, allowing
wild type parasites to outgrow any parasites harbouring the S19A mutation. Despite gen-
erating a parasite line harbouring the S19D mutations, the growth of these parasites in
comparison to wild type parasites was not compared in a growth-based assay.
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Figure 6.3. Mutation of the endogenous MyoA locus to generate parasites expressing
phosphomutant (S19A) and phosphomimetic (S19D) MyoA. A. Schematic representation of
the marker-free CRISPR/Cas9-mediated approach used to introduce the S19A or S19D
mutations, or the S19 control wild type sequence into the endogenous MyoA locus. Scissors
indicate CRISPR/Cas9 cleavage sites, while arrows represent the relative position of
oligonucleotide primers used for diagnostic PCR screens. B. Diagnostic PCR analysis
confirming integration of the S19 control and S19D phosphomimetic mutation by amplification of
a smaller 1.6 kb product. Amplification of a larger 2 kb product in parasites transfected with the
repair construct that would integrate the S19A phosphomutation confirms presence of wild type
unedited locus and failure to integrate this mutation.
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6.1.3 Genetic complementation of MyoA:mCherry:cKO parasites with MyoA(S19A)
or MyoA(S19D) leads to a significant growth defect in asexual blood
stages
Since the S19A phosphomutation could not be directly introduced into the endogenous
MyoA locus, the approach used to conditionally complement MyoA:mCherry:cKO para-
sites with RAP-inducible MyoA:GFP in Chapter 5 was modified so that RAP treatment
would lead excision of the endogenous MyoA gene and concomitant induction of ex-
pression of MyoA(S19A):GFP or MyoA(S19D):GFP. To achieve this, MyoA:mCherry:cKO
parasites were transfected with the pDC2-p230p-Cas9-gRNA plasmid to introduce a double
strand break in the p230p locus (Knuepfer et al., 2017; Mogollon et al., 2016) and linear-
ised repair templates designed to integrate a promoterless second copy of the MyoA gene
harbouring either an S19A or S19D mutation, fused to the enhanced green fluorescent
protein (eGFP) gene (Figure 6.4.A). Two days after transfection, parasites were treated
with 5 µg/ml BSD (Sigma) for one week to select for integration. BSD-resistant parasites
were observed around 4 weeks post transfection and the resulting phosphomutant and
phosphomimic lines were called MyoA:mCherry:cKO + p230p:MyoA(S19A):eGFP and
MyoA:mCherry:cKO + p230p:MyoA(S19D):eGFP, respectively. Live fluorescence micro-
scopy confirmed that parasites from these lines were both mCherry and GFP positive,
with the mCherry signal localising to the periphery of individual merozoites, consistent
with MyoA localisation; while the GFP signal was diffuse, encompassing the parasite
cytosol (Figure 6.4.B).
This strategy was designed so that RAP treatment of MyoA:mCherry:cKO + p230p:MyoA-
(S19A):eGFP and MyoA:mCherry:cKO + p230p:MyoA(S19D):eGFP parasites would give
rise to deletion of the endogenous MyoA:mCherry and the floxed eGFP:T2A:BSDr coding
sequences in the p230p locus, placing the respective MyoA:GFP mutant sequences un-
der the control of the ectopic MyoA promoter (Figure 6.5.A). Live fluorescence microscopy
revealed that RAP treatment resulted in a loss in mCherry signal and a change in GFP
pattern from cytosolic to peripheral, confirming deletion of the endogenous MyoA:mCherry
sequence and expression of the ectopic MyoA-GFP mutants in each line (Figure 6.5.B).
Western blot analysis also confirmed RAP treatment led to a reduction but not total loss of
MyoA-mCherry expression and induction of MyoA-GFP expression in both parasite lines
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Figure 6.4. Generation of MyoA:mCherry:cKO parasite lines genetically complemented
with RAP-inducible MyoA(S19A):GFP and MyoA(S19D):GFP. A. Schematic representation of
the CRISPR/Cas9-mediated approach used to generate conditional MyoA(S19A):GFP and
MyoA(S19D):GFP lines. Integration into the p230p locus leads to the expression of cytosolic
eGFP and BSD, under the control of the MyoA promoter. Scissors indicate CRISPR/Cas9
cleavage sites. B. Live fluorescence microscopy showing cytosolic expression of eGFP in
MyoA:mCherry:cKO + p230p:MyoA(S19A):eGFP and MyoA:mCherry:cKO +
p230p:MyoA(S19D):eGFP parasites, confirming successful integration of the repair templates.
The GFP and mCherry signals do not overlap, confirming that expression of MyoA(S19A)-eGFP
and MyoA(S19D)-eGFP could not be detected prior to RAP treatment. Scale bar, 5 µm.
(Figure 6.5.C). Surprisingly, a ~30 kDa band, the predicted molecular weight of eGFP,
could not be detected in either the DMSO- or RAP-treated samples.
To assess whether dependence on expression of the S19 phosphomutant or phospho-
mimetic versions of MyoA-GFP had an effect on parasite growth, flow cytometry-based
growth assays were performed on DMSO- and RAP-treated MyoA:mCherry:cKO + p2-
30p:MyoA(S19A):eGFP and MyoA:mCherry:cKO + p230p:MyoA(S19D):eGFP parasites.
Complementation of the MyoA knockout with MyoA(S19A)-GFP and MyoA(S19D)-GFP
resulted in a 63% and 60% rescue in growth, respectively (Figure 6.6.). As shown in
Chapter 5, complementation with GFP-tagged wild type MyoA, using the exact same
set up, fully rescued MyoA knockout parasites. These data therefore demonstrate that
mutations, which ablate or mimic phosphorylation of MyoA S19, lead to reduced growth
during the asexual blood stages of the life cycle. Therefore, phosphorylation and dephos-
phorylation of MyoA S19 is important but not absolutely essential for parasite survival
in vitro. Interestingly, although both mutations led to a similar growth defect in indu-
cible complementation experiments, only the S19A mutation failed to directly integrate
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Figure 6.5. RAP treatment leads to the transgenic expression of either the
MyoA(S19A)-GFP phosphomutant or the MyoA(S19D)-GFP and loss of MyoA-mCherry
expression. A. Schematic representation of RAP-induced deletion of MyoA-mCherry at the
endogenous locus and and deletion of eGFP:T2A:BSDr at the p230p locus leading to
expression of MyoA(S19A)-GFP and MyoA(S19D)-GFP in MyoA:mCherry:cKO +
p230p:MyoA(S19A):eGFP and MyoA:mCherry:cKO + p230p:MyoA(S19D):eGFP parasites,
respectively. B. Live fluorescence microscopy showing cytosolic expression of eGFP in
MyoA:mCherry:cKO + p230p:MyoA(S19A):eGFP and MyoA:mCherry:cKO +
p230p:MyoA(S19D):eGFP parasites, confirming successful integration of the repair templates.
The GFP and mCherry signals do not overlap, confirming that expression of MyoA(S19A)-eGFP
and MyoA(S19D)-eGFP could not be detected prior to RAP treatment. Scale bar, 5 µm. C.
Western blot analysis showing RAP-inducible expression of the MyoA-GFP mutants from the
p230p locus by probing with an α-GFP antibody, and reduction in MyoA-mCherry expression by
probing with an α-mCherry antibody.
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into the endogenous MyoA locus (Figure 6.3.B). Phosphomimetic mutations simulating
phosphorylated serine are not always successful, since the chemical environment cre-
ated by negatively charged amino acids such as aspartic acid is different to the chem-
ical environement of phospho-serine (Hunter, 2012). Therefore, it is possible that the
MyoA S19D mutation mimics non-phosphorylated rather than phosphorylated MoyA S19.
This could explain why the growth rates of both lines are very similar, however it is also
conceivable that constitutive phosphorylation of MyoA could have a negative impact on
growth. Testing a different phosphomimetic substitution, such as glutamic acid instead of
aspartic acid, could be attempted in the future to test whether the S19E mutation is better
at mimicking phosphorylated S19.
Figure 6.6. RAP-induced transgenic expression of either the MyoA(S19A)-GFP
phosphomutant or the MyoA(S19D)-GFP phosphomimetic leads to a moderate but
incomplete rescue following deletion of MyoA:mCherry from the endogenous locus.
Growth curves showing parasitemias of MyoA:mCherry:cKO + p230p:MyoA(S19A):eGFP and
MyoA:mCherry:cKO + p230p:MyoA(S19D):eGFP parasites treated with either DMSO or RAP,
measured by flow cytometry-based sorting of SYBR Green positive cells. Data points plotted are
means from two repeat experiments, each performed in triplicate. Error bars represent the
standard deviation.
Several other approaches were also attempted to conditionally switch from expressing
wild type MyoA-mCherry to MyoA-GFP harbouring either the S19A or S19D mutations,
however these approaches either failed or showed only partial success and are described
in further detail in the appendix.
6.1.4 Phosphorylation of Myosin A modulates motor activity by increasing
the motor speed
Having demonstrated that mutations that mimic or ablate MyoA S19 phosphorylation led
to a defect in parasite growth, in vitro motility assays were performed using parasite-
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derived MyoA to determine whether MyoA S19 phosphorylation is involved in modulating
the activity of the motor. Motility assays were set up as described in section 2.3.4 and
involved tracking ATP-driven movement of rhodamine-phalloidin-labelled rabbit actin fil-
aments over glass cover slips coated in mCherry-tagged MyoA captured from mature
schizont or merozoite lysates with an α-mCherry antibody (Figure 6.7.A). To ensure that
actin binding was specific to MyoA captured via the α-mCherry antibody, actin was added
to flow cells that were or were not pre-coated with α-mCherry antibody. Actin filaments
could only be detected in the antibody-coated flow cells, confirming that actin binding
was due to the capture of MyoA-mCherry from parasite lysates (data not shown). In the
absence of ATP, actin filaments remained bound to the surface and did not display any
motility (Figure 6.7.B). Upon addition of ATP-containing buffer to the flow cell, and activa-
tion of the captured MyoA motors, actin filament motility could readily be observed (Figure
6.7.B), confirming that active myosin motors could be isolated from parasite lysates.
Motility assays were performed using MyoA:mCherry C2- and E64-blocked schizonts and
purified merozoites to test whether blocking PKG-dependent phosphorylation of MyoA
S19 had an effect on filament motility (Figure 6.8.A). The average filament velocity for C2-
treated samples was 0.398 µm/s, while E64-treated samples moved 13% faster with an
average velocity of 0.455 µm/s (Figure 6.8.B). Merozoite samples displayed an average
filament velocity of 0.636 µm/s, 38% and 29% faster than C2- and E64-blocked samples,
respectively. Therefore there appears to be a correlation between motor speed and
phosphorylation levels of MyoA S19 since merozoite samples display highest levels of
S19 phosphorylation and actin displacement velocities, followed by E64 then C2-blocked
samples. However, since MyoA co-precipitates with other components of the glideo-
some, including GAP40 and GAP45 (Green et al., 2017), which are also phosphorylated
in a PKG-dependent manner (Alam et al., 2015), it is possible that this change in actin
filament velocity could be due to the altered phospho-status of these other components
and not solely due to the changed phospho-status of MyoA S19.
To overcome this issue and to ensure that the only difference between samples was the
phospho-status of MyoA, wild type 3D7 parasites were transfected with plasmids driv-
ing episomal expression of MyoA(S19)-mCherry, MyoA(S19A)-mCherry or MyoA(S19D)-
mCherry, while the endogenous MyoA locus was left unaltered (Figure 6.9.A). Since
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Figure 6.7. In vitro motility of actin over parasite-derived MyoA-mCherry. A. Schematic
representation of the flow cell set up, showing fluorescently-labelled actin moving over
parasite-derived MyoA-mCherry captured via an α-mCherry antibody on glass cover slips. B. In
the absence of ATP, actin filaments remain bound, and no motility is observed, however addition
of ATP-containing imaging buffer leads to the activation of the MyoA motors and movement of
the actin filaments can be observed. Motility tracks for each filament are highlighted in different
colours. Scale bar, 30 µm.
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Figure 6.8. PKG-dependent phosphorylation of MyoA S19 increases the motor’s speed. A.
Schematic representation of the motility assay samples used, where non-phosphorylated
MyoA-mChery was obtained from C2-blocked schizonts, while phosphorylated MyoA-mCherry
was obtained from E64-blocked schizonts and purified merozoites. B. Western blot analysis of
the samples used in the gliding assay, confirming MyoA-mCherry from C2-blocked schizonts was
non-phosphorylated at S19, while MyoA-mCherry from E64-blocked schizonts and purified
merozoites was phosphorylated at S19. Blots were probed using a phosphoS19-specific MyoA
antibody and a pan-specfic MyoA antibody to determine relative levels of phosphorylation in
each sample. C. Speed distributions from in vitro motility assays using MyoA-mCherry from C2-
or E64-blocked schizonts or released merozoites.
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MyoA expressed from the endogenous locus is untagged in these lines, only MyoA-
mCherry expressed from the respective episomes is expected to be precipitated onto
the slide.The expression plasmids also encoded a BSDr cassette to select for episome
formation. After transfection, parasites were treated with 2.5 µg/ml BSD, and resistant
parasites for all transfections were observed within 3 weeks after transfection. Puri-
fied merozoite samples were harvested for all lines, however motility assays were only
performed on the wild type phosphorylatable MyoA(S19)-mCherry and phosphomutant
MyoA(S19A)-mCherry samples. The average filament velocity for MyoA(S19)-mCherry
samples was 0.603 µm/s, while MyoA(S19A)-mCherry samples moved 24% slower with
an average velocity of 0.457 µm/s (Figure 6.9.B).
Therefore by using chemical or genetic approaches, these data demonstrate that non-
phosphorylated MyoA S19 displays reduced motility compared to phosphorylated MyoA
S19. This confirms that phosphorylation of residue plays an important role in modulating
the speed of the actomyosin motor.
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Figure 6.9. MyoA(S19A)-mCherry displays reduced motility compared to wild type
MyoA(S19)-mCherry. A. Schematic representation of the plasmid used to episomally express
either MyoA(S19A)-mCherry of MyoA(S19D)-mCherry mutants or wild type MyoA(S19)-mCherry
in wild type 3D7 parasites. B. Speed distributions from in vitro motility assays using episomally
expressed wild type MyoA(S19)-mCherry or phosphomutant MyoA(S19A)-mCherry from
merozoites.
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6.1.5 Motor activity is not altered when PKAc is knocked out
Since PKAc knockout parasites display an invasion defect (Patel et al., 2019), similar to
that of MyoA knockout parasites, it is possible that the MyoA motor shows reduced activ-
ity when PKAc is depleted. To test this, MyoA(S19)-mCherry was episomally expressed
in the published RAP-inducible PKAc knockout line, PKAc-HA:loxP (Patel et al., 2019).
DMSO- and RAP-treated PKAc-HA:loxP merozoites expressing MyoA(S19)-mCherry were
harvested and used in in vitro gliding motility assays as described earlier. The aver-
age filament velocity for DMSO and RAP-treated samples was 0.619 and 0.6346 µM/s,
respectively (Figure 6.10.). Therefore it appears that motor function is not impaired in
PKAc-deficient parasites, and is not the reason why PKAc-deficient parasites are unable
to invade.
Figure 6.10. Deletion of PKAc does not affect motor speed or activity. Speed distributions
from in vitro motility assays using episomally expressed wild type MyoA-mCherry from DMSO-
and RAP-treated PKA conditional knockout merozoites.
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6.2 Discussion
Phosphorylation is an important post-translation modification that can influence the prop-
erties and function of proteins. Activation of cAMP and cGMP signalling culminates in the
phosphorylation of a large number of proteins in P. falciparum schizonts, as evidenced by
recent phosphoproteomic studies (Alam et al., 2015; Flueck et al., 2019). Understanding
which of these individual phosphorylation events bring about the changes observed upon
activation of cyclic nucleotide and calcium signalling will be important for expanding our
understanding of how these intricate signalling networks function.
One cGMP-dependent phosphorylation event that particularly stands out is phosphoryla-
tion of MyoA S19. This is the only phosphorylation site in MyoA that can be detected
across schizont, merozoite and salivary gland sporozoite phosphoproteomes (Solyakov
et al., 2011; Treeck et al., 2011; Lasonder et al., 2012; Pease et al., 2013; Alam et al.,
2015; Swearingen et al., 2017). Phosphorylation of only one other site at MyoA S29 in
merozoite samples has been identified (Lasonder et al., 2012), however this site has not
been detected in any of the other phosphoproteomes.
The main aim of this chapter was to determine whether phosphorylation of MyoA S19
is required for asexual blood stage growth. Complementation of the MyoA:mCherry:cKO
line described in Chapter 5 with RAP-inducible MyoA-GFP mutants which either mimic
(S19D) or ablate (S19A) phosphorylation demonstrated that phosphorylation is important
but not essential for asexual blood stage growth. Complementation with either mutant led
to around a 40% reduction in growth when compared to parasites expressing wild type
phosphorylatable MyoA. Therefore, not only is MyoA S19 phosphorylation important, but
it appears that the motor also needs to be dephosphorylated, since the phosphomimetic
mutation also resulted in a growth defect. In vitro motility assays using MyoA(S19A)
isolated from merozoites revealed that the phosphomutation led to reduced motor speed
when compared to wild type phosphorylatable MyoA. Furthermore non-phosphorylated
MyoA harvested from PKG-inhibited schizonts also showed slower velocities when com-
pared to phosphorylated MyoA from E64-blocked schizonts. Together these data demon-
strate that blocking phosphorylation of MyoA S19 either chemically or genetically leads
to reduced motility. Future in vitro motility assays will be performed using MyoA(S19D),
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which have been harvested, in order to determine whether this mutation is able to mimic
phosphorylation and achieve speeds comparable to wild type MyoA.
The work described in this chapter has also provided greater resolution into the timing
of MyoA S19 phosphorylation during the asexual blood stages of infection. Prior to PKG
activation, MyoA S19 is predominantly non-phosphorylated. Once cGMP signalling is
triggered, MyoA S19 is rapidly phosphorylated, however maximal phosphorylation levels
are only achieved once merozoites egress. Shortly after merozoites have invaded and
formed rings, MyoA S19 phosphorylation intensity decreases. It remains unclear how
these changes in MyoA S19 phosphorylation are achieved. Although it was previously
thought that MyoA S19 is phosphorylated by PKAc (Lasonder et al., 2015), conditional
disruption of PKAc revealed that this phosphorylation event is not affected (Patel et al.,
2019). Consistent with this, in vitro motility assays demonstrated that MyoA isolated
from PKAc-deficient merozoites displayed similar actin displacement velocities to wild
type parasites. Future work identifying the kinase and phosphatase responsible for phos-
phorylation and dephosphorylation of MyoA S19 will provide a better understanding of
how this dynamic phosphorylation event is regulated.
Overall the data presented in this chapter demonstrate that phosphorylation of MyoA
S19 plays an important role in modulating motor activity. Since ablating phosphorylation
of MyoA S19 leads to a slower motor, future work involving time-lapse video microscopy
capturing MyoA(S19A) mutant parasites invading erythrocytes will be required in order
to determine whether these parasites take a longer time to invade RBCs than wild type
parasites. Previous work has shown that the invasive capacity of P. falciparum merozo-
ites declines relatively quickly following merozoite egress (Boyle et al., 2010), therefore a
slower motor could explain the growth defect observed in MyoA knockout parasites com-
plemented with MyoA(S19A)-GFP.
In a recently published paper, which demonstrated that MyoA deletion leads to an in-
vasion defect during asexual blood stage growth, the crystal structure of PfMyoA was
also solved (Robert-Paganin et al., 2019). This revealed that the phosphorylated S19
residue, which is located on an unusual N-terminal extension, is able to interact with
the positively charged K764 residue, which forms part of the converter domain. Typic-
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ally, converter domains influence the kinetic properties of the motor (Swank et al., 2002),
therefore this interaction could point toward the involvement of MyoA S19 phosphoryla-
tion in modulating the activity of the motor. Robert-Paganin et al. also performed motility
assays using recombinant PfMyoA expressed in Sf9 cells harbouring either the S19A or
K764E mutations, which would ablate the interaction formed by these two residues. Each
of these mutations led to a two-fold reduction in motor speed, consistent with the in vitro
motility data presented in this chapter. Furthermore, the recombinant PfMyoA S19A and
K764E mutants were able to generate two-fold more force than wild type MyoA. From
these data, the authors propose a model where MyoA S19 is expected to be dephos-
phorylated in merozoites such that the parasite is able to generate sufficient force for
parasite entry, while in sporozoites the motor needs to be phosphorylated to achieve high
gliding velocities.
If the model is true, it is unclear why MyoA S19 is so highly phosphorylated in merozo-
ites. Although the literature suggests that merozoites do not display gliding motility (Baum
et al., 2005), recent work has provided evidence that Plasmodium merozoites do indeed
display gliding motility (personal communication Melissa Hart LSHTM, London UK). Al-
though gliding motility is more prominent and noticeable in P. knowlesi merozoites, which
are larger than P. falciparum merozoites, gliding motility can also be observed to some ex-
tent in P. falciparum. Therefore, it is possible that in merozoites phosphorylation of MyoA
S19 could be important for gliding motility to help the parasite find an erythrocyte to in-
vade. Although work in this chapter has demonstrated that in ring stage parasites MyoA
S19 is dephosphorylated, it remains unclear when dephosphorylation occurs. Probing
the phosphostatus of MyoA S19 in tightly synchronised ring stage parasites may help
reveal this.
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7 Conclusions
Cell signalling is a fundamental process which allows cells to sense their surroundings
and mediate internal responses (Uings and Farrow, 2000). Accordingly, signalling path-
ways regulate critical events across all stages of the malaria parasite lifecycle (Brochet
and Billker, 2016; Baker et al., 2017a). Recent advances have been made using re-
verse genetic techniques to unravel the complexities of the signalling pathways employed
by the malaria parasite, revealing that cGMP, cAMP and calcium signalling interact with
one another, forming complex networks. The essential nature of these pathways make
them attractive areas of research, since a deeper understanding of how they operate
may help inform the discovery of novel antimalarial compounds through the identification
of novel druggable targets. Recent adaptation of the DiCre system and CRISPR/Cas9
gene editing for use in Plasmodium falciparum has paved the way for a new era of re-
search, allowing the study of genes that were previously not amenable to direct knockout.
Activation of cGMP signalling during the asexual blood stages of infection leads to re-
lease of internal Ca2+ stores (Brochet et al., 2014), triggering calcium signalling; and the
secretion of proteins from specialised organelles including micronemes and exonemes
(Collins et al., 2013b). This culminates in the egress of merozoites from infected eryth-
rocytes and the activation of cAMP signalling, which is vital for invasion and the estab-
lishment of a new replication cycle leading to exponential parasite growth (Patel et al.,
2019). To further our understanding of how cGMP signalling governs important events
during egress and invasion, this study investigates two integral components of this sig-
nalling cascade during the intraerythrocytic stages of Plasmodium falciparum parasites.
Firstly, this includes GCα, a predicted guanylyl cyclase thought to be essential for cGMP
synthesis during the asexual blood stages; and secondly Myosin A, an actomyosin motor
protein that is phosphorylated as a result of activation of this signalling pathway (Alam
et al., 2015).
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7.1 GCα - a tale of two domains that cooperate to mediate
asexual blood stage egress
Prior to the start of this project, very little was known regarding GCα. This large, seem-
ingly bifunctional protein encodes an N-terminal putative type IV P-type ATPase, pre-
dicted to be involved in flipping aminophospholipids from the outer to the inner leaflet
of a lipid bilayer based on sequence homology to other flipases; as well as a C-terminal
guanylyl cyclase domain. However, it was unknown whether PfGCα was in fact a guanylyl
cyclase, since GC activity could not be detected by performing assays on recombinant
catalytic domains of GCα expressed in E. coli (Carucci et al., 2000). Furthermore, pre-
vious efforts to detect GCα in schizonts using immunoelectron microscopy were unsuc-
cessful (Carucci et al., 2000). Despite this, the transcriptional profile of GCα (López-
Barragán et al., 2011; Zanghì et al., 2018) coupled with the fact that GCβ is not required
for blood stage growth (Hirai et al., 2006; Taylor et al., 2008; Moon et al., 2009; Gao
et al., 2018) are consistent with GCα being the cyclase responsible for cGMP production
to initiate cGMP signalling in asexual blood stage schizonts and in gametocytes during
gametogenesis. We therefore hypothesised that GCα would be essential for asexual
blood stage growth, and predicted that disruption would lead to the abrogation of cGMP
production and the inability of mature schizonts to egress from erythrocytes. Using a
combination of mutagenesis and conditional disruption, work presented in this thesis has
definitively demonstrated that GCα is indeed expressed during the asexual blood stages
and is essential for survival. Disruption of GCα results in the ablation of cGMP synthesis,
consistent with this protein being the sole GC in blood stage schizonts. As a result, PKG
remains inactive and schizonts are unable to release Ca2+ from internal stores or egress
from the host erythrocyte. It is predicted that microneme and exoneme secretion is also
impeded in the absence of GCα, and future IFA experiments will be done to determine
whether this is indeed the case.
Failure to recover parasites harbouring mutations in a conserved residue in the ATPase
domain strongly suggests that activity of this domain is required for parasite survival.
Despite the disruption of both ATPase and GC domains, the phenotype observed in
GCα-deficient parasites was consistent with loss of the GC domain, with no obvious addi-
tional phenotype arising due to loss of the ATPase domain. In an attempt to override the
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egress defect and discern the phenotype that arises due to loss of the ATPase domain,
GCα-deficient parasites were chemically complemented with PET-cGMP, a membrane
permeable cGMP analogue, to bypass cGMP production. To our surprise, PET-cGMP
was able to stimulate egress in GCα-null parasites and even resulted in the formation of
ring stage parasites. Furthermore, we found that PET-cGMP could sustain GCα-deficient
parasite growth over several cycles with no obvious second phenotype arising due to lack
of the ATPase domain. Although previous reports have shown that in Toxoplasma, PET-
cGMP could trigger microneme release in TgGC-deficient parasites, the study did not
report whether parasite growth was rescued (Brown and Sibley, 2018). The work presen-
ted here demonstrates that in P. falciparum, the ATPase domain is ultimately involved in
cGMP production by potentially mediating or regulating the activity of the GC domain,
however it remains unclear how the ATPase domain achieves this. In Toxoplasma, re-
lease of Ca2+ from internal stores can be triggered by increased levels of phosphatidic
acid (PA) or decreases in pH or K+ levels in a TgGC-dependent manner (Bisio et al.,
2019; Yang et al., 2019). The authors of these studies suggest that the ATPase domain
is able to sense these changes, triggering the synthesis of cGMP. Although it is possible
that Plasmodium GCα also senses changes in pH, K+ or PA levels, preliminary data from
Abigail Perrin (personal communication, Francis Crick Institute London UK) has demon-
strated that PA does not trigger schizont egress. Furthermore, since cGMP signalling is
activated prior to egress, it remains unclear how parasites would experience changes in
pH or K+ levels from within the erythrocyte. To address this, future work using genetic
complementation of the GCα knockout line with the GC domain only, using the conditional
expression approach used for MyoA described in this thesis, may help elucidate the role
of the ATPase during the asexual blood stage.
Since the transcriptional profile of GCα also suggests that it is the predominant GC found
in gametocytes, it will be interesting to determine the role this protein plays during gam-
etogenesis when cGMP signalling is activated. Previous studies have shown that in the
presence of a PKG-specific inhibitor, mature stage V gametocytes are unable to round
up and emerge from the host erythrocyte following stimulation with xanthurenic acid (XA)
coupled with a decrease in temperature (McRobert et al., 2008). Therefore, it is likely that
GCα-deficient gametocytes will be unable to round up and emerge, similar to inhibition
of PKG. Since addition of XA to gametocyte membrane preparations led to an increased
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synthesis of cGMP (Muhia et al., 2001), it is possible that XA may directly stimulate GCα
activity. To test whether this is the case, cGMP enzyme activity assays can be performed
with immunoprecipitated GCα from stage V gametocytes following addition of XA. It will
also be interesting to determine whether a drop in temperature is also important for cGMP
production. Unfortunately the 3D7 1G5 DC line that was used to generate the GCα knock-
out parasites is unable to generate viable stage V gametocytes (personal communication
Eloise Walker, previously at LSHTM). Therefore to address these questions, a new GCα
knockout line will have to be made in a gametocyte producing 3D7 background.
7.2 Phosphorylation of Myosin A S19 puts the motor in "turbo"
mode
Activation of cGMP signalling leads to the phosphorylation of many downstream proteins
involved in a myriad of different processes ranging from egress and invasion to chromatin
and transcriptional regulation (Alam et al., 2015). Understanding which of these individual
phosphorylation events bring about the changes observed upon activation of cGMP sig-
nalling will be important for expanding our understanding of how this signalling pathway
functions and how it forms networks with other signalling pathways. The second half of
the work presented in this thesis involved investigation of PKG-dependent phosphoryla-
tion of MyoA S19. Previous studies have shown that phosphorylation of TgMyoA S21,
the equivalent residue in Toxoplasma, appears to be important for tachyzoite egress from
the infected host cell, and is required for efficient gliding motility (Tang et al., 2014; Gaji
et al., 2015). At the outset of this PhD, it was thought that PfMyoA is essential for asexual
blood stage growth, with pharmacological evidence suggesting that it most likely plays a
role in powering invasion (Miller et al., 1979; Mizuno et al., 2002). Despite the fact that
unlike Toxoplasma tachyzoites, Plasmodium merozoites are not thought to display gliding
motility (Baum et al., 2005), we hypothesised that PKG-dependent phosphorylation of
MyoA S19 would be required for activating the motor prior to invasion. Prior to testing this
hypothesis, the role of MyoA in egress and invasion had to be established. Conditional
disruption of PfMyoA revealed that unlike in Toxoplasma, the motor is not required for
merozoite egress and instead plays a vital role in erythrocyte invasion, as MyoA-deficient
parasites are unable to invade. These results are consistent with recent work showing
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that disruption of GAP45, a structural component of the glideosome that links the IMC to
the PPM, also leads to a block in merozoite invasion, but has no effect on egress (Perrin
et al., 2018). However, unlike GAP45, MyoA is not required for glideosome assembly,
consistent with its non-structural role.
Inducible complementation of the conditional MyoA knockout line with a mutant non-
phosphorylatable version of MyoA harbouring an S19A mutation, revealed that phos-
phorylation of S19 is important for parasite growth. However, parasites harbouring the
MyoA S19A mutation were still able to proliferate, albeit at a slower rate compared to
wild type parasites. In vitro motility assays using parasite-derived wild type MyoA(S19)
or non-phosphorylatable MyoA(S19A) revealed that blocking phosphorylation of the mo-
tor leads to reduced motility, suggesting that this phosphorylation event modulates the
activity of the actomyosin motor. Consistent with the work presented in this thesis, a very
recent publication has shown that recombinant MyoA(S19A) displays reduced motility
compared to wild type parasites (Robert-Paganin et al., 2019). Interestingly, Robert-
Paganin et al. also reported that MyoA(S19A) is able to generate more force than wild
type MyoA. Therefore contrary to the original hypothesis instead of activating the motor,
phosphorylation of MyoA S19 appears to be involved in fine tuning the activity of the mo-
tor. Interestingly, we observed that MyoA S19 becomes hyper-phosphorylated in released
merozoites. Since is likely that a CDPK is responsible for phosphorylating MyoA S19, it
is possible that the hyper-phoshorylation observed in merozoites is due to the calcium
flux experienced by the parasites upon RBC attachment (Singh et al., 2010; Gao et al.,
2013) which promotes further activation of CDPKs. Identifying the kinases responsible
for phosphorylating MyoA S19 could provide further insight into how this phosphorylation
event is regulated. This could be achieved by N-terminally tagging MyoA with a proximity-
dependent labelling protein such as BioID.
Perhaps surprisingly, MyoA knockout parasites complemented with MyoA(S19D), a mutant
version which mimics phosphorylation, demonstrated a similar growth defect to parasites
depending on MyoA(S19A). It was predicted that complementation with the phospho-
mimic would lead to a complete rescue, however it is feasible that the S19D substitution
does not effectively mimic phospho-serine. To address whether this is the case, in vitro
motility assays using parasite-derived MyoA(S19D) will help determine whether the motor
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displays normal or reduced speeds similar to wild type MyoA or MyoA(S19A), respect-
ively. However, it is also possible that constitutive phosphorylation of MyoA leads to a
growth defect. Consistent with this model, MyoA S19 appears to be dephosphorylated
in ring stage parasites shortly after or during invasion. Furthermore, in PDEβ knockout
parasites, which display a 70% reduction in invasion, MyoA S19 is prematurely phos-
phorylated (Flueck et al., 2019). It is therefore conceivable that over stimulation of the
motor contributes to the invasion defect observed in PDEβ-null parasites. Future work will
be required to address the exact timing of MyoA S19 dephosphorylation during or shortly
after invasion and whether blocking this results in a growth defect similar to PDEβ-null
parasites.
7.3 Morphological changes observed during gametocyte de-
velopment and gametogenesis do not require Myosin A
P. falciparum parasites undergo remarkable changes in morphology as they develop from
stage I to stage V gametocytes. Recent work has shown that subpellicular membrane
complex (SMC) proteins are required for this process (Parkyn Schneider et al., 2017).
Having generated the conditional MyoA knockout line, the involvement of the motor in
driving the elongation of gametocytes was assessed. This revealed that the motor is not
required for gametocyte development. Furthermore, MyoA-deficient mature stage V gam-
etocytes were able to round up and emerge from the host erythrocyte upon XA-stimulated
gametogenesis. It remains unclear why this motor is expressed in gametocytes, however
future experiments assessing whether exflagellation is impaired in MyoA knockout para-
sites will help rule out the requirement of the motor in this stage. With the establishment
of a transmission lab at LSHTM, it will be possible to assess whether MyoA is required
during the mosquito stages of the life cycle. It is likely that MyoA-deficient parasites will
display a defect in the ookinete stage, which requires gliding motility to penetrate the
midgut of the mosquito.
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7.4 Final conclusions
The work performed over the course of this PhD has helped expand our understand-
ing of cGMP signalling in Plasmodium falciparum parasites, by confirming the central
role that GCα plays in initiating this signalling cascade, and by elucidating the effect of
phosphorylation on a downstream effector of this pathway. Future work on other pro-
teins which are phosphorylated in a PKG-dependent manner will be required to further
expand our knowledge of how cGMP signalling regulates events required for egress and
invasion. Of particular interest are other signalling proteins, including GCα, PDEβ, ACβ
and CDPK1, which are phosphorylated in a PKG-dependent manner, pointing towards a
potential means of cross talk between these different signalling pathways.
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8 Appendix
CRISPR/Cas9 gRNAs
Number Target Off targetscore(%)
On target
score(%) Sequence
1 GCα 99 46 TTTAATATGTGTTCTATAGCAGG
2 GCα 94 30 CCTAAATGATTATGATGAATATG
3 GCα 99 47 TCTATAGCAGGAAAAACATATGG
4 MyoA 100 25 CCTTCTCTTTTGAGAGTACAAGC
5 MyoA 100 61 CCATACGATATTGATCCAACTCA
6 MyoA 99 70 GTTGTACAAATTGATCCACCCGG
7 p230p 98 46 GAATATTATTCTAATGATAAAGG
Table 3. List of gRNAs used for CRISPR/Cas9-mediated gene editing. Protospacer adgja-
cent motifs are highlighted in bold. On and Off target scores are from Bechnling’s CRISPR
gRNA design software (www.benchling.com). Higher on and off target values indicate bet-
ter gRNAs
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Primers
Number Nucleotide sequence
1 ATTGAACATAATGAAGAAGATTACA
2 ATAACTTCGTATAATGTATGCTATAC
3 CCCTTTAAAGGTCGATTCTTCTCA
4
TTATTTTTACCGTTCCATGGTCGGAAAAATATTCATGTG-
CATAAAT
5 GTATTAAAAGTAAAATTAAATCTATATCACAATCAAATACT
6
AGTCTTATCAGTGAAAATGAAATCTACATTTCCTAAATC-
TCCAT
7 CGTCGTAGTCGTTCAAATTGT
8 ACCCAAATTCAACAGAGGTAAGT
9
TAGAGGATCCCCATGGAGCTTTACATAAGGAAGATTTCA-
ACAC
10 AGAAGTAGAATCATCAAACCACTC
11 CTACCTTAAGTACGTAACTAGTACTT
12
GACGGCCAGTGAATTCCTCTGAAGATTCATCAAATAAT-
AAATATAAACAG
13
GACGGCCAGTGAATTCTATTCCATGAAGAGCTAGATTT-
GTACTT
14 AAAAGACATGGGGTCTACTTGAGA
15 GTATATATAAGTAAATAAGGGCATTCTT
16
GCCATATCCCTCCCCGGGTTACTTGTACAGCTCGTCCA-
TGC
17 CGTTTATAGATATTTTTCAGCGAAC
18
TTTTACCGTTCCATGGGCACCGTCTCTGTTTTTGTTGG-
TATC
19 ACACACCCATATCCTCATCCA
20 TTCAACCCAAGTTTTATGTGGA
21 TCCATGTCTGATTTCTTTTTAGCTT
22 GCAGGTGAATTCTATTTATTTTTTTTTGTGAACCATACGG
23 AAAAAAAAAAGGATCCATAACTTCGTATAG
Table 4. List of oligonucleotide primers used in this study.
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8.1 Failed approached used to generate P. falciparum lines
which conditionally express MyoA harbouring mutations
which ablate or mimic phosphorylation of MyoA S19.
Several attempts were made to generate a P. falciparum parasite line which would enable
conditional deletion of the endogenous MyoA:mCherry gene and switch to the expres-
sion of a second MyoA:GFP gene harbouring mutations that would either mimic (S19D)
or ablate (S19A) phosphorylation of MyoA S19 to determine whether this phosphorylation
event is required for parasite survival. In total, four different approaches were employed,
with the successful approach described in Chapter 6. The other three approaches, which
either failed or only worked for some of the mutations, are detailed below.
CRISPR/Cas9-mediated gene editing was used to modify the loxP:MyoA line generated
in chapter 5 to introduce an mCherry tag at the 3’ end of the endogenous MyoA gene,
replace the endogenous 3’UTR with the PbDT 3’UTR and introduce a hDHFR cassette
which confers resistance to WR99210 in order to select for integration. The repair tem-
plate would also introduce a second loxP site followed by a promoterless second copy of
MyoA fused to an eGFP tag. Three different version of the repair template were generated
to introduce either S19A or S19D mutations or the wild type S19 sequence (Figure 8.1.A).
Rapamycin treatment of the resulting line, termed MyoA:mCherry:cMutMyoA:GFP, would
lead to the excision of the endogenous MyoA:mCherry gene, and place the MyoA:GFP
gene under the control of the endogenous promoter, allowing for conditional expression
of the second copy of MyoA (Figure 8.1.B). However, after several attempts to integ-
rate all three repair templates, the only repair template that integrated correctly was the
wild type MyoA(S19):GFP version (Figure 8.1.C). Although the mutant MyoA(S19A):GFP
and MyoA(S19D):GFP versions also integrated, there was a truncation of the integ-
rated repair template in both these lines as evident by PCR and live fluorescence mi-
croscopy since these two lines were not mCherry positive. Surprisingly, treatment of the
MyoA:mCherry:cMutMyoA(S19):GFP did not lead to ablation of MyoA-mCherry levels,
however MyoA-GFP expression was activated following treatment (data not shown). It
remains unclear how both copies were expressed simultaneously, since there is only one
promoter, and no leaky MyoA-GFP expression could be detected prior to RAP treatment.
Since it was possible that MyoA-mCherry expression was being driven from the looped
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out floxed DNA, it would be expected that after several cycles in culture, the floxed DNA
would be lost. However, after maintaing RAP-treated MyoA:mCherry:cMutMyoA(S19):GFP
parasites in culture for 8 cycles MyoA:mCherry and MyoA:GFP could still be observed by
live fluorescence microscopy (data not shown). Due to the various problems encountered
with this line, further experiments were not performed to characterise them.
Figure 8.1. First approach used to generate conditional MyoA mutant parasite lines using
CRISPR/Cas9-mediated gene editing. A. Schematic representation of the
CRISPR/Cas9-based approach used to simultaneously introduce an mCherry tag and a loxP site
downstream of the endogenous MyoA gene and install a second promoterless copy of
GFP-tagged MyoA downstream of the endogenous gene. Scissors indicate CRISPR/Cas9
cleavage sites, while arrows represent the relative position of oligonucleotide primers used for
diagnostic PCR screens. B. RAP treatment would lead to excision of the endogenous
MyoA:mCherry sequence and place the MyoA:GFP sequence harbouring the S19 mutations
under the control of the endogenous promoter. C. Diagnostic PCR analysis confirming
integration of the repair template in all parasite lines, however only the MyoA(S19)-GFP
sequence resulted in the amplification of a PCR product of the correct predicted size (~1.5 kb).
The amplification of smaller PCR products at around 0.9 and 0.8 kb in the parasite lines
transfected with the MyoA(S19A):GFP and MyoA(S19D):GFP repair templates indicates a
truncation in the integrated repair templates somewhere between the MyoA and mCherry
interface.
Since the CRISPR/Cas9 based approach to integrate a second MyoA gene downstream
of the endogenous one was unsuccessful, another approach using selection-linked in-
tegration (SLI) (Birnbaum et al., 2017) to integrate the second MyoA gene was adopted.
This approach relies on single homologous recombination integrating a plasmid of in-
terest which would result in the introduction of a T2A skip peptide gene and a neoymycin
resistance (NeoR) cassette, which confers resistance to G418, at the 3’ end of a gene of
interest. Expression from the NeoR cassette can only be achieved once the plasmid has
integrated, however presence of the T2A peptide ensures that the NeoR gene is trans-
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lated as a separate polypeptide from the gene of interest. SLI plasmids were generated
to tag the endogenous MyoA locus of loxP:MyoA parasites with an mCherry tag, and
introduce a second loxP site followed by the promoterless second MyoA gene fused to
GFP (Figure 8.2.). Versions that would integrate MyoA:GFP harbouring either S19A or
S19D mutations or wild type S19 were generated. After transfecting loxP:MyoA parasites
with the SLI plasmids, parasites were treated with 2.5 nM WR99210 to select for episome
formation. After around 4 weeks, WR99210 resistant parasites for all three lines were ob-
tained. However, no parasites could be observed up to 6 weeks following treatment with
400 µg/ml G418, indicating that integration was unsuccessful.
Figure 8.2. Second approach used to generate conditional MyoA mutant parasite lines
using SLI. A. Schematic representation of the approach used to introduce an mCherry tag and
a loxP site downstream of the endogenous MyoA gene and install a second promoterless copy
of GFP-tagged MyoA downstream of the endogenous gene via single homologous cross over.
Integration would lead to the expression of the NeoR gene, conferring resistance to G418. B.
RAP treatment would lead to excision of the endogenous MyoA:mCherry sequence and place
the MyoA:GFP sequence harbouring the S19 mutations under the control of the endogenous
promoter.
After generating the MyoA:mCherry:cKO line, described in Chapter 5, a third approach
was attempted, whereby MyoA:mCherry:cKO parasites were complemented with epi-
somally expressed MyoA(S19)-GFP, MyoA(S19A)-GFP or MyoA(S19D)-GFP. To do this,
expression plasmids were generated, encoding a BSDr cassette to select for episome
formation, and placing the the second MyoA gene fused to GFP under the control of
the MyoA promoter to ensure correct timing of expression hyperlinkAP3(Figure 8.3.A).
MyoA:mCherry:cKO parasites were transfected with the expression plasmids encoding
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either MyoA(S19):GFP, MyoA(S19A):GFP or MyoA(S19D):GFP. Parasites were treated
with 2.5 g/ml BSD, and resistant parasites for all transfections were observed within 5
weeks post transfection. However, while most of the MyoA:mCherry:cKO+MyoA(S19):GFP
and MyoA:mCherry:cKO+MyoA(S19D):GFP appeared to express MyoA-GFP, only a very
small proportion of the MyoA:mCherry:cKO+MyoA(S19A):GFP line were GFP positive.
This indicates that there could be a dominant negative effect as a result of expressing the
S19A MyoA phosphomutant. Therefore despite the system working well to complement
MyoA:mCherry:cKO parasites with wild type S19 and phosphomimetic S19D versions of
MyoA hyperlinkAP3(Figure 8.3.B), this approach was unsuccessful for the S19A phos-
phomutant.
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Figure 8.3. Third approach used to generate conditional MyoA mutant parasite lines by
complementing MyoA:mCherry:cKO parasites with episomally expressed MyoA-GFP
harbouring either S19A or S19D mutations or the wild type S19 sequence. A. Schematic
representation of the method used to complement the MyoA:mCherry:cKO line with episomally
expressed MyoA-GFP mutants. Prior to RAP treatment, parasites would express both
MyoA-mCherry and mutant MyoA-GFP. RAP treatment would lead to excision of the endogenous
MyoA:mCherry sequences, leaving parasites reliant on the MyoA-GFP mutants. B. Live
fluorescence microscopy of MyoA:mCherry:cKO+ episomal MyoA(S19):GFP and
MyoA:mCherry:cKO+ episomal MyoA(S19D):GFP parasites. In DMSO treated parasites, both
mCherry and GFP signals overlap and localise to the parasite periphery, consistent with MyoA
localisation. In RAP-treated parasits, mCherry signal is no longer detected, confirming deletion
of MyoA-mCherry. Scale bar, 5 µm.
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